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Peritoneal Carcinomatosis: the Role of Debulking Procedures
Peter R. Knight, MB, ChB, ChM, FRCSC, FACS, FRCS
Professor, Department o f Surgery, McMaster University, St. Joseph's Hospital, Hamilton, Ont.
During the 3 days of his stay in Southern Ontario, Dr. Paul Su- 
garbaker, the 1988 Du Pont visit­
ing professor, conducted grand 
rounds at the Brantford General 
Hospital, McMaster University Med­
ical Centre and the Stratford Gener­
al Hospital and also addressed the 
annual meeting of the Southern 
Ontario Surgical Society. His paper 
on the surgical treatment of perito­
neal carcinomatosis appears in this 
issue of the Journal (pages 164 to 
170).
The concept of debulking tu­
mours to give chemotherapeutic 
agents better exposure to residual
tumour cells is, of course, not new. 
For many years, gynecologists have 
used omentectomy and other de­
bulking procedures in combination 
with various chemotherapeutic regi­
mens in the treatment of carcinoma 
of the ovary.
Pseudomyxoma peritonei is a le­
sion of low-grade malignancy that 
does not metastasize but recurs 
locally. Repeated removal of these 
locally recurring tumour masses in 
the peritoneal cavity is usually asso­
ciated with long-term survival. Re­
moving such masses with laser or 
ball-tipped cautery may well be a 
reasonable approach.
For general surgeons, accus­
tomed to the ravages wrought by 
recurrent and metastatic carcinoma 
of the rectum and colon, this ap­
proach may cause raised eyebrows. 
Such patients usually present with 
extensive seeding of the peritoneum 
and bowel surfaces and neoplastic 
adhesions so vicious that the ab­
dominal contents are solidly stuck 
together with multiple areas of ob­
struction. The prospect of freeing 
these peritoneal plaques of carcino­
ma and disentangling and freeing 
multiple loops of bowel by ball- 
tipped cautery on high voltage may 
make even the most aggressive,
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optimistic surgeon pale. The addi­
tion to this of excision of transverse 
colon, spleen and terminal ileum, 
the ligament of Treitz and the 
greater and lesser omentum, makes 
the procedure even more over­
whelming.
The role of intraperitoneal che­
motherapy1 has evolved from the 
finding that patients who had ovari­
an cancer and ascites had a high 
rate of chemotherapy-induced mye- 
losuppression when chemotherapy 
was given intravenously. It was 
found that the drugs accumulated 
in the ascitic fluid and, eventually, 
the ascitic fluid concentration of the 
drug exceeded the plasma concen­
tration. The ascitic fluid then pro­
vided a slow release form of the 
drug into the plasma, slurring the 
terminal disappearance curve. It 
was concluded that a diffusion bar­
rier associated with the peritoneum 
was the responsible factor.
The problem of poor distribution 
of chemotherapeutic agents instilled 
into the peritoneal cavity is obvious 
in patients with bulky disease and 
multiple adhesions. This distribu­
tion can be shown radiologically by 
adding Hypaque to the fluid intro­
duced into the peritoneal cavity. 
The distribution of dye-containing 
fluid in ovarian cancer patients is 
known to be excellent.1 For patients 
who have metastatic colonic and 
rectal carcinoma with dense adhe­
sions and matting of the loops of 
bowel, the distribution is likely to 
be poor. The benefits of local che­
motherapy may thus be lost. Dr. 
Sugarbaker makes no comment on 
the distribution pattern of his che­
motherapeutic fluid.
The ability of intraperitoneally
administered drugs to penetrate 
solid intra-abdominal tumour mass­
es directly has not been shown 
experimentally for most anti-cancer 
drugs. However, a mathematical 
model defined by a set of non-linear 
partial differential equations has 
predicted 5-fluorouracil tumour 
penetration to a depth of 600 ^m. 
This represents a thickness of ap­
proximately 50 to 60 cells.2 Thus, 
intraperitoneal therapy would ap­
pear to be limited in usefulness to 
tumour nodules of only a few mil­
limetres in diameter. 5-fluorouracil 
is absorbed from the peritoneal cav­
ity, thus the tumour would also be 
exposed to chemotherapeutic cyto­
toxicity via its capillary blood sup­
ply. The vascularity of the deeper 
parts of large, bulky tumours is 
poor, limiting the availability of 
chemotherapeutic levels of cytotox­
ic drugs within large tumour mass­
es. For these reasons, debulking is 
a rational approach if it can be 
achieved, even though after such a 
procedure adhesions are very likely 
to reform, preventing local access 
of chemotherapeutic agents to the 
debulked tumour masses.
The mortality and morbidity asso­
ciated with debulking is obviously 
high and many patients who under­
go these procedures are probably 
poor candidates in terms of nutri­
tion and healing capability. Their 
immune competence to deal with 
infection is also probably depressed. 
If satisfactory debulking can be 
achieved, then a course of chemo­
therapy given intraperitoneally, as 
outlined by Dr. Sugarbaker, must 
require a robust recipient indeed. 
Such an undertaking is obviously 
not suitable for anything but well-
equipped research departments with 
trained oncologists and with patient 
and aggressive surgeons who are 
prepared to embark upon prolonged 
surgical “tours de force” as part of 
a research study. The aim of any 
procedure should be to prolong life 
which is of good quality. Patients 
such as Sugarbaker describes run a 
high risk of tumour recurrence, and 
the masses may never be completely 
or successfully removed. This raises 
the questions, How much of their 
remaining lives will these patients 
spend in hospital undergoing re­
peated surgical and oncologic treat­
ment? and Can such a program 
really achieve our desired aim?
On the other hand, progress is 
made through people with courage 
and the willingness to tilt at wind­
mills and challenge problems from 
which others turn. From such be­
ginnings, new pathways may ap­
pear, and it is good to realize there 
are people prepared to undertake 
what appears impossible. From 
such beginnings the impossible may 
become a reality.
The area covered by Dr. Sugar­
baker in his Du Pont Lecture is just 
part of a program he is undertak­
ing. Most of us must await his 
ongoing results and achievements 
before embarking on what must be 
a hazardous and rocky path for 
both surgeon and patient.
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CORRESPONDENCE
Treatment of Genital Herpes: 
an Option
To the editors. A number of well- 
documented articles on the diagno­
sis and management of genital her­
pes have appeared recently,U6 the 
treatment of both acute and chronic 
herpatic lesions generally involving 
the use of acyclovir. I would like to 
suggest a further treatment option, 
one that has been used effectively at 
the University Health Services in 
Edmonton for a number of years.
Liquid nitrogen as a freezing pro­
cedure has met with excellent pa­
tient acceptance and provided amaz­
ing clinical healing within 1 week 
of treatment, whether used for a 
primary outbreak of herpes or for 
recurrent lesions. The liquid nitro­
gen is applied with a cotton-tipped 
applicator to the involved area, no 
matter how extensive, to freeze the 
entire thickness of the lesions. Pa­
tients who have widespread involve­
ment of the vulvar area and are 
obviously in severe distress are 
most grateful for the immediate 
relief and rapid healing. No other 
medication is required.
This method is also used in the 
treatment of condyloma acumina­
tum, molluscum contagiosum and
ulcerative lesions of the vulva (e.g., 
Lipschutz ulcers).
I hope this alternative treatment 
for genital herpes will prove helpful 
to others who must deal with this 
distressing condition.
Y. Yoneda, MD, FACS, FRCSC
University Health Services, 
University o f Alberta,
Health Sciences Building,
111th Street and 88th Avenue, 
Edmonton, Alta.
T6C 2R1
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are welcome. They should be typewritten 
and double spaced.
Primary Omental Torsion
To the editors. I read with interest 
Appleby’s report on primary omen­
tal torsion in the January 1989 
issue (page 7). Having seen a num­
ber of these cases in my surgical 
career, I would like to add to Apple­
by’s description.
First, these patients usually do 
not present with nausea and vomit­
ing, and the abdominal pain and 
tenderness seem disproportionate to 
their generalized symptoms. Sec­
ond, most cases of primary omental 
torsion that I have seen are associ­
ated with an indirect inguinal her­
nia on the right side. These are 
noted in one of the classic descrip­
tions of the condition.1
W.R. Ghent, MD, CM, FRCSC,
FACS, FICS
Department o f Surgery,
Hotel-Dieu Hospital,
Queen’s University,
10 Montreal St.,
Kingston. Ont.
K7L 3G6
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HOW I DO IT
Meatal-Based Tubularized Skin Flap For 
Distal Hypospadias Repair
M. Gleave, MD; H.W. Johnson, MD, FRCSC; G.U. Coleman, MD, FRCSC; 
M.G. McLoughlin, MD, FRCSC
D istal or anterior hypospadias accounts for approximately 
70% of all cases of hypospadias, 
including those in which the ureth­
ral meatus opens proximal to its 
normal position in either a glanular, 
coronal or subcoronal position. 
When possible, we use a meatal 
advancement and glanuloplasty.1 
However, when the urethral meatus 
is either too proximal or is associat­
ed with a ventral chordee, this 
procedure will not produce the best 
results. Our choice in these circum­
stances is a modified Mustarde pro­
cedure,2 using a meatal-based tubu­
larized skin flap.
Patients
Since 1984, we have treated 40 
boys for correction of distal penile 
hypospadias using a meatal-based 
tubularized skin flap. In 25, the 
repair was the primary treatment, 
and in 15, previous attempts (rang­
ing from two to five procedures) at 
repair had failed.
The group who underwent prima­
ry repair ranged in age from 1 to 5 
years. We prefer to operate when 
the boys are between 12 and 18 
months of age after a 1-week 
course of androgens. The 15 boys 
who had revision repairs ranged in 
age from 5 to 15 years.
Accepted for publication Nov. 16, 1988
Surgical Procedure
A suture of 3-0 silk is placed 
through the glans and secured to 
the drapes cephalad. After the me­
atus has been sounded to 12F, a 
rectangular skin flap is outlined 
proximal to the urethral meatus 
(Fig. 1). The width of the flap 
determines the urethral circumfer­
ence and is approximately one-third 
the circumference of the penile 
shaft (12 to 14 mm). The length is 
determined by the distance of the 
meatus from the tip of the glans. 
Any chordee between the corona 
and the meatus is divided complete­
ly before the proximal limit of the 
flap is marked, because some proxi­
mal migration of the meatus may 
occur as the penis is straightened. 
Saline erections are used to aid in 
the excision of the chordee if neces­
sary.
The flap is then incised sharply 
down to Buck’s fascia and under­
mined distally to the urethral me­
atus. The base of the flap now lies 
at the urethral meatus. The flap is 
tubularized (Fig. 2) into the neoure­
thra over a no. 8 feeding tube or 
10F Silastic stent with running 6-0 
polyglycolic acid sutures. This sin­
gle suture line is buried facing 
dorsally away from other surface 
suture lines.
After the glans has been infiltrat­
ed with 1 in 200 000 epinephrine, 
the neourethra is extended to the 
tip of the glans in one of two ways. 
If the glans is flat, a glanular tunnel
FIG. 1. Rectangular skin flap is 12 to 
14 mm wide and length is equal to 
distance of meatus from tip of glans.
FIG. 2. Tubularization of skin flap 
over 10F Silastic tube.
From the Division o f Urology, Department o f Surgery, University of British Columbia, 
Vancouver, BC
Reprint requests to: Dr. H. W. Johnson, Department o f Surgery, 3rd Floor - Rm. 3100, 910 
West 10th Avenue, Vancouver, BC V5Z 4E3
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is created between the ventral glans 
and underlying distal corpora (18 
patients) (Fig. 3a). If a ventral 
groove is present, then glanular 
flaps are raised (22 patients) and 
sutured over the neourethra with 
interrupted mattress sutures of 6-0 
polyglycolic acid suture material 
(Fig. 3b).
Byars’ flaps are then raised from 
the dorsal hood of foreskin and 
wrapped ventrally to cover the ven­
tral defect (Fig. 4). A 10F silicone 
stent or Silastic catheter is placed 
for 5 to 7 days. The penis is 
wrapped in a cling compression 
dressing for 48 hours.
Results
The complication rate in boys 
who had primary repair was low. 
Two had small fistulas, one of them 
in association with a meatal steno­
sis. Both underwent a single surgi­
cal repair of the fistulas on a day­
care basis with good results.
The 15 boys who had revision 
repairs did not fare as well. Five 
(33%) had fistulas, associated with 
meatal stenosis in three. One of the 
five had a wound infection that 
likely contributed to the fistula for­
mation. All five had the fistulas and 
stenoses corrected on a day-care 
basis, although one required a sec­
ond subsequent fistula repair.
Two boys required a day-care 
procedure to remove redundant 
skin tags.
Overall, nine patients (22.5%) re­
quired additional surgical proce­
dures, all carried out on a day-care 
basis. No significant difference in 
complications was seen between the 
glanular tunnel technique and the 
flap technique.
The early functional and cosmetic 
results were good in 38 (95%) of 
the boys. They had a good urinary 
stream, straight erections and a 
glanular meatus. In two boys, these 
aims were not achieved; both com­
plained of a deflected or splayed 
urinary stream.
Discussion
Several single-stage procedures 
to repair distal hypospadias and 
produce a meatus at the tip of the 
glans have been described. When 
meatal advancement and glanulo- 
plasty are not applicable, we like to 
use a meatal-based tubularized skin 
flap, initially described by Mustarde3 
and later modified by Belman.2 
Other options include the Mathieu4 
or Horton-Devine5 flip-flap proce­
dures, various mobilized vascular
FIG. 3. Extension of tubularized flap 
to glanular tip via glanular tunnel 
(top) or by raising glanular flaps (bot­
tom).
flaps6 7 or free skin grafts.8 The last 
two are usually reserved for mid- 
penile or proximal hypospadias. 
The flip-flap procedures cannot be 
performed in one stage if there is 
an associated chordee, but mea­
tal-based tubularized flaps can be 
used as a single-stage procedure 
in distal to mid-penile hypospa­
dias, with or without chordee.
The low incidence of complica­
tions in primary repairs and the 
overall good functional and cosmet­
ic results in 38 of the 40 boys 
reaffirms the effectiveness of the 
modified Mustarde procedure re­
ported by others.49 The higher 
complication rate associated with 
secondary or revision repairs (33%) 
results from mobilizing flaps with
FIG. 4. Covering ventral defect with 
Byars’ flaps.
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compromised blood supply from 
previous operations. Despite this, a 
good final result was still obtained 
in 13 of these 15 problem patients.
The Mustarde meatal-based tubu- 
larized skin flap produces compara­
ble results to other procedures used 
in the repair of mid-penile to distal
hypospadias. The advantages in­
clude some flexibility in construct­
ing the glanular course of the 
neourethra (flaps versus tunnel), 
creation of a neourethra with a 
single suture line that abuts the 
corpora dorsally to reduce the risk 
of fistulization and the ability to
excise associated chordee allowing 
a single-stage repair.
We thank Dr. David Minninberg for 
guidance in establishing this technique.
References
1. Duckett JW: MAGP1 (meatoplasty and
TUBULARIZED FLAP FOR HYPOSPADIAS REPAIR
glanuloplasty): a procedure for subcoron­
al hypospadias. Urol Clin North Am 
1981; 8: 513-519
2. B elman AB: The modified Mustarde hy­
pospadias repair. J Urol 1982; 127: 88- 
90
3. Mustarde JL: One stage repair — IV. In 
Horton CE: Plastic and Reconstructive 
Surgery o f the Genital Area, Little, Bos­
ton, 1973: 290
4. Gonzales ET jr , Veerarachavan KA, De- 
laune J: The management of distal hy­
pospadias with meatal-based, vascularized 
flaps. J Urol 1983; 129: 119-120
5. Devine CJ jr , Horton CE: Hypospadias 
repair. J Urol 1977; 118 (1 pt 2): 188- 
193
6. Nasrallah PF, Minott HB: Distal hypos­
padias repair. J Urol 1984; 131: 928-930
7. Hodgson NB: Use of vascularized flaps in
hypospadias repair. Urol Clin North Am 
1981; 8: 471-481
8. Duckett JW: Repair of hypospadias. In 
Hendry WF: Recent Advances in Urolo- 
gy/Andrology, Churchill, Edinburgh, 
1981: 279-290
9. K limberc I, W alker RD: A comparison of 
the Mustarde and Horton-Devine flip-flap 
techniques of hypospadias repair. J Urol 
1985; 134: 103-104
standard
s
t)F COMMUNITY-ACQUIRED INFECTIONS
*
Clinical experience gained over the past 
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Ann Intern Med t03(1):10-16, July 1985.
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Presidential Address, 1988. Surgical 
Research: Its Importance in the Evolution 
of the Specialty of General Surgery
Bernard Langer, MD, FRCSC, FACS
General surgery is a specialty that has gradually been defined by the evolution of 
surgery in general, the major events being the identification and separation of 
subspecialties. Advances in knowledge brought about by research have been the 
major determinants in allowing the development of these subspecialties. Research 
has played a major role in the redefinition of general surgery, which has now in its 
own right become both the parent specialty and a subspecialty: the parent specialty 
because of its continued concern with disease states of a general nature, such as 
trauma, critical care, nutrition, transplantation, oncology; a subspecialty because of 
its focus on specific areas of surgery, particularly gastrointestinal surgery. Future 
developments in general surgery depend on fostering research in both the general 
and specific areas, and also across the whole spectrum from the most basic to 
applied clinical research.
La chirurgie generale est une specialite qui s’est definie progressivement avec 
devolution de la chirurgie en general. Les principaux evenements qui ont marque 
cette evolution sont l’identification, puis la separation des sous-specialites. La 
recherche est a l’origine de l’avancement des connaissances, determinant majeur du 
developpement de ces sous-specialites. La recherche a joue un role preponderant 
dans la redefinition de la chirurgie generale, laquelle est devenue, a la fois, la 
specialite mere et une sous-specialite en soi: la specialite mere, car elle continue de 
s’interesser aux etats morbides de nature generale tels que traumatismes, reanima­
tion, nutrition, transplantation, oncologie; une sous-specialite, parce qu’elle s’est 
concentree sur des domaines specifiques de la chirurgie, particulierement sur la 
chirurgie gastro-intestinale. Les developpements futurs de la chirurgie generale 
dependront de l’encouragement accorde a la recherche, aussi bien dans ses aspects 
generaux que specifiques, et allant de la recherche la plus fondamentale jusqu’aux 
essais cliniques d’application.
The Canadian Association of General Surgeons (CAGS) has 
come a long way in only 11 years. 
It has concerned itself with a num­
ber of important issues. Education 
has been a top priority and is most
apparent in the annual scientific 
meeting. From the beginning, it 
was the intention of this organiza­
tion to appeal equally to the broadly 
based surgeon in community prac­
tice and the highly focused special-
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ist general surgeon in an academic 
institution. The association has 
played an important role in estab­
lishing new training standards for 
general surgeons and in recogniz­
ing and promoting the development 
of new and special expertise in 
general surgery. As you are all 
aware, this is a constantly chang­
ing game, and there has been 
anxiety about the changes that 
have taken place in general surgery. 
When, for example, does specializa­
tion become fragmentation, and 
what will become of the specialty of 
general surgery as we know it?
In my address today, I would like 
to review some of the changes that 
have taken place in the specialty of 
general surgery, indicating the role 
of research in bringing about these 
changes and emphasizing the im­
portance of maintaining strength in 
research to continue this process of 
evolution.
Pioneers of Surgical Research
The birth of surgical research 
occurred in the 18th century, the 
landmark being the career of John 
Hunter who “introduced a new spir­
it of enquiry, a philosophy, which 
not only transformed the medical 
theory and practice of his epoch, 
but profoundly influenced scientific 
thinking everywhere down to our 
own times.”1
A century later, Lord Lister intro­
duced the principles of antisepsis 
which made possible a remarkable 
expansion of surgical potential. 
Surgical research developed in the
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19th century, not only in anatomy 
laboratories, but especially in the 
developing field of physiology. The 
chief figures were Heidenhain in 
Germany, Eck and Pavlov in Russia 
and Claude Bernard in France.
In the 20th century there was an 
explosion of knowledge in all fields 
of medicine as the scientific method 
became established and universities 
developed laboratories dedicated to 
medical research. Alexis Carrel is a 
premier example of the new breed 
of 20th-century surgeon scientist. 
He carried out some of the earliest 
experiments using tissue culture of 
cells. He was interested in organ 
preservation and developed appara­
tus for that purpose. His most 
important work was in the area of 
vascular surgery where he devel­
oped the techniques for anastomo­
sing blood vessels that are still in 
use today.
W.E. Gallie lived at about the 
same time as Carrel, and although 
he is best known for organization 
of a formal, structured, integrated 
training program at the University 
of Toronto, he was also a brilliant, 
innovative thinker whose research 
involved the autotransplantation of 
tissues, particularly fascia in hernia 
reconstruction and the use of xeno­
graft bone material in the fixation 
of fractures.
Other notable 20th-century re­
searchers include Frances Moore, a 
broadly based general surgeon who 
had no specific organ interest, but 
worked on the principle of studying 
the whole patient. Jonathan Rhodes 
at the University of Pennsylvania 
and Stanley Dudrick developed a 
system to provide all of the require­
ments for maintenance of normal 
nutrition to patients by the intrave­
nous route. This research expanded 
the capabilities of surgery and, par­
ticularly, those of alimentary tract 
surgeons.
Lloyd MacLean and his group at 
McGill University focused on the
body’s response to injury, particu­
larly immunologic responses. They, 
along with Altemeier and others in 
the United States, have emphasized 
the importance of studying in detail 
the host response to infection in 
order to develop better strategies of 
treating it, especially in the manipu­
lation of nutrition and immunologic 
factors.
In organ transplantation, no one 
has contributed as much over as 
long a time as Tom Starzl. He 
almost single-handedly created the 
field of liver transplantation, and 
carried out fundamental studies of 
factors involved in liver growth and 
regeneration which have helped to 
open up the field of liver surgery in 
general.
The Surgical Specialties
The development of specific sur­
gical specialties was occurring si­
multaneously, partly as a result of 
new capabilities for surgical treat­
ment arising from research and 
partly from expanding patient care 
needs. Urology was built around the 
cystoscope, a unique advance in 
technology. Thoracic surgery was 
made possible by the introduction 
of endotracheal anesthesia and con­
trolled ventilation. In the same way, 
cardiac surgery did not develop as a 
unique specialty until the extracor­
poreal pump oxygenator was per­
fected. In the course of all this, 
general surgery has been defined by 
a process of progressive amputa­
tion, the field of general surgery 
consisting of those parts of the 
body left behind.
The Changing Face of General 
Surgery
There have also been major re­
ductions in general surgery as a 
result of new scientific and techno­
logic advances. In the upper gas­
trointestinal tract, these include en­
doscopic procedures such as scle­
rotherapy for varices, papillotomy 
for biliary stenosis and stone ex­
traction, coagulation for upper gas­
trointestinal bleeding and endoscop­
ic removal of polyps in the lower 
gastrointestinal tract. Lithotripsy 
has been developed for the nonsur- 
gical management of renal stones 
and is in its early days of evolution 
for treating biliary stones.
Pharmacologic developments 
have also changed the face of sur­
gery. They are best exemplified by 
the development of H2 blockers and 
other more advanced drugs which 
can control gastric acid secretion 
and have almost eliminated surgery 
for the elective treatment of duode­
nal ulcer disease. Chemotherapy for 
cancer has not had the success 
anticipated, but has modified our 
approach to the treatment of some 
malignant tumours.
Despite these developments, the 
specialty of general surgery can be 
kept strong by (a) buying into the 
scientific and technologic develop­
ments rather than worrying about 
competing with them and (b) taking 
advantage of the position we hold 
as the surgical specialty which is 
concerned about the whole patient.
With regard to technological ad­
vances, general surgeons must be 
involved where these advances are 
applied to the treatment of surgical 
diseases. Endoscopy, for example, is 
an essential part of the alimentary 
tract surgeon’s capability. The 
CAGS and the general surgical 
committee of the Royal College of 
Physicians and Surgeons of Canada 
have established endoscopy as an 
essential part of the training of the 
general surgeon. As endoscopy con­
tinues to develop in the future, it is 
essential that general surgeons be 
involved in the advances related to 
it, which also means in the research 
related to it.
There are other areas where new 
technology offers alternatives to
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surgery. Extracorporeal shock-wave 
lithotripsy (ESWL) was developed 
by physicists and engineers under 
the leadership of a urologic sur­
geon. In most centres, ESWL for 
kidney stones has developed as a 
team approach with the surgeon 
playing a prominent or leading role 
and considering this as one of the 
options in the whole spectrum from 
long-term medication to open surgi­
cal procedures. The applications of 
this technology to biliary stone dis­
ease are currently under study and 
the same approach must be taken. 
Extracorporeal shock-wave litho­
tripsy must develop as complemen­
tary therapy to surgery, and stone 
dissolution and the clinical trials 
and subsequent treatment protocols 
must involve general surgeons in 
leadership roles. This is the rational 
use of surgical expertise in a dis­
ease which is, in its most lethal 
form, a surgical disease.
Likewise, when other scientific 
advances are made that may change 
our own field, we must be sure to 
develop appropriate expertise. We 
must understand the pharmacology 
of new drugs and their applications, 
and be involved in the cutting edge 
of science. This is obviously not for 
every surgeon or surgical investiga­
tor, but our surgical research ef­
forts must include appropriate 
training in this field so that we do 
research that is current and com­
petitive.
I emphasize that general sur­
geons must take advantage of their 
role in the diseases of the whole 
body. In the area of cancer, new 
developments in chemotherapy will 
come from the large pharmaceutical 
firms. The field of immunotherapy, 
however, is open and requires an 
innovative mind and understanding 
of the fields of immunology and cell 
biology. It is difficult, but not im­
possible, for surgeons to compete 
with pure basic scientists in this 
area. Clinical research in cancer is
the area in which we general sur­
geons can be most competitive. The 
ultimate testing of new therapy in­
volves controlled clinical trials, and 
we are the ones who have the 
patients to carry out these studies.
Transplantation began as a pure­
ly surgical specialty with technical 
problems being predominant. Once 
the technical problems were solved, 
immunologic issues became the 
major limiting factors, and a variety 
of medical specialists now play a 
major role in transplantation pro­
grams. New immunosuppressive 
drugs will be tested by pharmaceuti­
cal companies, but immunologic 
manipulation will be developed by 
scientists with backgrounds in cell 
biology and immunology. Surgeons 
must be among those working in 
the field. We, as surgeons, still tend 
to be preoccupied with the technical 
aspects of the operation and to 
leave patient selection and prepara­
tion, postoperative care and follow­
up to others. This is a mistake. 
Transplantation is an interdisciplin­
ary field which has a common base 
in science, and surgeons must play 
a major role in every aspect of 
transplantation programs. General 
surgeons are particularly appropri­
ate to this role.
Another area in which surgeons 
must maintain an important interest 
is that of critical care. This includes 
polytrauma, nutrition, sepsis and 
organ failure. The general surgeon 
should be the key individual in 
trauma centre organization, and in 
actual resuscitation and manage­
ment of critically ill patients after 
injury and surgery. We must also 
contribute to research in critical 
care from basic studies of cellular 
events in organ failure to clinical 
trials of new therapies.
Universities and Surgical 
Research
Having considered the role of
research in shaping the develop­
ment of general surgery, I would 
like now to examine what role the 
universities play in this kind of 
research, whether there is any role 
for the surgeon in clinical practice, 
and what function the CAGS has in 
general surgical research.
The role of the university is to 
train undergraduate students and 
postgraduate specialists. Included 
in every university’s mission is the 
need to do research. As Malcolm 
Brown, former president of the 
Medical Research Council of Cana­
da, has pointed out, the most im­
portant role of research is to create 
new knowledge. There are, howev­
er, two other important reasons for 
research in university hospital set­
tings. First, research focuses atten­
tion on the diseases being studied in 
such a way that there is much 
closer and more systematic assess­
ment of patient selection, outcome 
and follow-up; as a result, patient 
care is better. The other important 
role of research is in helping to 
create an environment of critical 
thinking and questioning, so that 
students and residents will develop 
better judgement, literature evalua­
tion skills and appraisal of existing 
dogma.
Role of the Practising General 
Surgeon
This brings me to the role of 
those of you who are surgeons in 
busy clinical practice. You are obvi­
ously not in a position to do re­
search yourselves. It is important, 
however, to maintain a sense of 
enquiry and questioning of existing 
practice. If those of you who are 
over 50 years old remember how 
you treated breast cancer during 
your residency and compare that 
with the way you treat it now, you 
will recognize how important it is to 
be aware of change and the need for 
a good set of standards to evaluate
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what appears in the literature as an 
advance in knowledge. Do you re­
member the excitement about gastr­
ic freezing and how large numbers 
of freezing machines were sold, not 
to mention the thousands of pa­
tients who had their stomachs fro­
zen, before it finally became appar­
ent that not only did this new 
treatment not work, but there were 
serious complications as a result of 
it?
Surgical Research and CAGS
The role of the CAGS in research 
development is to support and pro­
mote research in general surgery in 
every way possible. This was recog­
nized at the time our organization 
was founded. In addition to our 
advisory committee on research, 
and under the leadership of Neil 
Watters, we have created the Cana­
dian Surgical Research Fund to 
promote, lobby and raise money for 
general surgical research — for 
specific projects, for residents-in- 
training and to support research 
training fellowships. Three potential 
sources of funds include patients, 
industry and our membership, 
which is the major source of in­
come. The contributions of our 
members attest in a tangible way to 
their commitment to supporting re­
search. Much more is needed and 
the members of the Board of the 
research fund are seeking ways to 
tap other sources. Our patients 
have shown their willingness to 
support research — but they have 
to be asked. You, our members, can 
help by approaching your patients 
to support the Canadian Surgical 
Research Fund. You will be pleas­
antly surprised at the response.
The General Surgeon’s 
Support for Surgical Research
The final question is, How are we 
doing overall in relation to research
in general surgery? In a nutshell, 
we are not doing as well as we 
should. Interest in research has 
increased in medical schools in 
terms of numbers of summer stu­
dents and research fellows, but 
major problems exist.
Funding for research in general 
has decreased in terms of real dol­
lars, particularly in the area of 
surgical research. This has oc­
curred both in the US and Canada, 
because of the increasing sophisti­
cation of basic research and the 
difficulty clinicians, especially sur­
geons, have in competing with full­
time basic scientists for limited re­
search dollars. We have responded 
by increasing the training period for 
committed surgeon/scientists and 
moving to develop within surgical 
departments groups of investigators 
that include dedicated basic scien­
tists.
Another problem is the peer- 
review system in granting agencies 
on whose committees, for a variety 
of reasons, surgeons are often not 
represented. The Canadian surgical 
chairmen have formed the Canadian 
Council on Surgical Research to act 
as a lobby group and, it is hoped, 
help to secure increased representa­
tion of surgeons in the review proc­
ess of scientific granting organiza­
tions.
Another problem has been the 
difficulty of maintaining the career 
path of the surgeon/scientist in a 
clinical department. This involves a 
complexity of issues including time 
protection, financial support and 
image, all of which are now being 
addressed.
Regarding the general surgical 
community at large, there is a need 
for support in terms of such bodies 
as the Canadian Surgical Research 
Fund. The CAGS has responded to 
that need. Those dollars, however, 
will always be a relatively small part 
of the overall support required. Of 
equal importance is the role of
surgeons in the community and of 
the regional surgical societies in 
recognizing the value of research, 
in transmitting the knowledge 
gained to their patients, and where 
possible in helping to convince poli­
ticians and other legislators of the 
need for increased research support.
Future of General Surgery
What does the future hold for 
general surgery? Perhaps the best 
way to answer this is to look 
through the window provided by 
those currently working at the cut­
ting edge in our medical schools. A 
conference supported by the Cana­
dian Surgical Research Fund was 
held in Mississauga last June. The 
topics covered by these young re­
searchers included the following.
•  “Regulation of intracellular 
pH in resident and activated perito­
neal macrophages” . In this study 
the researchers are trying to identi­
fy the molecular mechanisms that 
lead to activation of peritoneal mac­
rophages. It is a very important 
issue in our host defences in perito­
nitis and of interest to every abdom­
inal surgeon.
•  “31P NMR spectroscopy of 
liver and skeletal muscle in a model 
of cancer cachexia”. New technolo­
gy of surface coil spectroscopy is 
being used to measure serially vis­
ceral energy stores in an experimen­
tal model of cancer cachexia. This 
may provide a simple way to assess 
nutritional deficits in cancer pa­
tients.
•  “Allotransplantation of single 
donor purified canine islets into the 
spleen or renal subcapsular space 
using cyclosporine”. This very ex­
citing piece of work won the CAGS 
Resident’s Research Prize for 1988. 
It is a study of transplantation of 
highly purified islets in diabetic 
dogs. Many investigators believe 
that islet transplantation is more 
likely to be successful in managing
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the difficult human diabetic than 
whole organ transplantation.
•  “Islet cell differentiation and 
proliferation induced by pancreatic 
cytosol extract”. This important in­
vestigation was carried out in ham­
sters to study the factors that pro­
mote growth and development of 
islets. Such factors will be essential 
in developing the ultimate tech­
niques for islet transplantation in 
the human.
•  “Extracorporeal shock-wave 
lithotripsy (ESWL): a valuable ad­
junct in the management of difficult 
biliary tract calculi”. This is a pre­
liminary report of clinical experi­
ence. It is the equivalent of a phase 
II cancer trial and is very important 
at present; ultimately, carefully con­
trolled prospective studies will be 
required.
•  “The reversal of cyclosporine:
a mediated suppression of allogene­
ic induced monocyte procoagulant 
activity by H2 antagonists in vitro”. 
Most transplant patients must take 
multiple drugs. This study docu­
ments the potentially detrimental 
effect that H2 blockers may have on 
cyclosporine immunosuppression in 
transplant patients.
•  “The critical injury of cold 
preservation of liver allografts in 
the rat is sinusoidal lining cell dam­
age”. This is a careful morphologic 
study in the rat, demonstrating the 
typical endothelial cell injury char­
acteristic of cold preservation of the 
liver during transplantation. This 
provides a simple model for the 
study of better preservation tech­
niques and focuses attention on an 
important target cell in preservation 
injury.
•  “The effect of cisplatin on
liver regeneration in the rat after 
two-thirds hepatectomy”. The re­
sults of this experimental study of 
chemotherapy on liver regeneration 
will have a bearing on the role of 
adjuvant chemotherapy in patients 
after resection of hepatic tumours.
These are some of the studies 
which will change the way in which 
we practise and will redefine the 
specialty of general surgery. We 
have come a long way since I 
became a general surgeon 25 years 
ago. I expect we will progress even 
further in the next 25. I hope that I 
will be around to see it and I know 
that many of you, and certainly the 
Canadian Association of General 
Surgeons, by which 1 have been 
honoured as president, will play an 
important role in continuing to 
shape the specialty of general sur­
gery. ■
SESAP VI Question
Item 105
The most frequently encountered metabolic complication of urinary 
diversion through an ileal segment is
(A) hyperkalemic, hypochloremic metabolic acidosis
(B) hyperchloremic metabolic acidosis
(C) hypokalemic metabolic alkalosis
(D) hypochloremic metabolic alkalosis
(E) combined metabolic acidosis and respiratory alkalosis
For the incomplete statement above, select the one completion that is 
best of the five given.
For the critique of Item 105 see page 170.
(Reproduced by permission from SESAP VI Syllabus; Surgical Educa­
tion and Self-Assessment Program No. 6. For enrolment in the Surgical 
Education and Self-Assessment No. 6, please apply to the American 
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
Corrections
In the January 1989 issue, the arti­
cle entitled “Acute scrotal pain in 
children: prospective study of diag­
nosis and management”, which ap­
pears on pages 29 to 32, contains an 
error. On page 31 the illustrations 
for Figs. 1 and 2 are reversed, but 
the legends are correct. The left- 
hand picture illustrates a case of 
spermatic cord torsion and the right- 
hand figure a case of epididymitis. 
We apologize to both the authors 
and our readers for this mistake.
Also in the January 1989 issue, the 
name of R.M. Baird, MD, FACS, 
FRCSC, was inadvertently omitted 
as one of the coauthors of the article 
“The risk of occult invasive breast 
cancer after excisional biopsy show­
ing in-situ ductal carcinoma of com­
edo pattern”, which appears on 
pages 56 to 60.
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Carotid Body Tumours: the University of 
Alberta Hospital Experience
►
►
►
►
i
l
►
►
i
F.A. Daudi, MD; O.G. Thurston, MD, FRCSC
At the University of Alberta Hospital between 1950 and 1988, 17 patients who had a 
diagnosis of carotid body tumour were seen; 15 of them were followed up for an 
average of 8 years (range from 1 to 38 years).
In 14 patients the tumour was removed surgically. There were no operative 
deaths and no strokes occurred. The most frequent complication was cranial nerve 
deficit. Of the 15 patients followed up, 10 (67%) manifested a deficit of the facial, 
vagus or hypoglossal nerve.
The primary tumour was diagnosed histologically as a benign neoplasm in all 14 
patients operated on, but in 3 distant metastases developed or there was invasive 
local recurrence. Patients with malignant tumour were significantly (p < 0.01) 
younger than those with a benign tumour.
Carotid body tumours can be managed safely with respect to stroke complications, 
but cranial nerve injuries continue to be a problem. Malignant tumours are difficult 
to distinguish from benign tumours except that they tend to occur in younger 
patients. Prompt surgery and close follow-up is particularly important in patients 
with carotid body tumour.
Entre 1950 et 1988, 17 patients de l’hopital de TUniversite d’Alberta ont re?u un 
diagnostic de tumeur du glomus carotidien; 15 d’entre eux ont ete suivis pendant 
une periode moyenne de 8 ans (ecart de 1 a 38 ans).
Chez 14 patients, la tumeur fut enlevee chirurgicalement. II n’y eut pas de 
mortality peroperatoire et aucun accident cerebrovasculaire n’est survenu. La 
complication la plus frequente fut un deficit des nerfs craniens. Des 13 patients qui 
ont survecu et qui ont fait l’objet d’un suivi, 10 (77%) manifestaient un deficit des 
nerfs facial, vague ou hypoglosse.
La tumeur primitive fut diagnostiquee histologiquement comme tumeur benigne 
chez chacun des 14 patients operes bien que, dans 3 cas, il y eut metastase a 
distance ou recidive avec envahissement local. Les patients porteurs de’tumeurs 
malignes etaient significativement plus jeunes (p < 0.01) que ceux qui souffraient 
de tumeurs benignes.
Les tumeurs du glomus carotidien peuvent etre traitees sans crainte d’un accident 
cerebrovasculaire, mais les lesions des nerfs craniens sont une complication 
courante. Les tumeurs malignes se distinguent difficilement des tumeurs benignes, 
sauf qu’elles semblent survenir chez des patients plus jeunes. Une chirurgie precoce 
et une surveillance etroite des suites therapeutiques sont particulierement importan- 
tes chez les patients souffrant d’une tumeur du glomus carotidien.
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Carotid body tumour is an un­common neoplasm which arises 
from paraganglionic cells at the 
bifurcation of the common carotid 
artery. The tumour is extremely 
vascular. However, in the follow-up 
of patients operated on for carotid 
body tumours we have noted that 
cranial nerve complications have 
been more numerous and more seri­
ously disabling than vascular com­
plications. We believe that because 
surgeons are preoccupied with po­
tential vascular complications, vas­
cular control is well handled, but 
neurologic complications, because 
of cranial nerve damage, remain a 
challenge. In this study of 17 pa­
tients with carotid body tumours we 
have attempted to demonstrate the 
importance of cranial nerve compli­
cations.
Patients and Methods
Between 1950 and 1988, 17 pa­
tients seen at the University of 
Alberta Hospital in Edmonton had a 
diagnosis of carotid body tumour. 
The medical records of these pa­
tients were reviewed and data tabu­
lated with particular attention to 
duration of symptoms, methods of 
investigation, operative findings and 
techniques, postoperative complica­
tions and histologic features of the 
tumours. Fifteen patients were fol­
lowed up by clinic visit or letters 
from other physicians with particu­
lar attention paid to persisting disa­
bilities and tumour recurrence.
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Findings
The 17 patients (7 men and 10 
women) ranged in age from 15 to 
79 years (mean 48 years). All pre­
sented with a neck mass which had 
been present from 2 months to 13 
years. Three patients had bilateral 
tumours and three had a family 
history of carotid body tumour. 
Diagnosis was confirmed by arteri­
ography in 12 patients; computed 
tomography was also done in 2 of 
these. In four patients the diagnosis 
was made at the time of neck 
exploration and in one patient by 
computed tomography alone, car­
ried out just before surgery. Four­
teen patients underwent surgical re­
section of the tumour. In 13 of 
these, an adventitial dissection and 
resection was carried out after se­
curing proximal and distal vascular 
control. In one patient, the carotid 
bifurcation was resected and com- 
mon-to-internal carotid artery conti­
nuity was restored with a saphe­
nous vein graft. Three patients were 
not operated because of advanced 
malignant disease not related to the 
carotid body tumour, previous 
stroke and pending resection of an 
adrenal pheochromocytoma. Imme­
diate postoperative complications 
were hematoma requiring re­
exploration of the neck in two 
patients. There were no operative 
deaths. Pathological examination of 
excised tumours confirmed the di­
agnosis of benign carotid body tu­
mour in all 14 patients.
The mean follow-up of the 15 
patients was 8 years (range from 1 
to 38 years). At the time of writing, 
eight patients were alive and free of 
recurrent tumour. Four patients 
died of unrelated causes. One pa­
tient died of metastatic carotid body 
tumour in bone. One patient was 
alive with metastatic carotid body 
tumour to the spine and associated 
paraplegia. One patient was alive 
with locally recurrent carotid body
tumour extending to the base of the 
skull. Thus, in 3 of the 15 patients 
the tumour behaved in a malignant 
fashion, although this was not an­
ticipated from the histologic appear­
ance of the primary tumour. The 
age of these 3 patients was 25 ± 9 
years (mean ± SD) whereas the age 
of the 14 other patients was 53 ± 
15 years (p < 0.01, Student’s f- 
test).
The 15 patients available for fol­
low-up showed a high incidence of 
persisting cranial nerve deficits. 
Voice changes, including hoarse­
ness and inability to raise the voice 
to a loud level, were noted in six 
patients. Three patients had a uni­
lateral (and ipsilateral) hypoglossal 
nerve palsy and one patient had a 
palsy of the marginal mandibular 
branch of the facial nerve. Thus, 10 
of 15 patients (67%) had a localized 
deficit of the facial, vagus or hypo­
glossal nerve.
Discussion
In this series, postoperative vas­
cular complications were confined 
to two postoperative hematomas, 
which required evacuation. No pa­
tient suffered a stroke either in- 
traoperatively or postoperatively, 
and there were no operative deaths. 
However, postoperative complica­
tions related to cranial nerve lesions 
were noted frequently, and this has 
been a consistent finding in series 
of patients with carotid body tu­
mours reported from other institu­
tions.1-3 Surgeons operating on pa­
tients with carotid body tumours 
have become increasingly aware of 
the devastating effects of interrup­
tion of carotid blood flow. As a 
result, the perioperative mortality 
and stroke rates have fallen dramat­
ically in the last 20 years4 as vascu­
lar techniques have been refined.
Unfortunately, the rate of cranial 
nerve injuries has not fallen corre­
spondingly. Low death and stroke 
rates for carotid body tumour resec­
tion should result in patients being 
operated on sooner for carotid body 
tumours when they are relatively 
small (stage I in the classification of 
Shamblin and colleagues5). Small 
tumours, an awareness of potential 
cranial nerve injury and refinement 
of technique6 should result in a 
decline in the incidence of cranial 
nerve injuries resulting from the 
removal of carotid body tumours.
There is general agreement that 
it is difficult to predict the malig­
nant potential of carotid body tu­
mours from the histologic appear­
ance of the primary tumour, al­
though cellular pleomorphism has 
been observed to be an indication of 
malignancy.2 In our series, one pa­
tient had local recurrence of the 
primary tumour after what was con­
sidered to be a complete excision 
and two patients had frank metasta- 
ses to bone. In each case, the 
primary tumour was thought to be 
benign pathologically. This is in 
keeping with the findings of Meyer 
and colleagues6 who noted a meta­
static rate of about 5% for carotid 
body tumours regardless of histo­
logic appearance. In this series of 
patients, young age at the time of 
diagnosis was a more reliable index 
of aggressive tumour behaviour 
than the histologic appearance of 
the tumour. This finding argues for 
early surgery and close follow-up 
for patients in the second, third and 
fourth decades of life, who have a 
carotid body tumour.
The majority of patients with 
carotid body tumours present with 
a unilateral lesion and have no 
family history of this condition. 
However, familial occurrence and 
bilateral lesions have been docu­
mented. Bleker and Wereldsma7 
noted a 25% incidence of bilateral 
tumours in patients with a family 
history compared with 5% other­
wise. Three patients in our series
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had a family history and one of 
them had bilateral tumours. The 
other patient with bilateral carotid 
body tumours had no family histo­
ry. The patient with bilateral carotid 
body tumours and a positive family 
history of the tumour was also 
found to have an adrenal pheo- 
chromocytoma. This association 
has been noted8 and represents an 
additional consideration in the 
work-up preoperatively of patients 
with carotid body tumours.
Carotid body angiography has 
been the gold standard for the 
diagnosis of carotid body tumours, 
its accuracy approaching 100%.3 
Computed tomography shows a 
well-circumscribed, strong contrast 
enhancing mass at the bifurcation 
of the common carotid artery and 
these findings appear to be typical 
of this lesion.9 In one of our most
NOTICES
Annual Meeting of American Soci­
ety of Colon and Rectal Surgeons
More than 1000 surgeons are expected 
to attend the 88th annual meeting of 
the American Society of Colon and 
Rectal Surgeons which will be held in 
Toronto, June 11-16, 1989. The pro­
gram features workshops, guest lec­
tures, exhibits and, of particular inter­
est, a panel discussion on the optimal 
surgical technique for colorectal cancer. 
For further information contact: Execu­
tive Office, The American Society of 
Colon and Rectal Surgeons, Ste. 1080, 
800 East Northwest Highway, Palatine, 
IL, 60067, USA; (312) 359-9184.
Continuing Education at Univer­
sity of Toronto
A course entitled “Hepatic Surgery: 
New Anatomy, New Techniques” is 
being offered by the Faculty of Medi­
cine at the University of Toronto. Fur­
ther information about the course,
recent patients, the combination of 
clinical assessment and computed 
tomography accurately defined the 
lesion, and this patient was operat­
ed on without difficulty. We believe 
that as more experience is gained 
with computed tomography, it will 
replace angiography in the diagno­
sis of carotid body tumours, except 
in special situations in which carot­
id body stenosis is suspected or in 
the rare situation when emboliza­
tion is contemplated before surgery.
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Edmonton. The program includes post­
graduate courses, poster sessions, 
workshops, symposia, free communica­
tion sessions and medical and surgical 
exhibits. Over 2500 specialists, interns 
and residents are expected to attend. 
For further information contact Anna 
Lee Chabot, Head - Meetings and As­
semblies Section, Office of Fellowship 
Affairs, The Royal College of Physi­
cians and Surgeons of Canada, 74 Stan­
ley Ave., Ottawa, Ont. KIM 1P4; (613) 
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CMA Annual Meeting
The Canadian Medical Association’s 
122nd annual meeting is scheduled for 
Aug. 20-25, 1989 in Quebec City. In 
conjunction with the meeting, a scien­
tific program on “highway traumatolo­
gy” is being offered by the CMA and 
the “Regie de Tassurance automobile 
du Quebec”. Further information can 
be obtained from the CMA Meetings 
Department, PO Box 8650, Ottawa, 
Ont. K1G 0G8; (613) 731-9331.
N EW  FROM M ILES
A REVOLUTIONARY 
ORAL ANTIBIOTIC
THE POW ER O F PARENTERALS. 
TH E FREEDOM OF TABLETS.
AND FREEDOM
WIDE RANGE OF INDICATIONS lower respiratory tract — urinary tract 
skin/soft tissue — bone and joint
BROAD SPECTRUM
Highly active* in vitro against a broad range of gram-positive and gram-negative 
pathogens, “...the most potent anti -pseudomonas agent...”1 Editorial, The Lancet.
HIGH TISSUE PENETRATION
Serum, tissue and fluid levels well above inhibitory levels.2
EXCELLENT PATIENT COMPLIANCE
Convenient B.I.D. dosage. Well tolerated — low incidence of side effects.1
CIPRO HOT LINE
For more information, 
please call 
1- 800- 227-7766
*tn vitro activity does not necessarily 
imply a correlation with in vivo results.
MILES
NEW
TABLETS
POTENT
YETP.O.
For prescribing information see page 194
SOUTHERN ONTARIO SURGICAL SOCIETY
Surgical Treatment of Peritoneal 
Carcinomatosis: 1988 Du Pont Lecture
Paul H. Sugarbaker, MD, FACS*
Tumour spread onto peritoneal surfaces is frequent in patients who have recurrent 
gastrointestinal cancer. In this study the author describes (a) a cytoreductive 
surgical technique of ball-tipped electrocautery dissection, which can rapidly and 
definitively remove large volumes of intra-abdominal tumour, (b) a procedure for 
immediate postoperative lavage of the abdominal cavity to remove blood and tissue 
debris, and (c) a regimen of early and delayed intraperitoneal chemotherapy to 
destroy small quantities of residual cancer cells on intra-abdominal surfaces. 
Forty-seven patients underwent cytoreductive surgery to remove large volumes of 
adenocarcinoma widely disseminated through the abdomen. Most patients had 
intraperitoneal chemotherapy to destroy small volumes of cancer remaining within 
the abdomen. In the absence of previous radiotherapy, one patient died and the 
morbidity was acceptable. In eight patients who received radiotherapy, seven had 
bowel perforation and one died. Surprisingly, the majority of patients who had 
cytoreductive surgery plus intraperitoneal chemotherapy had disease-free long-term 
survival. In patients with peritoneal carcinomatosis, long-term disease-free survival 
correlated with low tumour aggressiveness, adequate cytoreductive surgery and the 
use of intraperitoneal chemotherapy.
Chez les patients souffrant de cancer gastro-intestinal, l’envahissement tumoral des 
surfaces peritoneales est frequent. L’auteur decrit a) une technique de dissection a 
l’electrocautere a pointe mousse permettant de reduire rapidement et definitivement 
de telles tumeurs, b) une technique de lavage postoperatoire immediat de la cavite 
abdominale pour eliminer le sang et les debris tissulaires, et c) un regime 
therapeutique compose d’une chimiotherapie intraperitoneale immediate et retardee, 
destinee a eliminer de petites quantites de cellules cancereuses residuelles sur les 
surfaces intra-abdominales. Quarante-sept patients ont subi une chirurgie cytoreduc- 
trice d’importantes masses d’adenocarcinomes largement dissemines dans l’abdomen. 
La plupart des patients refurent une chimiotherapie pour detruire de petites masses 
tumorales qui restaient dans l’abdomen. En l’absence de radiotherapie prealable, un 
patient est decede et la morbidity fut acceptable. Des huit patients qui refurent de la 
radiotherapie, sept subirent une perforation intestinale et un mourut. On a constate 
avec etonnement que la majorite des patients qui eurent une chirurgie cytoreductrice 
accompagnee d'une chimiotherapie intraperitoneale, a beneficie d’une survie a long 
terme, exempte de rechute. Dans les cas de carcinomatose peritoneale, une survie 
libre de maladie, de longue duree, correspond a une tumeur peu agressive, a une 
chirurgie cytoreductive adequate et a une chimiotherapie intraperitoneale.
The surgical treatment of cancer is dictated by the anatomic lo­
cation of the tumour and its histo­
logic grade of malignancy. In le­
sions of low-grade malignancy, 
such as mucinous adenocarcinoma 
which may appear in the colon or 
appendix, resection including mini­
mal margins (less than 1 mm) of 
healthy tissue has resulted in cure. 
Unfortunately, when this tumour 
extends through the bowel wall, 
mucin-producing cells disseminate 
throughout the peritoneal cavity. 
The resulting clinical entity is com­
monly referred to as cystadenocar- 
cinoma, malignant pseudomyxoma 
peritonei or mucinous peritoneal 
carcinomatosis. In the past, it was 
considered impossible to render pa­
tients who had peritoneal carcino­
matosis clinically free of tumour.
I shall describe a technique for 
cytoreductive surgery and in­
traperitoneal chemotherapy and re­
port the results to date in a group 
of patients who had these treat­
ments for peritoneal carcinomatosis 
from colonic and appendiceal can­
cer.
Surgical Problems Posed by 
Peritoneal Carcinomatosis
From the Department o f  Surgery, Emory University School o f Medicine, Winship Clinic and 
Cancer Center, Atlanta, Ga.
Presented as the Du Pont Lecture at the annual meeting o f the Southern Ontario Surgical 
Society, Stratford, Ont., June 3, 1988
*Sponsored as visiting professor by Du Pont Canada Inc., Mississauga, Ont.
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Peritoneal carcinomatosis is char­
acterized by an “omental cake” of 
tumour attached to stomach and 
colon (Fig. 1). It can usually be 
removed by a combined omentecto- 
my-splenectomy; however, if the 
colon is encased by tumour, an 
en-bloc resection of omentum, 
spleen and abdominal colon may be 
necessary. Next to stomach and
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colon, the pelvic peritoneum is most 
frequently affected; the cul-de-sac is 
generally filled by tumour. Also 
involved are the undersurfaces of
FIG. 1. “Omental cake” is characteris­
tic of peritoneal carcinomatosis. It in­
volves omentum, spleen and may en­
case abdominal colon.
FIG. 2. Small-bowel sparing by perito­
neal implants. Even though thick lay­
ers of tumour are present on most 
abdominal surfaces, small-bowel sur­
face is relatively spared of tumour. 
Portions of small bowel fixed to ab­
dominal wall are at ligament of Treitz 
and terminal ileum. These sites may be 
encased in mucinous tumour.
the right and left hemidiaphragm, 
the right suprahepatic space be­
tween the diaphragm and liver and 
the inferior aspect of the liver (right 
subhepatic space) just above the 
right kidney. Tumour beneath the 
right hemidiaphragm may fix liver 
and diaphragm together. The right 
and left paracolic gutters may be 
filled by tumour adherent to perito­
neum. The fatty tissue of the porta 
hepatis, falciform ligament and less­
er omentum are often involved; the 
gallbladder and porta hepatis are 
commonly a single mass of cancer.
One aspect of this condition, not 
previously appreciated, is the rela­
tive sparing of small-bowel surfaces 
by tumour implants (Fig. 2), be­
lieved to be due to peristalsis. Only 
after several laparotomies will the 
small bowel become encased by tu­
mour, because tumour emboli ad­
here to abraded peritoneum and are 
trapped within fibrous adhesions on 
small-bowel surfaces. Continued 
growth of tumour within small- 
bowel adhesions makes cytoreduc- 
tion unsafe.1 However, early in the 
disease, removal of tumour from 
peritoneal surfaces can be accom­
plished without trauma to the small 
bowel. There are two exceptions to 
this tumour-sparing effect. The ter­
minal ileum and ligament of Treitz 
are both anchored to the re- 
troperitoneum. These anatomic 
sites are much less mobile than the 
remaining small bowel and may be 
encased by tumour. The terminal 
ileum must often be resected with 
the cecum. Wedge excision of small 
bowel at the ligament of Treitz may 
also be necessary.
The optimal timing for the cy­
toreductive procedure may not be 
the same in all patients. Ideally, 
removal of bulky tumour, including 
greater omentum, and opening up 
of all abdominal adhesions should 
be accomplished before in- 
traperitoneal chemotherapy is start­
ed. Some patients will be referred
for definitive treatment of peritoneal 
carcinomatosis shortly after explor­
atory laparotomy. They are often 
not capable, physically or emotion­
ally, of enduring a major abdominal 
procedure at that time. Placement 
of a peritoneal access device and 
several cycles of intraperitoneal che­
motherapy are used to preserve gas­
trointestinal function and reduce 
small-volume disease on peritoneal 
surfaces. If the disease does not 
disseminate to distant sites and the 
patient’s physical status improves 
over 4 to 6 months, then definitive 
treatment of peritoneal carcinoma­
tosis with cytoreductive surgery is 
indicated.
Surgical Technique for 
Cytoreduction
With sufficient courage, knowl­
edge of anatomy, patience and per­
sistence, the surgeon can dissect all 
peritoneal surfaces within the abdo­
men free of tumour using ball- 
tipped electrocautery on pure cut 
and at high voltage (Table I). Dis­
section with the ball tip just be­
neath the tumour leaves visceral 
structures intact, removing only the 
lesion and involved peritoneal sur­
faces. An important aspect of this 
technique is strong traction and 
countertraction between tumour 
and normal tissue (Figs. 3 to 5). 
This will expose vascular and ductal 
structures and avoid damage to 
them as the dissection proceeds. 
Electrocautery on pure cut evapo­
rates tumour tissue and does little 
damage to fibrous tissue and nor­
mal fat, so normal anatomic struc­
tures encased in fat but covered by 
mucinous tumour should not be 
affected. Tissues rich in collagen, 
such as ureters, large blood vessels, 
common duct and intestinal wall 
may be severely damaged unless the 
surgeon’s technique is meticulous 
and these structures are irrigated
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frequently with cool water during 
the procedure.
The undersurface of the dia­
phragm poses special problems. If 
the ball-tipped electrocautery con­
tacts diaphragmatic muscle, marked 
unpredictable contractions occur; 
the cautery tip may perforate the 
hemidiaphragm or pericardium. Tu­
mour in this area is best removed 
using a combination of blunt dissec­
tion and contact yttrium-aluminum- 
garnet (YAG) laser. The latter will 
maintain hemostasis and a margin 
of dissection but will not cause 
contractions of diaphragmatic mus­
cle. An essential piece of equipment 
for this procedure is the laser 
smoke evacuator, which minimizes 
the foul odour and excessive 
smoke, thus maintaining the sur­
geon’s view of the operative field, 
and eliminates the possible inhala­
tion hazard to operating-room per­
sonnel.
In patients who must undergo 
reoperation, tumour within fibrous 
adhesions must be removed from 
small-bowel surfaces, and this can 
be hazardous. Frequent irrigation 
of the operative site with saline will 
minimize the possibility of full­
thickness thermal damage to bowel 
wall. If multiple areas of the bowel 
are damaged, then a high, diverting 
loop jejunostomy should be 
brought out through a transverse 
incision in the left upper quadrant. 
This will prevent the formation of 
small-bowel fistulas and associated 
intraperitoneal sepsis. When pelvic
tumour implants are removed there 
may be trauma to the large bowel, 
requiring temporary exteriorization 
of the sigmoid colon. The ostomies 
are closed when bowel integrity is 
demonstrated radiologically.
Cytoreduction of tumour in the 
porta hepatis presents a special 
problem. Cystadenocarcinoma char­
acteristically implants and grows in 
the “nooks and crannies” of the 
abdomen. The recesses created by 
the gallbladder, falciform ligament 
and common-duct structures are 
usually heavily involved by tumour. 
An ultrasonic dissector has been a 
valuable tool by which to remove 
the mucinous cancer (high in water 
content) from around the vital tubu­
lar structures (high in collagen con­
tent) that constitute the porta hepa­
tis.2
Gross tumour within the lesser 
omentum may require a lesser 
omentectomy with sacrifice of the 
right branch of the vagus nerve and 
a portion of the left gastric artery. 
If this is needed, a gastric drainage 
procedure (pyloroplasty or gas­
trojejunostomy) should be per­
formed.
Technique for Immediate 
Postoperative Intraperitoneal 
Lavage
When the dissection is complet­
ed, a Tenckhoff catheter is placed 
through the abdominal wall at a 
convenient location lateral to the
Table I. Requirements for Dissection of Gastrointestinal Tumour From Peritoneal Surfaces
1. Meticulous bowel preparation, removing bacteria and fungus from the gastrointestinal tract.
2. Electrocautery machine placed on high voltage, pure cut, with the ball tip employed for tissue 
contact.
3. Strong traction-counter traction placed at the tumour-healthy tissue interface.
4. Use of laser smoke evacuator.
5. Frequent irrigation for cooling nearby tissues when the dissection is used adjacent to a vital 
structure such as small bowel, ureter or common duct.
6. Wide exposure using a self-retaining retractor.
7. Postoperative peritoneal lavage to remove tissue debris. Large-volume instillations in the 
immediate postoperative period should contain antibiotics.
8. Intraperitoneal chemotherapy to minimize the recurrence of microscopic residual disease. 
Lavage fluid should contain antibiotic agents.
rectus muscles and anchored at the 
peritoneal level by a pursestring 
suture.
Postoperatively, the abdominal 
cavity is lavaged for 24 hours with 
a dialysis solution containing antibi­
otics. This will remove blood and 
tissue debris, which may plug the 
catheter, and will help prevent in­
fection and the formation of adhe­
sions (Table II).
FIG. 3. Mucinous tumour implant on 
peritoneal surface overlying pancreas.
FIG. 4. Traction at tumour-normal 
tissue interface. Ball-tipped electrocau­
tery on pure cut at high voltage is 
used to evaporate tumour and separate 
it from normal tissue.
FIG. 5. Tumour-free abdominal surface 
following electrocautery dissection. 
Damage to underlying pancreatic tis­
sue is minimal.
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To minimize catheter-related 
complications, there must be meti­
culous hemostasis, and the perito­
neal cavity must be irrigated clear 
of blood and clots before the abdo­
men is closed. Cytotoxic agents 
used for intraperitoneal chemother­
apy prevent neutrophil replication 
within the abdominal cavity for the 
first week postoperatively, so antibi­
otics are needed in the lavage solu­
tion to control bacterial growth.
Drains in the abdomen should be 
of the closed suction type, placed 
low in either flank so that they can 
be used for dependent drainage if 
peritonitis occurs (Fig. 6). When 
early postoperative intraperitoneal 
chemotherapy is completed and in­
traperitoneal drainage ceases, the 
Romel tourniquets, used to provide 
a watertight seal, are removed. This 
allows gravity drainage of any re­
curring intra-abdominal fluid, which 
will help to prevent late abscess 
formation. It also facilitates removal 
of the suction drains, which are 
usually placed beneath the left he- 
midiaphragm and occasionally with­
in the pelvis.
Peritoneal lavage can be per­
formed postoperatively in patients 
who have ostomies, but leakage of 
intraperitoneal fluid will be exces­
sive unless the bowel wall is se­
cured circumferentially with individ­
ual sutures to the peritoneum plus 
fascia.3
Intraperitoneal Chemotherapy
Cytoreductive surgery to remove 
malignant tumour usually results in 
limited short-term benefit to pa­
tients. Bowel obstruction can be
relieved and bulk tumour removed. 
Yet long-term disease-free survival 
cannot be achieved unless the ex­
tensive tumour contamination of 
intra-abdominal surfaces can be 
controlled. The use of early and 
delayed postoperative intraperito­
neal chemotherapy has been used 
successfully to eliminate from the 
abdominal cavity single cancer cells 
and tumour emboli. These malig­
nant foci become imbedded in the 
fibrinous exudate that accumulates 
on raw tissue surfaces within the 
abdomen after surgical trauma.4 
They develop into recurrent peri­
toneal carcinomatosis over time no 
matter how complete the surgical 
cytoreduction.
Intraperitoneal chemotherapy has 
been used to combat the regrowth 
of cancer within the fibrous adhe­
sions that form after cancer sur­
gery. Optimally, the drugs should 
be instilled in a large volume of 
fluid to distend the abdomen and 
reach all exposed surfaces. The che­
motherapy does not penetrate tu­
mour masses of appreciable size but 
should destroy all small-volume dis­
ease. It is best utilized in the first 5 
postoperative days when drug dis­
tribution to all intra-abdominal sur­
faces is complete. Delayed postoper­
ative intraperitoneal chemotherapy 
is designed to augment the effects 
of the surgery and the early postop­
erative intraperitoneal chemothera­
py. Drug distribution is less uni­
form after abdominal adhesions 
have formed and retroperitoneal fi­
brous reaction has occurred. The 
current plan for early and late in­
traperitoneal chemotherapy for 
large bowel tumours is shown in 
Table III.
Patient Groups
Forty-seven consecutive patients 
with advanced primary or recurrent 
colorectal or appendiceal tumours 
underwent laparotomy and cytore­
ductive surgery; none were merely 
explored surgically, the abdomen 
closed and no further action con­
templated. They ranged in age from 
16 to 74 years. They were divided 
into four groups. Group 1 (18 pa­
tients) represented the ideal situa­
tion in which patients had grade 1 
or less mucinous cancer. All had 
malignant pseudomyxoma perito­
nei; no patient had benign mucocele 
of the appendix.1 Group 2 patients 
(17) had moderate- to high-grade 
mucinous colonic or rectal adeno­
carcinoma implanted on peritoneal 
surfaces, but had no hematogenous 
or distant lymphatic metastases. 
Group 3 patients (eight) had either 
high- or low-grade tumour that had 
been treated with radiation (abdomi­
nal or pelvic) or intraperitoneal io- 
dine-131 monoclonal antibody. 
Group 4 (four) had peritoneal carci­
nomatosis and, subsequently, dis­
tant metastases.
In each group of patients, some 
were treated with intraperitoneal 
chemotherapy and some were not. 
In patients who did not receive 
intraperitoneal chemotherapy, ab­
dominal infection or an adhesive 
process developed that prevented
FIG. 6. Romel tourniquet used to pro­
vide watertight seal around closed suc­
tion drains inserted through generous 
stab incisions.
Table II. Abdominal Lavage Instilled Immediately After Completion of Surgery
1. Instill 1 litre 1.5% dextrose peritoneal dialysis fluid as rapidly as possible. The fluid should 
contain antibiotics for broad-spectrum coverage.
2. One hour dwell time, drain fluid as rapidly as possible.
3. Repeat instillations every 1 hour four times, then every 4 hours four times, then every 8 hours 
until chemotherapy begins.
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drug delivery by a peritoneal access 
device.
Results
All of the low-grade mucinous 
tumours were of appendiceal origin. 
Moderately differentiated but clini­
cally nonmetastasizing tumours 
originated in the appendix (six) and 
other parts of the colon (eleven). 
Nearly all of the 47 patients were 
symptomatic before they were treat­
ed for peritoneal carcinomatosis. 
The asymptomatic patients had le­
thal seeding of peritoneal surfaces, 
established by a previous laparoto­
my and a rising carcinoembryonic 
antigen level.
The short-term results of the 
ball-tipped electrocautery technique 
were surprisingly good. All patients 
but one had at least transient relief 
of intestinal obstruction. Patients 
who seemed to profit most over the 
long term had three clinical features 
in common (Table IV). First, and 
most important, they did not have 
distant lymphatic or hematogenous 
spread of the disease. Of four pa­
tients with metastases (group 4), 
only one remains disease free, and 
he underwent a pneumonectomy for 
lung metastases. Second, patients 
who were made clinically disease 
free by cytoreductive surgery 
seemed to be in a favourable group, 
even though some required several 
staged surgical procedures to reach 
this status. Of course, a larger 
proportion of low-grade cancers 
were completely removed. Finally, 
only patients who had in- 
traperitoneal chemotherapy or im­
munotherapy, in addition to sur­
gery, remained well for long peri­
ods. Over half of the patients with 
mucinous adenocarcinoma may be 
expected to have prolonged disease- 
free survival. They represent the 
first report of cure after treatment 
for peritoneal carcinomatosis.
Unfortunately, in these early clin­
ical studies, these favourable results 
were not obtained without cost. The 
majority of patients who had cy­
toreductive surgery after abdominal 
radiotherapy had bowel perforation 
postoperatively. A similar complica­
tion occurred in four of the patients
who did not have preoperative ab­
dominal radiotherapy. There were 
no cases of anastomotic breakdown. 
Of the patients who did not have 
radiotherapy preoperatively, six had 
peritonitis in the presence of an 
intact bowel. The organisms were 
Staphylococcus epidermidis and 
Candida albicans. There were two 
postoperative deaths, one from 
staphylococcal pneumonia and the 
other from the formation of multi­
ple fistulas in a patient who had 
irradiated bowel.
Discussion
Complications of cytoreductive 
surgery are frequent, the most se­
vere being seen in patients who 
have previously undergone abdomi­
nal or pelvic radiotherapy. I recom­
mend that such patients be exclud­
ed from this treatment plan unless 
all of the irradiated tissue can be 
resected.
If this procedure is attempted in 
the presence of invasive tumours, 
there may be dangerous hemorrh-
Table III. Early and Delayed Postoperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Large-Bowel Cancer
Cycle
Time 1 2* 3* 4*
Day of surgery 
Postop day 1
Abdominal lavage only 
Mit C 10 mg/m2 in 1 L 1.5% 5-FU 900 mg/m2 plus 50 Mit C 12 mg/m2 in 2 L 5-FU 900 mg/m2 plus 50
Postop day 2
dextrose dialysate solution. 
Infuse as rapidly as 
possible; 23-hour dwell 
time. Maximum dose 20 
mg. Drain abdomen 
completely before next 
instillation
5-FU 800 mg/m2 plus 50
mmol sodium bicarbonate 
in 2 L 1.5% dextrose 
dialysate solution. Infuse as 
rapidly as possible; 24-hour 
dwell time and no drainage
Same dose of 5-FU in 1 L 5-FU 900 mg/m2 plus 50
mmol sodium bicarbonate 
in 2 L
Same dose of 5-FU in 1 Lto 5 mmol sodium bicarbonate solution. The soft tube used mmol sodium bicarbonate
Postop day 6
in 1 L 1.5% dextrose 
dialysate solution. Infuse as 
rapidly as possible; 23-hour 
dwell time. Maximum dose 
1600 mg. Drain abdomen 
completely before next 
instillation
Drain abdominal cavity as 
completely as possible and 
remove Tenckhoff catheter.
for peritoneal access is 
removed after instillation 
on day 5
in 1 L
‘ Approximately 4 weeks separate cycles of intraperitoneal chemotherapy; drugs are instilled through a soft catheter positioned by paracentesis. Mit C =  
mitomycin C, 5-FU =  5-fluorouracil.
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age, damage to vital structures and 
an unsatisfactory surgical result. 
When tumours are invasive, dissec­
tion must be carried onto normal 
tissue. For low-grade lesions, it is 
adequate and safe, constituting ac­
ceptable principles of surgical on­
cology, to remove the tumour 
through the interface of normal and 
tumour tissue. However, when the 
tumour is of moderate- or high- 
grade malignancy, reasonable pallia­
tion can sometimes be achieved and 
long-term survival may result if 
distant metastasis does not occur. 
Cytoreductive surgery should be ac­
companied by intraperitoneal che­
motherapy because satisfactory pal­
liation or long-term disease-free 
survival was not achieved without 
it.
The Roswell Park group5 had 
excellent results when they used 
intraperitoneal cis-platinum chemo­
therapy in patients with ovarian 
cancer who had intra-abdominal 
tumour nodules 1 cm in diameter or 
smaller. A group from the Nether­
lands6 obtained good responses in 
patients treated with mitomycin C 
when there were only small tumour 
nodules in the abdominal cavity. 
We7 had good results with cytore­
ductive surgery plus intraperitoneal 
5-fluorouracil and mitomycin C in 
patients who had malignant mucin­
ous adenocarcinoma of colonic or 
appendiceal origin. Intraperitoneal 
chemotherapy in the presence of 
small-volume tumour may benefit 
patients with malignant disease dis­
seminated throughout the peritone­
al cavity.1
In selecting patients for cytore­
ductive surgery, certain factors 
must be considered. With moderate- 
or high-grade tumour, the long­
term disease-free survival is usually 
limited and metastases may occur at 
other sites, causing death. In these 
patients, the standard surgical indi­
cations for palliative surgery (intes­
tinal obstruction or uncontrollable 
abdominal distension from tumour 
or ascites) should be the indications 
for surgery.
Malignant pseudomyxoma perito­
nei will never metastasize, so, if the 
tumour is removed from the abdom­
inal cavity, these patients can be 
cured; the indication for cytoreduc­
tive surgery is the presence of the 
tumour itself, not any associated 
symptoms. Patients with pseudo­
myxoma peritonei may be expected 
to have a good prognosis with this 
treatment plan.
Patients with colonic adenocarci­
noma of the mucinous histologic 
type were also treated in this series. 
This tumour is locally more inva­
sive, so that a complete cytoreduc- 
tion is more difficult. Also, residual 
tumour is more solid and has a 
well-developed vasculature. This 
means that tumour penetration by 
chemotherapy will not be as great 
as with malignant pseudomyxoma 
peritonei. When tumour cells are 
suspended in an avascular protein 
gel (mucinous ascites), the chemo­
therapy diffuses into the mass, is 
not metabolized or removed and 
may be expected to exert maximal
Tab le  IV . Results of Treatment of Patients With Peritoneal Carcinomatosis
G ro up
Result 1 2 3 4
No. of patients 18 17 8 4
NED after operation 11 7 3 1
Primary site
Appendix 17 6 1 1
Colon 0 11 7 3
Unknown 1 _ _ _
Symptoms/signs
Bowel obstruction 3 5 5 2
Massive ascites 8 5 2 0
Abdominal mass 3 4 0 1
Rising CEA 4 3 1 1
Complications after cytoreductive surgery*
Peritonitis 3 3 0 0
Bowel perforation 2 2 6 0
Prolonged ileus 2 3 1 0
Abscess 2 0 0 0
Intraperitoneal chemotherapy/no intraperitoneal chemotherapy 13/5 14/3 3/5 4/0
NED 9/ 2T 6/0 3/0 1/0
AWD 2/0 5/1 0/0 0/0
DOD 0/2 3/2 0/4 2/0
DOC 2/1 0/0 0/11 1/0
NED =  no evidence of disease, CEA =  carcinoembryonic antigen, AWD =  alive with disease, DOD =  died of disease, DOC =  died of other causes.
'One patient died of staphylococcal pneumonia.
tBoth patients received 15 cycles of 7-interferon intraperitoneally; they were the only ones in the series who had no evidence of disease in the absence 
of intraperitoneal chemotherapy.
JDied with multiple small-bowel perforations.
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cell kill. Well-vascularized tumour 
nodules and normal structures rap­
idly remove chemotherapeutic 
agents by lymphatic channels and 
the capillary network. In summary, 
one expects intraperitoneal chemo­
therapy to produce its greatest cell 
kill when the tumour is avascular. 
This is just the opposite of chemo­
therapy given by the intravenous 
route.
Even though mucinous colonic 
adenocarcinoma may invade intra­
abdominal structures and implant 
widely on all peritoneal surfaces, it 
rarely metastases by lymphatic or 
hematogenous routes. By the theo­
ries of metastases suggested by 
Weiss,8 this tumour would have a 
metastatic inefficiency of infinity.
One may question the use of the 
ball-tipped electrocautery on pure 
cut at high voltage. Its advantages 
are speed, accuracy of dissection 
and hemostasis. A large amount of 
tumour tissue can be removed rap­
idly at one session, without the 
extensive blood loss that results 
from sharp dissection. Even the 
smallest amount of blood in the 
operative field will interfere with 
exposure and may result in damage 
to vital structures. Unless large ves­
sels are transected, the electrocau­
tery maintains absolute hemostasis 
and cleanly defines the plane of 
dissection between tumour and nor­
mal tissue. Early in the course of 
his experience, the surgeon will 
recognize the characteristic features 
seen when transecting tumour, fat, 
abdominal adhesions or vital struc­
tures.
Long-term (3 years) disease-free 
survival was seen in the majority of 
patients with nonmetastasizing tu­
mour in this series. These clinical 
data suggest that a combination of 
cytoreductive surgery with the ball- 
tipped electrocautery on pure cut at 
high voltage followed by in­
traperitoneal chemotherapy can 
cure selected patients with malig­
nant large-bowel cancer on perito­
neal surfaces.
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SESAP VI Critique
Item 105
Hyperchloremic metabolic acidosis is a recognized complication of 
diverting urine through an ileal segment. The problem occurs with 
varied incidence after construction of an ileal or colonic conduit, a 
continent ileal pouch, or a ureterosigmoidostomy. It may be seen in 
patients with normal renal function and in the absence of systemic 
electrolyte changes. Hyperkalemic, hypochloremic metabolic acidosis 
can occur when jejunal rather than ileal segments are used for urinary 
diversion.
Physiologic explanations of hyperchloremic metabolic acidosis in­
clude: selective reabsorption of urinary chloride by the ileal mucosa; a 
renal acidifying defect; reabsorption of ammonium chloride, and bicar­
bonate secretion by the colon in response to local introduction of urine.
The absence of significant changes in serum chloride or total C02 
should not be equated with an absence of metabolic abnormalities after 
urinary diversion. Therapy for hyperchloremic metabolic acidosis must 
include restriction of chloride intake, because of the relationship 
between chloride reabsorption and acid reabsorption. m
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Periosteal Neochondrogenesis for 
Biologically Resurfacing Joints: Its 
Cellular Origin
Rick Zarnett, MD, MSc;* Robert B. Salter, OC, MD, FRCSCt
The purpose of this study was to determine if the hyaline-like cartilage produced in 
major full-thickness defects of a joint surface, treated by a free periosteal graft and 
subjected to continuous passive motion (CPM), originated exclusively from the 
progenitor cells of the cambium of the graft. Free periosteal grafts were raised from 
the tibia of both hind legs of eight male New Zealand rabbits and transplanted into 
full-thickness defects across the entire width of the patellar groove of 15 female 
rabbits. Postoperatively, CPM was instituted and the animals were sacrificed after 3 
weeks. Cells from the regenerated tissue were grown from tissue explants and their 
karyotypes determined. In 33% of the rabbits, all cells contained a Y (male) 
chromosome, indicating that regenerated tissue originated exclusively from the 
progenitor cell of the periosteal graft. Karyotypes of the cells from the other 67% 
were mosaics (both female and male); thus, their cellular origin was from both the 
periosteal allograft and the pluripotential mesenchymal cells in the subchondral 
tissues.
Le but de la presente etude consistait a determiner si le cartilage de type hyalin, qui 
apparait quand des dysplasies interarticulaires majeurs sont traitees par greffe 
periostique libre et soumises a une mobilisation passive continue (MPC), provient 
exclusivement des cellules souches du cambium du greffon. Ces greffons ont ete 
obtenus a partir des tibias des membres inferieurs de huit lapins New Zealand 
males. Its ont ete transplants chez 15 lapines, dans des dysplasies completes sur toute la 
largeur de la gouttiere rotulienne. Apres l’operation, une MPC fut mise en place et les 
animaux furent sacrifies apres 3 semaines. Les cellules du tissu regenere furent mises en 
culture et leurs karyotypes furent determines. Chez 33% des lapines, toutes les cellules 
contenaient le chromosome Y (male), indiquant que le tissu de regeneration provenait 
exclusivement des cellules du greffon periostique. Le karyotype des cellules des 67% 
restant etait constitue d’une mosai'que (male et femelle); en consequence, leur origine 
cellulaire venait, a la fois, de l’allogreffe periostique et des cellules mesenchymateuses 
pluripotentes du tissu sous-chondral.
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P rosthetic joint replacement is a major advance in the treatment 
o f degenerative joint disease, but 
possible residual loosening and in­
fection make the procedure unac­
ceptable in the young or active 
person.
Recent investigations1"3 at our 
research laboratory demonstrated 
that major, full-thickness defects in 
a joint surface can be “ biologically 
resurfaced” by stimulating the cam­
bium of free periosteal grafts with 
continuous passive motion (CPM).
In a previous study,4 free autoge­
nous periosteal grafts were labelled 
with tritiated thymidine to deter­
mine if the cellular origin of the 
hyaline-like cartilage was progeni­
tor cells of the periosteal graft. This 
method enabled us to follow the 
pluripotential cells o f the cambial 
layer o f the grafts as they passed 
through the stages of neochon­
drogenesis. We were able to con­
clude that the thymidine-labelled 
cells in the regenerated tissue had 
originated from the periosteal graft. 
We were, however, unable to com­
ment on the origin of the entire 
mass o f regenerated tissue.
The rabbit has 22 pairs of chro­
mosomes.56 The 21 pairs of auto- 
somes can be arranged in descend­
ing order of length and numbered 
serially (Fig. 1). Chromosome pairs 
20 and 21 are the shortest 
acrocentric chromosomes, corre­
sponding to group G in the human 
karyotype. The acrocentric Y chro­
mosome is the smallest of the ka-
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ryotype and can be placed in a 
morphologic group with chromo­
some pairs 20 and 21.56 Thus, it is 
possible to differentiate between the 
karyotype of a female and a male 
cell by establishing if four or five 
small acrocentric chromosomes are 
present.
If an allograft of periosteum 
could be transplanted from a male 
to a female rabbit, the cells derived 
from the pluripotential cells of the 
cambial layer of the periosteum 
would carry a recognizable label 
(i.e., the Y chromosome). This label 
would not become diluted as the 
cells underwent subsequent mitosis.
This experiment was designed to 
answer the following question: Does 
the entire regenerated hyaline-like 
tissue originate from the progenitor 
cells of the periosteal graft or do 
the subchondral tissues provide plu­
ripotential cells which contribute to 
the “biological resurfacing” of 
these major, full-thickness defects?
Material and Methods
Twenty-three (15 female, 8 male) 
adolescent, New Zealand rabbits, 
weighing between 2.2 and 2.8 kg, 
were used as models. The surgical 
procedures were performed under 
general anesthesia induced by an 
intravenous injection of sodium 
pentobarbital (25 m g/kg body 
weight) and maintained by an inha­
lation mixture of 1% halothane, 
60% nitrous oxide and 39% oxygen.
In the male rabbit, the skin of the 
hind limbs was shaved from the hip 
to the ankle and prepared with 
povidone-iodine. A medial skin inci­
sion (6 cm long) was made over the 
proximal tibia, and a rectangular 
incision 7.5 X 15 mm was made in 
the underlying periosteum of both 
hind limbs. The periosteal graft was 
carefully elevated from the underly­
ing tibia by sharp subperiosteal dis­
section, and to distinguish the two
individual layers of periosteum a 
blue 5-0 polypropylene suture was 
placed in the fibrous layer of each 
graft. The grafts were placed in 
0.9% sterile saline solution until 
transplantation.
Each female rabbit was anesthe­
tized and the appropriate limb pre­
pared as in the donor. A medial 
arthrotomy of one knee joint was 
performed on each rabbit. The pa­
tella was dislocated laterally and the 
allograft of periosteum transplanted 
into a 5-mm full-thickness defect 
across the entire patellar groove, as 
previously described3 4 (Fig. 2).
While under anesthesia, the ani­
mals were placed on the CPM appa­
ratus where they remained until 
they were killed 3 weeks later.7
Tissue Culture
The involved knee joints were 
exposed under sterile conditions. A 
portion of the newly formed tissue 
from the patellar groove was re­
moved and placed in a Petri dish 
containing cold sterile phosphate- 
buffered saline (PBS). The sample 
was obtained from the centre of the 
defect, well above the underlying 
subchondral bone, in order to avoid 
contamination by the surrounding 
host (female) tissue.
To confirm the biopsy location, 
50% of the knees (randomly select­
ed) were fixed, decalcified and 
stained as previously described.4 
This allowed us to observe any 
signs of graft rejection.
FIG. 1. Karyotype of rabbit contains 22 pairs of chromosomes. As in human, male 
contains five small acrocentric chromosomes (pairs 20 and 21 plus Y). In contrast, 
female has only four small acrocentric chromosomes (pairs 20 and 21).
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FIG. 2. (Left) Transverse section through male periosteal allograft lying or 
subchondral bone. Cambium of graft faces into joint. Base of defect is flat in 
contrast to contour of patellar groove. (Right) Lateral view of periosteal graft 
sutured to periosteum of femur. Depth of defect varied from 2 mm in centre of 
groove to 5 mm at edge.
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The tissue sample was trans­
ferred to a sterile Petri dish with 3 
to 4 ml of medium, consisting of 
alpha minimal essential medium 
(MEM) supplemented with 15% fetal 
calf serum (FCS), penicillin (100 
units/m l), streptomycin (100 
mg/ml) and amphotericin B (2.5 
Mg/ml). The tissue was then cut 
into pieces approximately 0.5 mm2 
and 6 to 10 pieces were transferred 
to each of four Falcon plastic cul­
ture flasks. The flasks were placed 
upright for 30 minutes in the incu­
bator to allow the tissue explants to 
attach firmly to the flasks. With 10 
ml of medium the explants were 
incubated at 37°C in 95% humidi­
fied air plus 5% carbon dioxide. The 
medium was changed twice weekly.
Subculture Technique
At 4 to 6 weeks, the cells were 
separated from the flasks with 
0.25% trypsin/ethylene diamine 
tetra-acetic acid, and secondary cul­
tures were established on sterile 
glass microscope slides, which were 
placed in culture dishes and incu­
bated for a further 48 hours.
Harvesting of Chromosomes
After the 48 hours, colcemid 
(concentration 0.67 Mg/ml) was 
added to the medium and the Petri 
dishes were incubated for 3 more 
hours, after which the medium was 
removed and the cells were hypoto- 
nically expanded using 0.075 M 
potassium chloride.
Fixing the Cells
Ten millilitres of a 3:1 mixture of 
ice-cold methanol and glacial acetic 
acid were slowly added to the dish­
es, allowing the cells to fix for 15 
minutes. This procedure was re­
peated three times. The cells were 
spread and flattened on the glass 
slides and the chromosomes were 
then stained with Giemsa solution.
Examination for Chromosomes
The slides were screened under 
low power (125X) and chromosome 
spreads identified for counting and 
photography. When a cell in which 
all the chromosomes were clearly 
defined was identified, it was exam­
ined further under high power 
(1250X) and the number of 
acrocentric chromosomes (four indi­
cating a female karyotype and five 
indicating a male karyotype) docu­
mented.
Results
Tissues from the transplanted 
knees of the 15 female rabbits were 
studied. The first four rabbits made 
up a pilot group; their knees were 
examined for evidence of graft re­
jection. Of the remaining 11 rab­
bits, 1 was excluded because of a 
dislocated patella and 1 because the 
periosteal graft had become de­
tached from the subchondral bed. 
This left nine animals for chromo­
somal analysis of the regenerated 
tissue.
Gross Findings
In all rabbits, the patellar groove 
was fully restored; the defects were 
filled in by smooth tissue resem­
bling hyaline articular cartilage. 
There was no evidence of graft 
rejection.
Histologic Findings
The surface of the regenerated 
tissue was smooth and resembled 
hyaline articular cartilage. Round 
chondrocytes were contained in
well-formed lacunae. The extracel­
lular matrix stained well with Safra- 
nin O, indicating glycosaminogly- 
can production.
After 3 weeks of CPM there was 
no histologic evidence of graft re­
jection or cellular infiltration in the 
regenerated tissue.
Tissue samples from four knees 
were examined histologically. The 
sample was always taken from the 
central and superficial area of the 
graft, thus avoiding both the regen­
erated tissue in the base of the 
defect and the normal articular car­
tilage.
Chromosomal Analysis
The tissue explants grew slowly; 
it took 4 to 6 weeks for a sufficient 
number of cells to be available for 
subculture. A minimum of two 
flasks containing between 6 and 10 
tissue explants each were examined 
to give a wide sampling of tissue. 
The karyotypes of 194 cells were 
determined (average 21.6 cells/rab- 
bit).
In three of the nine female rab­
bits, 100% of the cells examined 
carried the male karyotype, proving 
that all these cells had differentiated 
from the pluripotential cells in the 
cambium of the periosteal graft 
(Fig. 3). In the other six rabbits, the 
karyotypes were sexual mosaics, 
containing both female (host) and 
male (graft) cells (Fig. 4).
Discussion
In their original investigation on 
the “biological resurfacing’’ of 
joints, O’Driscoll and colleagues3 
reported that in 20% of the control 
animals (i.e., those that did not 
receive a periosteal graft), hyaline 
cartilage was the predominant tis­
sue formed. In addition, 1-mm full­
thickness defects are capable of
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healing with hyaline-like cartilage 
when stimulated by CPM.8 There­
fore, the subchondral tissues can 
produce hyaline-like cartilage, al­
though it is inferior in quantity and 
quality to the tissue formed when 
full-thickness defects are grafted 
with periosteum.9
The present investigation demon­
strated that the hyaline-like carti­
lage produced when free periosteal 
grafts are transplanted into full­
thickness defects is not derived en­
tirely from the periosteal graft; in 
67% of rabbits the regenerated tis­
sue had a cellular origin from both 
periosteal graft and the subchondral 
tissues. In the remaining 33% the 
periosteal graft was exclusively re-
m
TV >
FIG. 3. Photomicrograph of chromo­
somal spread contains five small 
acrocentric chromosomes (arrows), 
proving that it originated from perios­
teal graft.
FIG. 4. This cell contains four small 
acrocentric chromosomes (arrows) and 
is therefore female. It has its origin 
from undifferentiated mesenchymal 
cells in subchondral tissues.
sponsible for the cellular origin of 
the regenerated tissue.
Early attempts at “biological re­
surfacing” failed because the tis­
sues underwent either necrosis and 
degeneration or, at best, conversion 
to fibrous tissue.10 Hoover and Cov­
entry11 believed that the various 
interposition materials acted only as 
a culture medium and had no effect 
on the ultimate repair tissue on the 
joint surface. Ruback and associ­
ates9 placed a cell-impenetrable fil­
ter between the cancellous bone and 
a periosteal graft in an attempt to 
demonstrate the origin of the carti­
lage-like tissue regenerated in their 
experimental model. At 4 to 8 
weeks, all the filters had fractured, 
making the contribution to the re­
pair tissue from the underlying 
bone difficult to assess. Because the 
cells represented clonal outgrowths 
from tissue explants, the proportion 
of male and female cells is an 
unreliable indicator of the actual 
proportion of tissue derived from 
each of the two sources.
We demonstrated that the hya­
line-like cartilage, either totally or 
in part, originates from the perios­
teal graft. Thus, the periosteum is 
of primary importance in this “bio­
logical resurfacing” model.
Conclusions
The hyaline-like cartilage pro­
duced when a free periosteal graft is 
transplanted into a major full-thick­
ness articular defect in a joint sur­
face and subjected to continuous 
passive motion, is derived either 
totally or in part from the periosteal 
graft. In two-thirds of the animals 
in this study, the subchondral tis­
sues provided pluripotential cells 
contributing to neochondrogenesis.
We thank Mr. Ajai Kumar and Mrs. 
Chin Ho for technical assistance. This 
research project was approved by the
Animal Experimentation Committee at 
The Research Institute, The Hospital 
for Sick Children, Toronto.
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Does Endoscopy Really Help the Surgeon 
Evaluate Gastric Cancer?
Nadey S. Hakim, MD, FRCS; Michael G. Sarr, MD, FACS; Jon A. van Heerden, MD, FRCSC
To determine whether gastroscopy helps the surgeon in preoperative planning and 
decision-making in patients with gastric cancer, the authors reviewed the charts of 100 
consecutive patients with surgically proven gastric cancer. The findings from 
gastroscopy, upper gastrointestinal series and computed tomography were evaluated for 
their ability to define the anatomic site of the lesion, proximal and distal extent of gastric 
involvement, presence of a mass or ulceration and the sensitivity of diagnosis. The 
sensitivity of endoscopic biopsy and brush cytology were also determined. Gastroscopy 
was found to be the most sensitive diagnostic test, both in recognizing the presence of an 
abnormality (100% versus 86% versus 76% respectively) and the possibility of a malignant 
condition (88% versus 71% versus 76%); in addition, endoscopic biopsy and brush 
cytology were diagnostic in 90% and 70% of patients, respectively. Gastroscopy and upper 
gastrointestinal series were equally accurate in determining proximal or distal extent of 
tumour. The authors concluded that gastroscopy is the most sensitive diagnostic test in 
patients with gastric cancer; upper gastrointestinal series does not add significantly 
useful information to the preoperative evaluation. Computed tomography can assess 
regional and distant metastasis, but its contribution as to the local extent of the tumour is 
limited.
Les auteurs ont etudie les dossiers medicaux de 100 patients consecutifs porteurs de 
cancers gastriques demontres a la chirurgie, afin d’etablir si, dans le cancer gastrique, la 
gastroscopie aidait le chirurgien dans sa planification preoperatoire et dans sa prise de 
decision. Les resultats des examens de gastroscopie, des cliches en serie des voies 
digestives hautes et de la tomodensitometrie ont ete mis en parallele pour etablir leur 
capacity de definir le siege de la tumeur, l’etendue proximale et distale de l’atteinte 
gastrique, la presence d’une masse ou d’ulceration et la sensibilite diagnostique. On a 
aussi determine la sensibilite de la biopsie endoscopique et de l’examen cytologique par 
brassage. La gastroscopie s’est averee le test diagnostique le plus sensible, tant pour 
reconnaitre la presence d’une anomalie (100% contre 86% et 76%, respectivement), que 
pour prevoir la possibility qu’il s’agisse d’une affection maligne (88% contre 71% et 76%); 
la biopsie endoscopique et la cy tologie par brassage avaient une valeur diagnostique chez 
90% et 70% des patients, respectivement. La gastroscopie et les cliches en serie des voies 
digestives superieures etaient d’une egale precision pour determiner l’etendue proximale 
et distale de la tumeur. Les auteurs concluent que la gastroscopie represente l’instrument 
diagnostique le plus sensible dans les cas de cancer de l’estomac; les cliches en serie des 
voies digestives n’ajoutent pas vraiment d’information utile a 1’evaluation preoperatoire. 
La tomodensitometrie peut evaluer les metastases regionales et a distance, mais sa 
contribution a 1’evaluation de l’etendue locale est limitee.
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F lexible fiberoptic gastrointestinal endoscopy has become a well- 
established procedure for evaluating 
the esophagus, stomach and duode­
num. In several studies'-4 the diagnos­
tic accuracy of radiologic contrast 
examination of the upper intestine has 
been compared with endoscopic tech­
niques. Contrast roentgenography 
was found to be accurate in at least 
90% of patients, and several authors3-4 
have advised that endoscopic exami­
nation be reserved for patients in 
whom the results of radiologic assess­
ment are inconclusive or when a 
histologic diagnosis of malignancy is 
required.
The purpose of this study was to 
compare, retrospectively, the accura­
cy of gastroscopy, conventional upper 
gastrointestinal roentgenography and 
computed tomography and to corre­
late results with surgical findings and 
the final pathology report, in patients 
with proven gastric carcinoma. Our 
aim was to determine if any of the tests 
provide more information than others 
to assist the surgeon in planning 
operative strategy.
Methods
One hundred consecutive patients 
seen at the Mayo Clinic between 1985 
and 1987 with surgically confirmed 
gastric cancer were studied retrospec­
tively. Only those who underwent 
preoperative gastroscopy carried out 
by a member of our group were 
included. The results of endoscopy 
and the histopathologic report of bi­
opsies or cytologic study were taken 
from the original records. The find­
ings of upper gastrointestinal con­
trast roentgenography and computed
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tomography, when performed in addi­
tion to the endoscopy, were also re­
viewed. Each diagnostic investigation 
was assessed for its ability to recog­
nize one or more of the following: a 
gastric abnormality defining accurate­
ly the macroscopic appearance (be­
nign versus malignant); the presence 
or absence of mass or ulceration; the 
site (upper third or lower third of 
stomach) and size of the lesion; the 
gross margins of the lesion (proximal 
extension in relation to the eso­
phagogastric junction and distal ex­
tension in relation to the pylorus) and 
the distensibility of the stomach. Bi­
opsies and brush cytologic samples 
taken during endoscopy were re­
viewed for diagnostic sensitivity.
Results
The mean age of the group was 69 
years and the ratio of men to women 
was 4 to 1. Thirty-five patients under­
went an upper gastrointestinal series 
and 34 abdominal computed tomogra­
phy, in parallel with the gastroscopy.
Ninety-eight patients underwent 
gastrectomy, 1 had a bypass for pallia­
tion and in the other the tumour was 
deemed unresectable. All had an ade­
nocarcinoma of the stomach.
The results of the three diagnostic 
procedures are shown in Table I.
With respect to gastroscopy, the 
distensibility of the stomach was men­
tioned in only seven reports and was 
correct in all cases. Multiple biopsies 
were performed in all cases and the 
accuracy in diagnosing malignancy
was 90%; thus, 10% of biopsy results 
were false negatives. Brush cytology, 
performed concomitantly in 25% of 
cases, gave positive results in 70%.
Of the 35 upper gastrointestinal 
series, 5 (14%) were interpreted as 
being normal (false negative). The 
orientation (anterior, posterior, lesser 
and greater curvature) was rarely 
mentioned and the distensibility of the 
stomach was never mentioned.
Of the 34 computed tomograms, 
abnormal features suggestive of a 
malignant lesion were detected in 26 
(76%). Thickening of the gastric wall 
was noted in 15 patients (45%) and 
was the most common indication of 
malignant disease. The other abnor­
mal scans showed, in addition, a mass 
within the stomach. Although the 
examination was accurate in defining 
the site of the lesion, its extent was 
poorly assessed. In patients with 
metastatic nodal disease the positive 
scans revealed local lymph-node en­
largement in nine. Thus, the sensitivi­
ty of recognition of nodal metastases 
was 9 of 20 (45%), whereas the speci­
ficity approached 100%. Liver metas­
tases were incorrectly suggested in 
one patient.
Discussion
Our study clearly demonstrates 
that gastroscopy with biopsy is a 
sensitive diagnostic procedure (90%), 
which provides an objective diagnosis 
of gastric cancer in patients with 
proven carcinoma of the stomach. 
Endoscopy identifies mucosal abnor­
malities related to gastric cancer with 
greater sensitivity (100%) than either 
gastrointestinal contrast studies 
(86%) or computed tomography 
(76%). Gastroscopy and gastrointesti­
nal contrast studies were equally ac­
curate in determining proximal and 
distal extent of the malignant disease. 
Computed tomography may provide 
information concerning the presence 
or absence of liver metastases and 
nodal involvement, but did not pro­
vide additional information on the 
local extent of the tumour.
In the past, the upper gastrointesti­
nal series has been the “gold stan­
dard” against which to judge the 
diagnostic accuracy of tests for gastr­
ic cancer; introduction of the air con­
trast technique in Japan further im­
proved its sensitivity, often allowing 
the diagnosis of superficial, early 
gastric cancers. However, the advent 
and rapid adoption of gastroscopy in 
the 1970s added a new dimension to 
the diagnostic armamentarium; sur­
geons are now asked to see many 
patients with endoscopically suspect­
ed (or proven) gastric cancer who have 
not undergone conventional contrast 
roentgenography. Before we carried 
out this study, our hypothesis, based 
on a subjective impression and now 
proven incorrect, was that upper gas­
trointestinal contrast studies were 
more accurate in determining the 
extent of the malignant disease, and, 
therefore, were helpful in aiding the 
planning of the operative procedure. 
Also, we confirmed the findings of 
several other studies2 3 5 that gastros­
copy was a very sensitive method for
T a b le  1. Diagnostic Procedures for Evaluating Gastric Carcinoma
P ro c e d u re
M a c ro s c o p ic  
A b n o rm a l im p re s s io n  of 
f in d in g s , %  c a rc in o m a , %
S ite  a n d  
o r ie n ta t io n ,
%
P re s e n c e  o r 
a b s e n c e  o f 
u lc e ra t io n , %
P re s e n c e  or 
a b s e n c e  of 
m a s s ,  %
P ro x im a l/d is ta l  
e x te n t of 
m a lig n a n c y , %
B io p sy ,
%
B ru sh
c y to lo g y , %
Gastroscopy 100 88 95 96 82 89 100 25
(n =  100)
Upper gastrointestinal 86 71 77 95 77 91
(90 +ve) (70 +ve)
contrast roentgenography 
(n =  35)
Computed tomography 76 76 100 76
(n =  26)
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diagnosing gastric carcinoma. It is, in 
our experience, superior to contrast 
studies in sensitivity and equally effi­
cacious in delineating the proximal 
and distal extent of the lesion. More­
over, gastroscopy provides the ability 
to obtain an objective diagnosis of a 
malignant condition through direct 
biopsy or by cytologic examination. 
Biopsies were diagnostic in 90% of 
cases, a rate similar to the sensitivity 
reported by others,6 and brush cytolo­
gy was diagnostic in 70%, which is 
substantially less than the 83% report­
ed by Pilotti and colleagues.6
Whether, by combining endoscopy 
and conventional radiologic contrast 
study, diagnostic sensitivity is im­
proved markedly and is thus cost 
effective, is difficult to answer. Of the 
10 patients in whom the endoscopic 
biopsy gave a false-negative result, 6 
had lesions that the endoscopist de­
scribed as highly suggestive of a 
malignant condition, and in the other 
4 the lesions were abnormal but equiv­
ocal with respect to malignancy. Of 
these four patients, three had abnor­
malities on radiologic contrast study 
which could have been considered 
suggestive of a malignant lesion; 
therefore the combined use of the two 
diagnostic tests might have benefited 
only three patients. Moreover, since 
radiologic contrast studies are no 
more accurate in delineating proximal 
or distal tumour extension, we con­
clude that they offer little additional 
preoperative information of impor­
tance to the surgeon when gastric 
cancer is suspected on endoscopic 
examination or proven by additional 
biopsy.
Two fundamental types of gastric
computed tomography are performed 
in clinical practice: (a) the directed 
examination, prompted by a history of 
known or suspected gastric disease 
based on previous surgery, endoscopy 
or barium study and (b) the incidental 
examination in which the stomach is 
studied as part of a more general 
search for intra-abdominal disease, 
when no known gastric disease exists. 
In our study, all such scans were 
directed studies, ordered when there 
was a suggestion of an abnormality on 
endoscopy or contrast roentgenogra­
phy. In spite of this, there were false­
negative results in 24% of cases. Had 
they not been “directed” tests, the 
sensitivity most likely would have 
been less. In several reported series,7-9 
wall thickness 1 cm or greater has 
been a reliable indicator of gastric 
malignant disease. Little information 
was available to assess the local extent 
of the tumour. None of the 26 patients 
who had computed tomography 
were found to have liver metastases 
at surgery and in only one scan was 
there a suspicion of hepatic involve­
ment.
Conclusions
Our study suggests that in the 
investigation of gastric disease, the 
routine use of upper gastrointestinal 
contrast roentgenography with only 
selective use of gastroscopy may re­
duce the number of endoscopic exam­
inations but sacrifices diagnostic sen­
sitivity and would be unacceptable. 
Gastroscopy, therefore, is the exami­
nation of choice in the patient with 
suspected gastric cancer; contrast ro­
►
►
entgenography should be performed 
as a second choice. On the other hand, 
gastroscopy is not necessarily indicat­
ed in the patient who has a mass that 
appears malignant on contrast study, 
unless operation will only be under­
taken if there is objective documenta­
tion of malignancy (i.e., biopsy proof). 
Computed tomography can assess the 
presence of regional node metastases, 
with a sensitivity of 45%, and possibly 
the absence of liver metastases but 
does not add important information 
on the local extent of the tumour.
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Comparison of Processed Bovine Internal 
Mammary Arteries and Autologous Veins 
as Arterial Femoral Substitutes in Dogs: 
Blood Compatibility and Pathological 
Characteristics
F.J. Teijeira, MD, PhD; Yves Marois, MSc; L. Aguiar, MD; R. Guidoin, PhD;
R. Bauset, MD; G. Lamoureux, MD; A. Downs, MD, FRCSC;* M. Marois, MD; 
D. Boyer, MSc
This study was undertaken to compare the chemically processed internal mammary 
artery (BIMA) and the autologous femoral vein as arterial grafts. The BIMA 
prosthesis was implanted as a left femoral artery bypass and the femoral vein as a 
right femoral artery bypass graft in 27 dogs. In groups of three dogs the grafts were 
implanted for predetermined durations: 4, 24 and 48 hours (short term), 1, 2 and 4 
weeks (medium term) and 3, 6 and 9 months (long term). All autologous veins were 
patent when the dogs were killed. The patency rates of the BIMA grafts were 100% 
in the short-term group, 67% in the medium-term group and 29% in the long-term 
group. The deposition of labelled fibrinogen and platelets on flow surfaces, the 
structural preservation of the wall of the BIMA prosthesis and accumulation of 
thrombi during the period of implantation were studied.
Cette etude a ete entreprise dans le but de comparer l’artere mammaire interne 
bovine traitee chimiquement (BIMA) et la veine femorale autologue utilisees comme 
greffons arteriels. La prothese BIMA a ete greffee chez 27 chiens comme derivation 
de l’artere femorale gauche alors que la veine femorale etait utilisee pour ponter 
l’artere femorale droite. Les animaux, repartis par groupes de trois chiens, ont re?u 
les greffes pour des durees predeterminees de 4, 24 ou 48 heures (le court terme), 
de 1, 2 ou 4 semaines (le moyen terme) et de 3, 6 ou 9 mois (le long terme). Quand 
les animaux furent sacrifies, toutes les veines autologues etaient permeables. Le 
taux de permeabilite des greffons BIMA etait de 100% a court terme, de 67% a 
moyen terme et de 29% a long terme. Ont aussi fait l’object d’une etude, le depot de 
fibrinogene marque et de plaquettes sur la surface luminale, la preservation de la 
structure de la paroi de la prothese BIMA et l’accumulation de thrombi durant la 
periode d’implantation.
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Chemically processed grafts are used as substitute blood con­
duits in peripheral vascular surgery 
when autologous vein is not avail­
able. Although human umbilical 
veins have performed satisfactorily 
for some12 and outstandingly for 
others,3 several authors4-5 have 
questioned their durability. Bovine 
heterografts (originating from ca­
rotid arteries) are now used only as 
a secondary vascular access;6-8 their 
primary use in peripheral vascular 
surgery was practically abandoned 
after reports of early thrombosis 
and aneurysm formation.9-11 Their 
secondary use is now being chal­
lenged by the polytetrafluoroe- 
thylene graft. 1213
Despite marginal improvements, 
bovine grafts have been disappoint­
ing clinically . 14-16 Nevertheless, 
chemically processed biologic grafts 
of small diameter are still being 
investigated. New ideas led Malone 
and colleagues17 to develop an acel­
lular matrix biograft, and Loisance 
and colleagues18 described a new 
biochemical processing of human 
placental arteries. In Brazil, Biocor 
Industrias19 explored the possibili­
ties of a chemically processed bo­
vine internal mammary artery (BI­
MA) as a vascular substitute for 
small- and medium-sized arteries. 
Although results in humans were 
satisfactory, 19 more, thorough in­
vestigation must be done before its
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final commercial release. We report 
our in-vivo evaluation of this new 
graft as a femoral artery substitute 
in the dog. The BIMA prosthesis 
was compared with the autologous 
femoral vein with respect to paten­
cy, morphologic features and plate­
let and fibrinogen deposition on the 
luminal surface of the graft placed 
for predetermined periods.
Materials and Methods
The Grafts
The BIMA prostheses (Fig. 1) 
were obtained from Biocor In- 
dustrias Ltda of Nova Lima, Brazil. 
The bovine internal mammary ar­
tery graft is chemically processed 
with glutaraldehyde for 3 months, 
then stored in sterile buffered 3% 
formaldehyde solution. It must 
therefore be abundantly and care­
fully rinsed in heparinized saline 
before implantation.
Autologous femoral veins were 
dissected during surgery in each 
dog and were interposed as arterial 
femoral substitutes.
Platelet Labelling
Whole blood (50 ml) was with­
drawn from each study dog after a 
24-hour fast. Platelets were isolated 
by double centrifugation and la­
belled with indium-111 oxinate 
(Mallinkrodt Canada Inc., Montreal, 
PQ) using a method that was modi­
fied from the one described by Tha- 
kur and colleagues.20 The platelets 
were labelled with 300 to 700 /uCi 
o f m In by incubation. They were 
washed in saline and resuspended in 
autologous plasma. Labelling effi­
ciency was typically around 85%, 
but no viability test was done.
Graft Implantation and Reoperation
Twenty-seven mongrel dogs,
weighing on average 20 kg, were 
selected as stipulated by the Canadi­
an Council on Animal Care. After a 
24-hour fast, they were anesthe­
tized with 25 m g/kg of intrave­
nous Pentothal and then mechani­
cally ventilated. Under strict sterile 
conditions, segments from both 
right and left femoral arteries were 
removed and the right femoral vein 
was harvested. In each case, a few 
minutes after injection of 1 m g/kg 
of heparin intravenously, 5 cm of 
autologous femoral vein was inter­
posed as a graft in the right femoral 
artery and the 5 cm of BIMA graft 
in the left femoral artery. End-to- 
side or end-to-end anastomoses 
were performed using Prolene 
(Ethicon Ltd., Peterborough, Ont.) 
6-0 or 7-0 suture. The dogs were 
given 15 000 units of prolonged- 
effect antibiotic (Penlong S; Rogar 
STB Inc., Montreal, PQ), returned 
to their cages and fed a normal diet. 
A second operation was carried out 
at predetermined intervals — 4, 24 
and 48 hours (short term), 1, 2 and 
4 weeks (medium term) and 3, 6 
and 9 months (long term) — for 
exposure to labelled platelets and 
fibrinogen. Overall, nine groups of
three dogs per duration of implanta­
tion were evaluated. Those in the 
long-term group underwent angiog­
raphy before the second operation.
Investigations
The dogs remained anesthetized 
for 4 hours after intravenous injec­
tion of platelets, labelled in the 
laboratory, and 125 nCi of label­
led 125I fibrinogen. The grafts were 
then removed. Both venous and 
prosthetic grafts were gently rinsed 
in heparinized physiologic saline 
and immediately cut into five seg­
ments of equal length, the first and 
fifth segments including the anasto­
motic areas and the other three 
segments located in between. Each 
segment was counted separately for 
deposition of labelled platelets and 
fibrinogen in a well counter (Compu 
Gamma 1282; LKB-Wallac, Broma, 
Sweden). The measured activity, 
corrected for time and background, 
was expressed as net counts per 
minute to give a relative measure of 
the platelet and fibrinogen deposits 
along grafts.
The specimens were then fixed in 
a 1.5% buffered solution of glutar-
FIG. 1. Processed bovine internal mammary artery (BIMA) prosthesis (external 
diameter 6 mm, wall thickness 0.4 mm).
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aldehyde and processed for light 
microscopy and scanning electron 
microscopy according to a previous­
ly described protocol.21
Statistical Analysis
Statistical analysis of the results 
was by analysis of variance, for 
repeated measures, using Fischer’s 
LSD (least significant difference) for 
a posterior two-by-two comparison.
Results
Three dogs died for reasons not
apparently related to the vascular 
surgery. Consequently, only 24 
dogs were available for examination 
of patency, quantification of platelet 
and fibrinogen deposition and 
pathological investigation.
Patency
The patency rates are summa­
rized in Table I. Patency of the 
BIMA grafts decreased with length 
of implantation, but all venous 
grafts were patent at the time of 
removal. Three dogs were with­
drawn from the study because of
generalized thrombosis: one in the 
short-term group and two in the 
long-term group. No aneurysmal 
formation was visible either in the 
BIMA grafts or the autologous 
veins.
Fibrinogen and Platelet Uptake
Fibrinogen accumulation is 
shown in Table II. Analysis of fi­
brinogen uptake revealed signifi­
cant increases (p < 0.05) in autolo­
gous vein grafts over the first 48 
hours, and when compared with 
BIMA over the same period the 
latter finding was evident in every 
segment analysed except the proxi­
mal one, for which the difference 
was not significant. The fibrinogen 
uptake in the autologous vein 
grafts of the medium- and long­
term groups was significantly (p < 
0.001) lower than in the short-term 
group, but not statistically different 
from the uptake in the BIMA 
grafts.
Figure 2 illustrates the pattern of 
fibrinogen uptake by graft seg­
ments for each period of implanta­
tion. Uptake by autologous vein 
grafts was substantial at the distal 
anastomoses and along the middle 
segments in the short-term group, 
compared with the proximal anasto­
moses. Fibrinogen uptake by the 
BIMA grafts showed a selective in­
crease at both distal and proximal 
anastomoses in the short-term 
group compared with the middle 
segments.
Platelet accumulation followed a 
similar pattern in that the increase
Table 1. Patency Rates of Bovine Internal Mammary Artery (BIMA) and Autologous Femoral Vein 
Grafts at Different Time Intervals After Implantation
Patency, % (no./total no.)
Group BIMA Femoral vein
Short term 100 (8/8) 100 (8/8)
Medium term 67 (6/9) 100 (9/9)
Long term 29 (2 /7 ) 100 (7/7)
FIG. 2. Graphic representation of fibrinogen uptake along graft segment by BIMA 
grafts and autologous femoral veins for short- (diamonds), medium- (squares) and 
long-term (triangles) implantations. Kcpm = net counts per minute.
Table II. Fibrinogen Uptake (Net cpm) by BIMA and,Autologous Femoral Vein Grafts
Implantation _________________________________ Gratt se9menl
Gratt group Distal 2 3 4 Proximal
Femoral vein Short term 37 788 29 269 30 531 30 662 16 891
Medium term 3 893 4 453 6817 6 633 5 932
BIMA
Long term 5119 6 953 9175 4 893 4 858
Short term 20 091 10111 8 320 8 488 22 962
Medium term 4 976 3 439 7 997 6 086 7 185
Long term 5 705 8 686 8 843 4 644 5 689
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was much greater in the autologous 
veins in the short-term group (Table 
III). Differences in pattern and in­
tensity between the two materials 
were not statistically significant, 
probably because of the extreme 
variation in the viability of the 
platelets for each dog in the study. 
Figure 3 demonstrates clearly the 
accumulation of platelets at both 
anastomoses of the BIMA grafts in 
the short-term group.
Pathological Investigations
The structure of virgin BIMA 
grafts was observed by both light 
and scanning electron microscopy. 
The latter revealed a carefully pro­
cessed graft whose defect-free sur­
face was smooth, with a number of 
endothelial cells no longer viable. 
The basement membrane appeared 
to be well preserved, thus separat­
ing the blood flow from the under­
lying collagen matrix (Figs. 4 to 6). 
The wall was also well preserved 
and the tunica externa appeared 
normal.
After short-term implantation, ac­
cumulation of thrombotic matrix 
was visible for up to 2 weeks adja­
cent to the sutures at both anasto­
moses (Fig. 7). The middle segment 
of the flow surface was smooth with 
scattered deposits of fibrin platelets 
and erythrocytes. A discrete fibrosis 
of the media occurred with occa­
sional displacement and restructur­
ing of the internal elastic lamina.
After 1 month of implantation, 
the thrombi at the anastomoses of 
the BIMA grafts were organized 
and extended along the artery; the 
surface of the pannus exposed to 
the blood flow showed early re- 
endothelialization. A few blood de­
posits were still evident in the medi­
al part of the smooth luminal sur­
face (Fig. 8). In the adventitia, 
granulomatous inflammatory tissue
reacted to become incorporated 
with vasa vasorum.
In the patent grafts after long­
term implantation, the pannus at 
both anastomoses exhibited a veil 
of newly formed endothelial-like 
cells. Flow surface appeared similar 
to that seen 1 month after implan­
tation. Mild medial fibrosis was not 
noticeable, the elastic lamina was 
not always apparent and a granulo­
matous inflammatory reaction with 
foreign-body giant cells in the ad­
ventitia was seen (Figs. 9 and 10).
The structure of the femoral 
veins altered slightly shortly after 
implantation. For 2 weeks, throm­
botic debris was visible at the anas­
tomoses and over the flow surface 
(Fig. 11). Forty-eight hours later, 
intimal fibrosis occurred at both 
anastomoses where a partial denu­
dation of the luminal surface was 
perceptible.
Between 1 week and 1 month, 
the subendothelial fibrosis became 
dense, with displacement and local­
ized ruptures of the elastic network. 
Also, peripheral sclerosis was ob­
served along the anastomoses after 
1 month of implantation, at which 
time the thrombi had almost disap­
peared and the sutures were totally 
incorporated in the newly grown 
pannus, coated with endothelial 
cells. The middle portion of the 
graft still had some debris and was 
still partially denuded. Over the 
long term, surface cells proliferated 
sufficiently to cover the whole lumi­
nal surface (Fig. 12). The wall be­
came thicker as a result of progres­
sive fibrosis (Fig. 13).
FIG. 3. Graphic representation of platelet uptake along graft segment of BIMA 
grafts and autologous femoral veins for short- (diamonds), medium- (squares) and 
long-term (triangles) implantations.
Table III. Platelet Uptake (Net cpm) by BIMA and Autologous Femoral Vein Grafts
Implantation _________________________________ Graft segment
Graft group Distal 2 3 4 Proximal
Femoral vein Short term 15 202 10 552 13 200 18 953 2 540
Medium term 892 588 920 1 885 1 300
BIMA
Long term 291 403 463 265 206
Short term 9 845 4 966 3 343 3 621 8 488
Medium term 1 501 1 240 1 542 1 724 2 993
Long term 393 429 571 387 412
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Discussion
Bovine heterografts have not 
evolved as outstanding blood con­
duits when used as primary vascu­
lar replacements.2223 Despite some 
enthusiastic reports,24- 26 there are
widely recognized weaknesses. 7 
Even the Solco prosthesis, an inter­
esting model, did not meet clinical 
needs and was wisely abandoned 
after biodegradation became evi­
dent.27 Caution is indicated before 
introducing any new chemically
processed bovine heterograft and 
the following questions must be 
asked:
•  Is the BIMA a valuable graft 
in terms of patency?
•  How stable biologically is this 
chemically processed artery?
FIG. 4. Scanning electron micrographs of external tunica of 
virgin BIMA graft (original magnification, A X 20, B X 200).
FIG. 5. Scanning electron micrographs of virgin BIMA graft. 
Luminal surface was smooth with no sign of rupture (original 
magnification, A X 20, B X 200).
FIG. 6. Flow surface of BIMA graft is still covered with 
endothelial cells. However, because of processing, those cells 
are no longer viable (original magnification, X 720).
FIG. 7. Thrombus matrix is still present at anastomotic sites 
of BIMA graft 2 weeks after implantation (original magnifica­
tion, X 60).
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FIG. 9. Light microscopic view of BIMA prosthesis implanted 
for 3 months. Elastic lamina is no longer visible (original 
magnification, X 100).
present an antithrombogenic sur­
face whose in-vivo properties 
should not be altered in order to 
maintain this blood compatibility.
The BIMA graft has demonstrat­
ed structural strength with preser­
vation of the elastic network during 
processing. A mild fibrosis was 
present in the media soon after 
implantation. The usefulness of this 
graft lies in its capacity to preserve 
the smoothness of the flow surface, 
and on the development of an exter­
nal fibrotic capsule. Quality control 
should be exacting to ensure that 
defect-free grafts are implanted. We 
are unconvinced that the currently 
accepted standards constitute a suf­
ficient guarantee.34 Additional test­
ing, involving endoscopy35 and mea­
surement of the electrical imped­
ance of the graft wall36 should be 
mandatory. It is evident that han­
dling should be atraumatic in order 
to maintain the integrity and anti­
thrombogenic characteristics of the 
graft material.
Experiments to date do not per­
mit researchers to predict the future 
failure mechanisms of the BIMA in 
humans; the dog remains a poor 
model for evaluating chemically 
processed grafts. 37 Usually, in dogs, 
the grafts develop fibrous hyperpla­
sia, which rapidly becomes occlu­
sive, and fail because of thrombo­
sis. Administration of acetylsalicylic 
acid contributes to better patency
•  What are the likely failure 
mechanisms?
Compared with autologous vein, 
the patency rates achieved with the 
BIMA are much lower, 2829 which is 
not unexpected, since the vein is 
the gold standard of arterial substi­
tutes.30 Yet, the patency rates com­
pare favourably with any synthetic 
blood conduit tested in our labora­
tories and the BIMA is second to 
homologous vein either fresh or 
frozen.31' 33 Moreover, fibrinogen 
and platelet retention are lower 
than that of alternative arterial sub­
stitutes. Healing is limited, howev­
er, to the development of a pannus 
over the anastomotic areas; the rest 
of the conduit should, therefore,
FIG. 8. Scanning electron micrographs of BIMA graft 1 month 
after implantation. Presence of endothelial cells along anasto­
mosis is limited to pannus (A) (original magnification, X 200). 
Luminal surface remained smooth with some nonviable origi­
nal cells (B) (original magnification, X 540).
FIG. 10. Light microscopic view of BIMA prosthesis implanted 
for 6 months. Fibrosis is mild and elastic lamina is still visible 
(original magnification, X 100).
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rates for chemically processed 
grafts.38 In humans, with the ab­
sence of complete endothelialization 
of the flow surface, failure mecha­
nisms are very different and proba­
bly related to lipid uptake. Lipids 
are retained on the luminal surface 
and then penetrate the wall and 
cannot be drained off because lym­
phatic vessels are absent. The colla­
gen bundles become plasticized and 
stretched; they may rupture, lead­
ing to tissue resorption.39 Dilatation 
is accompanied by additional cho­
lesterol uptake and any bacteremia, 
however transient, may permit colo­
nization of the glycocalyx biofilm.40
Because of its patency rates and 
firm structure, we believe that clini­
cal trials using the BIMA graft can 
be undertaken for specific purposes 
in selected patients. Its use in aor­
tocoronary bypass is not recom­
mended since results remain inferior 
to the autologous vein graft be­
cause neo-endothelialization is ab­
sent, and this leads to an unfavou­
rable prostacyclin-thromboxane bal­
ance. We would be reluctant to use 
the BIMA graft in peripheral vascu­
lar surgery where frequently associ­
ated lipid abnormalities and ulcers 
are likely to cause bacteremia. 
Thus, the recommended application 
for BIMA is as a secondary access 
for arteriovenous fistulas. Should 
the material prove highly success­
ful, its use might be extended.
Conclusions
The new bovine internal mamma­
ry artery heterograft has some in­
teresting features and is an accept­
able blood conduit in terms of pat­
ency rates and structural stability. 
The luminal surface of the graft is 
blood compatible, and the deposi­
tion of a thrombotic matrix is limit­
ed to both anastomotic areas. How­
ever, autologous vein is still the 
material of choice for aortocoronary 
bypass and in peripheral vascular 
surgery. Although the dog is a poor 
model for evaluating the BIMA 
prosthesis, encouraging results 
should stimulate researchers to pur­
sue clinical trials.
FIG. 11. Thrombus matrix is still present at anastomotic sites 
of autologous femoral vein 2 weeks after implantation (origi­
nal magnification, X 60).
FIG. 12. Fragile development of veil of endothelial cells on 
luminal surface 3 months after implantation (original magnifi­cation, X 600).
FIG. 13. Light microscopic views of femoral vein implanted for 
3 months with important parietal fibrosis (A) and granuloma­
tous reaction in adventitia (B) (original magnification, X 100).
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ORIGINAL ARTICLES
Effect of a Direct Current Field on Axons 
After Experimental Spinal Cord Injury
Michael G. Fehlings, MD;* Tat H. Wong; Charles H. Tator, MD, PhD, FRCSC; Michael Tymianski, MD
There is evidence that direct current (DC) stimulation promotes neurologic recovery 
in spinal cord injury. The authors conducted a morphometric analysis of axons at 
the site of spinal cord injury in adult rats treated with a DC field. Ten rats received a 
17-g and 15 rats a 53-g clip compression injury and were treated with either a sham 
(control) or a functioning DC stimulator for 8 weeks. Five normal rats were also 
assessed.
There was a significant relation (p < 0.0001) between the severity of injury and 
the number of axons at the injury site. After the 17-g injury, there was no 
significant difference in the number of axons between control and treated rats. 
However, after the 53-g injury, there were significantly (p < 0.05) more axons in 
treated than control rats. Both degrees of injury caused preferential destruction of 
large-calibre axons. Subsequent analysis showed that the axon diameter of treated 
rats with 17-g or 53-g injury was significantly greater (p < 0.05) than that of 
control rats with 17-g or 53-g injury. These data, for the first time, show that the 
application of a DC field increases the number and calibre of axons at the site of a 
spinal cord injury and enhances the survival or regrowth of axons following spinal 
cord injury in the rat.
II existe des preuves que, dans les cas de lesion spinale, la stimulation a l’aide de courant 
direct (CD) favorise la guerison neurologique. Les auteurs ont mene une analyse 
morphometrique des axones au siege des lesions spinales, chez des rats adultes traites a 
1 aide d’un champ de CD. Les lesions ont ete provoquees chez 10 rats par une compression 
de 17 g appliquee a l’aide d’une pince, et chez 15 autres rats par une compression de 53 g. 
Les animaux furent ensuite traites pendant 8 semaines soit par stimulation simulee 
(groupe temoin), soit par stimulation reelle a l’aide de CD. Cinq rats normaux furent aussi 
evalues.
On a constate une relation significative (p < 0.0001) entre la gravite des lesions et le 
nombre d’axones au siege des lesions. Dans les cas de lesions de 17 g, aucune difference 
significative n ’a ete observee dans le nombre d’axones entre les animaux temoins et les 
animaux traites. Toutefois, apres une lesion de 53 g, il y avait significativement plus 
d’axones (p < 0.05) chez les rats traites que chez les temoins. Quelle que soit leur gravite, 
les lesions causaient une destruction preferentielle des axones de gros calibres. L’analyse 
subsequente a revele que le diametre des axones des rats traites etait significativement 
plus gros (p < 0.05) que celui des temoins, qu’il s ’agisse de lesions de 17 g ou de 53 g. 
Pour la premiere fois, des resultats demontrent que l’application d’un champ de CD 
augmente le nombre et le calibre des axones au siege d’une lesion spinale et favorise la 
survie ou la regeneration des axones apres une lesion spinale chez le rat.
D irect current (DC) fields have been shown to enhance the 
proliferation of neurites in cul­
ture,12 to promote axonal sprouting 
and decrease retrograde axonal 
degeneration3 7 and to promote re­
covery89 and regeneration45 of in­
jured spinal cord axons in mam­
mals. In this study, we investigated
the effect on axon counts and other 
morphometric parameters, includ­
ing myelination index and axon 
diameter, of DC stimulation of 
axons at the site of cord injury, 
using a computer-assisted line-sam­
pling technique. Our aim was to 
provide insight into the cellular 
effects and mechanisms of action of
DC fields on injured spinal cord 
axons.
Methods
Experimental Procedures
A total of 30 rats were used in 
the study (25 with spinal cord inju­
ries and 5 normal controls). Twen­
ty-five adult rats underwent lami­
nectomy at C7-T1 and were sub­
jected to a 1-minute clip compres­
sion injury of the cord at C8. The 
rats were randomly allocated to one 
of two severities of cord injury by 
using a modified aneurysm clip to 
exert a force of either 17 g (10 rats) 
or 53 g (15 rats).10 They were 
further blindly randomized to re­
ceive either DC stimulation (14 pA) 
or act as controls (0 g.A) (Table I). 
The design, manufacture, electrical 
characteristics and method of im­
plantation of the DC stimulators 
have been described elsewhere.9
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ELECTRICAL STIMULATION OF AXONS
Briefly, immediately after cord inju­
ry, the electrodes, attached to the 
stimulator by insulated platinum 
wire, are placed epidurally with the 
anode proximal and the cathode 
distal to the injury site.
Postoperatively, clinical neuro­
logic function was assessed each 
week by the inclined plane tech­
nique.11 After 8 weeks, motor and 
somatosensory evoked potentials 
were recorded, and the axonal trac­
er, horseradish peroxidase (HRP), 
was introduced into the cord at T6. 
Coronal sections through the brain 
stem and motor cortex were exam­
ined, and the number of neurons, 
retrogradely labelled by HRP, were 
counted.
The injury site was sectioned 
transversely at 400 /urn with a vi- 
brotome, postfixed in a 2% osmium 
tetroxide/3% sodium ferrocyanide 
solution, immersed in 2% aqueous 
uranyl acetate and embedded in 
araldite plastic. The blocks were 
sectioned serially on an ultrami­
crotome for light and electron mi­
croscopy. A quantitative assessment 
of axons at the injury site was then 
performed. The spinal cord of five 
normal rats was similarly evaluated.
Line-Sampling Technique
Two independent, blinded observ­
ers (M.G.F. and T.H.W.) evaluated 
the spinal cord sections using the 
line-sampling technique of Blight.12 
The section with the most severe
lesion from each rat, determined by 
inspection, was selected. A Zeiss 
photomicroscope attached to a cam­
era lucida was used to measure the 
number, minor axis and myelin 
thickness of axons intercepted by 
48 radial sample lines (drawn from 
the centre of the cord at even 
intervals of 27r/48 radians) at 
1000X magnification with the aid 
of a digitizing tablet interfaced to a 
microcomputer. Myelination index 
(MI) was calculated according to the 
following formula: MI = a /a  + 2m, 
where a =  minor axis and m = 
myelin thickness.12 The estimated 
total number of axons within a 
section was derived using an algo­
rithm based on line-sampling theo­
ry.12
To confirm the accuracy of the 
line-sampling technique, area 
counts were performed in the five 
normal rats. The total number of 
axons in a quadrant of the cord (the 
area bounded by 12 of the 48 radial 
sample lines) was compared with 
the total number of axons in the 
same sector estimated by line sam­
pling.
Statistical Analysis
The data were analysed on the 
University of Toronto IBM 4381 
mainframe computer using the Sta­
tistical Analysis Systems (SAS ver­
sion 5.16) statistical programming 
language. Analysis of variance and 
linear regression were used to ana­
lyse continuous data. Later compar­
isons were made using Tukey’s 
HSD test.13 The results were ex­
pressed as mean ± SEM; differences 
were considered significant at p < 
0.05.
Results
This study is part of a larger 
investigation on the effects of DC 
fields in experimental spinal cord 
injury. In it, we document the de­
tailed quantitative analysis of axons 
at the injury site. Results of the 
inclined plane assessment, electro- 
physiologic recordings and axonal 
tracing studies have been reported 
elsewhere.9 They showed that DC 
stimulation promoted clinical recov­
ery of neurologic function, en­
hanced axonal function in the 
motor tracts of the cord and in­
creased the number of HRP-labelled 
axons traversing the injury site.
The axonal morphometric data 
are summarized in Table I. The 
number of axons in the cord of 
normal rats was 458 000 ± 50 000. 
Spinal cord injury resulted in a 
significant (p < 0.0001) decrease in 
the number of axons at the injury 
site. Although there were no signfi- 
cant differences in the number of 
axons between control and treated 
rats with 17-g injuries, for 53-g 
injuries the treated rats had signifi­
cantly (p < 0.05) more axons at the 
injury site than controls. When we
T a b le  1. Axon M o rphom etry  (Mean ±  S E M )*
No. of Axon Axon M y e lin a tio n
Group rats counts d ia m e te r , ^ m in d e x t
Normal 5 458 000  ±  50 000 A 1.94 ±  0 .07 A 0 .6 2  ±  0.01 A
17-g in jury
Treatm ent 6 55 100 ±  23 200 B 1.46 ± 0 .0 1 B 0 .66  ±  0.01 B
Control 4 52 200 ±  23 200 B 1.31 ± 0 .0 2 C 0 .67  ±  0.01 C
53-g in jury
Treatm ent 7 51 700 ±  8 300 B 1.39 ± 0 .0 1 D 0 .67  ±  0.01 C
Control 8 25 300  ±  8 500 C 1.17 ±  0.02 E 0 .72  ±  0.01 D
’ Means w ith  d iffe re n t le tters beside each co lum n are s ign ifica n tly  d iffe re n t (p <  0.05) by ana lys is  o f variance and T u key 's  HSD te s t, 
t  The ratio o f axon d iam eter to  fib re  diameter. Data fro m  axons sm a lle r than 3 ^ m  are excluded due to  lim ite d  prec is ion  o f the  m easurem en t apparatus.
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examined the distribution of axons 
in the various cord funiculi, we 
found that there were significantly 
(p < 0.05) more axons in the 
ventral and ventrolateral funiculi of 
the cord in 53-g injury treated rats 
than in controls; in contrast, there 
were no differences between axon 
counts in the dorsal and dorsolater­
al funiculi between control and 
treated rats. The axon counts of 
control and treated rats with 17-g 
injuries were similar in all funiculi, 
although treated rats showed a 60% 
increase in axon counts in the ven­
trolateral funiculus (29 100 ±
11 100 versus 18 200 ± 9100, p > 
0.05).
We noted a preferential destruc­
tion of large-calibre axons (Table I). 
For example, there was a significant 
difference (p < 0.0001) in the mean 
axon diameter between normal 
(1.94 ±  0.07 ^m) and injured cord 
(1.35 ±  0.10 nm, pooled data). 
Furthermore, the mean axon diame­
ters of 17- and 53-g treated rats 
were significantly greater than 
those of their respective controls 
(Table I).
Marked post-traumatic demyelin- 
ation resulted from the spinal cord 
injury. It was reflected by a signifi­
cant (p < 0.05) difference in the 
myelination index between axons in 
normal and injured cord (Table I). 
The demyelination was generally 
more severe in rats having 53-g 
injuries than in those with 17-g 
lesions. Furthermore, DC stimula­
tion was associated with less demy­
elination in axons larger than 3 /xm 
for both 17- and 53-g treated rats 
compared with their respective con­
trols (Table I).
Axon counts derived using 48 
sample lines showed an excellent 
correlation with the total counts of 
a cord quadrant. For example, the 
counts based on line sampling and 
the total counts differed by approxi­
mately ± 5% (t = 1.21, p > 0.05), 
confirming the validity and robust­
ness of the line-sampling technique. 
Discussion
This study is the first to evaluate 
quantitatively the effect of an ap­
plied DC field on axon counts and 
other morphometric parameters 
after spinal cord injury in a mam­
mal. The data show that the DC 
field is associated with an increased 
number of surviving myelinated 
axons at the injury site, particularly 
large-calibre axons, and that it de­
creases the extent of post-traumatic 
demyelination.
The data are consistent with our 
previous demonstration9 that DC 
stimulation of the injured mamma­
lian cord results in an increased 
number of axons, retrogradely la­
belled by HRP, which traverse the 
site of cord injury. Furthermore, 
the effects on axon number, diame­
ter and myelination index provide a 
structural basis for the clinical neu­
rologic and electrophysiologic ef­
fects of DC fields on cord injured 
rats.89
Although it is unclear why axon 
counts were not increased in treated 
rats with 17-g injuries, the results 
are consistent with our previous 
finding of a lack of clinical, electro- 
physiologic or anatomical improve­
ment at this severity of injury. It is 
possible that the failure to detect a 
difference in axon counts in the 
17-g injury group may represent an 
artifact of the relatively small sam­
ple size (n = 10). For example, 
treated rats with 17-g injuries, 
when compared with controls, had 
a 60% increase in the number of 
axons in the ventrolateral funiculus. 
A post hoc calculation of sample 
size13 affirmed that this difference 
would have achieved statistical sig­
nificance had the sample size been 
approximately doubled. In future 
studies, it may prove fruitful to 
re-examine whether DC fields can
effect functional and anatomical re­
covery in mild or moderate spinal 
cord injuries.
Spinal cord injury resulted in a 
preferential loss of large-calibre ax­
ons, similar to the findings of 
Blight12 and Blight and Decre- 
scito,14 who suggested that axonal 
shearing may be a major mecha­
nism of axonal injury after cord 
compression. The modulus of rigidi­
ty, defined as the amount of stress 
required to produce a unit of shear, 
varies inversely as the fourth power 
of the radius of a cylinder,15 and 
may explain the selective loss of 
large axons which would be more 
vulnerable to shear forces. We 
showed that the applied DC stimu­
lation enhanced the survival of 
large-calibre axons in treated rats 
with both 17-g and 53-g injuries. It 
is possible that DC stimulation 
equally enhances the survival of all 
axons, regardless of size, but be­
cause cord injury results in the 
preferential loss of large-calibre ax­
ons, the stimulation effect is most 
apparent in large spinal cord axons.
Although the mechanism of ac­
tion of DC fields on injured axons is 
incompletely understood, there is 
evidence that modulation of tran- 
scellular ionic fluxes may be in­
volved. For example, around sev­
ered axons there exists an extracel­
lular field which is associated with a 
strong inward “injury current”, due 
mainly to Na+ and Ca++ ions.16 It 
has been proposed6 that the distal 
placement of the cathode of an 
applied electrical field should drive 
this “injury current” in the oppo­
site direction. Since Ca++ is known 
to disrupt neurofilaments and to 
promote axonal degeneration,17 one 
major effect of applied DC fields 
might be to reduce retrograde axo­
nal degeneration, which in turn 
might facilitate recovery and regen­
eration. We are studying this hy­
pothesis.
In conclusion, in this investiga­
te) CJS, VOL. 32, NO. 3, M A Y  1989
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tion we have demonstrated that DC 
fields promote the survival of myeli­
nated spinal cord axons and reduce 
the extent of demyelination follow­
ing experimental spinal cord injury.
We thank D. Wilken and M. Moncada 
for their technical assistance.
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ORIGINAL ARTICLES
Nonoperative Management of 
Complications of Percutaneous Renal 
Nephrostomy
Susan Dian Goldberg, MD, FRCSC;* Robin R. Gray, MD, FRCPC;t Eugene L. St. Louis, MD, FRCPC;t 
John Mahoney, MD; Michael A. Jewett, MD, FRCSC;* Ara G. Keresteci, MD, FRCSC*
Between 1984 and 1986 at the Wellesley Hospital in Toronto, 210 percutaneous 
renal nephrostomies were performed for drainage and 140 were done to provide 
access for nephrolithotomy. Less than 2% of the patients experienced complications 
requiring intervention and less than 0.5% required an open surgical approach for 
the management of procedure-related problems. Complications that were managed 
conservatively included splenic puncture, false aneurysm, laceration of the renal 
artery, arteriovenous fistula, hemorrhage requiring transfusion, pneumothorax- 
empyema, urinoma, septic shock and the hemolysis-hyponatremia-renal 
shutdown syndrome.
Entre 1984 et 1986, 210 nephrostomies renales percutanees ont ete pratiquees pour 
fins de drainage a THopital Wellesley de Toronto, et 140 autres ont ete effectuees 
pour offrir une voie d’acces pour une nephrolithotomie. Moins de 2% des patients 
ont souffert de complications necessitant une intervention chirurgicale et moins de 
0.5% ont necessity un abord chirurgical ouvert pour corriger un probleme cause par 
1’intervention. Parmi les complications traitees de fa?on conservatrice, on compte: 
perforation splenique, faux anevrisme, laceration de l’artere renale, fistule arterio- 
veineuse, hemorragie necessitant une transfusion, empyeme de pneumothorax, 
urinome, choc septique et le syndrome hemolytique, hyponatremique et oligo-anuri- 
que.
Over the past decade, percutane­ous nephrostomy has emerged 
as the primary therapeutic approach 
for retained renal calculi. In combi­
nation with extracorporeal shock- 
wave lithotripsy, percutaneous ne­
phrolithotomy has virtually elimi­
nated the need for an open proce­
dure. Likewise, the need for an 
open approach to obstruction at the 
ureteropelvic junction has been 
markedly reduced by using percuta­
neous pyeloplasty (endopyelotomy). 
Whether access is obtained under 
fluoroscopic or ultrasonic guidance, 
morbidity, mortality and convales­
cence time are decreased compared 
with an open surgical procedure.
Patients and Methods
Between January 1984 and De­
cember 1985, 350 percutaneous 
renal nephrostomies were per­
formed for drainage (210) or ne­
phrolithotomy (140). Patients 
ranged in age from 21 to 81 years, 
with a 2:1 male predominance. Du­
ration of hospital stay ranged from 
3 to 28 days (mean 11 days).
Renal access was achieved in all 
cases under fluoroscopic guidance. 
Retrograde placement of a ureteric 
occlusion balloon catheter for injec­
tion of contrast medium, or as an 
aid to dilation of the renal system, 
preceded percutaneous puncture in 
most nephrolithotomy cases. All 
procedures were performed using
From the *Department o f  Surgery and fDepartment o f  Radiology, The Wellesley Hospital, 
University o f  Toronto, Toronto, Ont.
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PERCUTANEOUS RENAL NEPHROSTOMY
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local anesthetic, supplemented by 
analgesics administered intrave­
nously. The following five brief case 
reports illustrate the problems en­
countered and their management.
Case Reports
Case 1
One patient suffered laceration of 
the right renal artery. This was 
managed by temporary balloon oc­
clusion of the main renal artery 
(Figs. 1 and 2), after which the 
percutaneous tract was embolized 
with Gelfoam (Fig. 3). On release of
FIG. 1. Case 1. Balloon tamponade of 
renal artery laceration before applica­
tion of Gelfoam.
FIG. 2. Case 1. Massive extravasation. 
Balloon catheter is in place.
the occlusion balloon, after 8 min­
utes, the hemorrhage had ceased 
and normal perfusion was noted 
through the main renal artery.
Case 2
A renal artery pseudoaneurysm 
(Fig. 4) formed after a percutaneous 
access procedure. It was successful­
ly managed nonoperatively by selec­
tive cannulation of the involved 
vascular branch and by emboliza­
tion with autologous clot and Gian- 
turco coils.
Case 3
One patient suffered perforation
FIG. 3. Case 1. Bleeding tamponaded 
with Gelfoam.
FIG. 4. Case 2. False aneurysm in 
branch of renal artery.
of the upper ureter complicated by 
an obstructive clot in the lower 
ureter. This resulted in the forma­
tion of a massive urinoma. Nephros­
tomy drainage was by placement of 
a ureteric stent from above, paren­
teral administration of antibiotics 
and intravenous administration of 
furosemide. The urinoma resolved 
completely within 24 hours.
Case 4
During attempted placement of a 
left internal ureteric stent this pa­
tient suffered laceration of the 
spleen (Fig. 5). After receiving 
blood transfusion the patient re­
mained hemodynamically stable and 
was discharged 14 days later. There 
were no late sequelae.
Case 5
After routine dilatation of a per­
cutaneous tract, established for ne­
phrolithotomy, the balloon could 
not be deflated. A second percuta­
neous nephrostomy provided access 
to the balloon which was punc­
tured, permitting the entrapped di­
lator to be removed.
Results
Complications requiring active in­
tervention occurred in less than 2% 
of the 350 patients; they included 
hemorrhage requiring transfusion 
(8), pneumothorax-empyema (2),
FIG. 5. Case 4. Splenic perforation.
CJS, VOL. 32, NO. 3, M A Y  1989 193
NEW  FROM MILES
TABLETS
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ORAL ANTIBIOTIC
THE POWER OF PARENTERALS. 
THE FREEDOM OF TABLETS.
“ CIPRO"
Ciprofloxacin Hydrochloride 
THERAPEUTIC CLASSIFICATION
Antibacterial Agent
p r e s c r ib in g
ACTIONS
Ciprofloxacin, a synthetic fluoroquinolone, has a bactericidal mode of action. This action is 
achieved through inhibition of DNA gyrase, an essential component of the bacterial DNA 
replication system. Inhibition of the alpha subunit of the DNA gyrase blocks the reseafing of 
the nicks on the DNA strands induced by this alpha subunit, leading to  the degradation ofthe 
DNA by exonucleases. This bactericidal activity persists not only during the multiplication 
phase, but also during the resting phase of the bacterium.
Ciprofloxacin retained some o f its  bactericidal activity after inhibition of RNA and protein 
synthesis by rifamycin and chloramphenicol, respectively. These observations suggest 
ciprofloxacin may possess two bactericidal mechanisms,, one mechanism resulting from 
the inhibition o f DNA gyrase and a second mechanism which may be independent on RNA 
and protein synthesis.
INDICATIONS AND CLINICAL USES
CIPRO' (Ciprofloxacin Hydrochloride Monohydrate, may be indicated lor the treatment of patients 
w ith the follow ing infections caused by susceptible strains of the indicated microorganisms. 
RESPIRATORY TRACT INFECTIONS:
Acute bronchitis and acute pneumonia caused by 
Enterobacter cloacae Proteus mirabilis
Escherichia coli Pseudomonas aeruginosa
Haemophilus influemae Staphylococcus aureus
Klebsiella pneumoniae Streptococcus pneumoniae
Due to the nature ot the underlying conditions which usually predispose patients to 
Pseudomonas infections of the respiratory tract, bacterial eradications may not be achieved 
in patients who display clinical improvement despite evidence of in vitro sensitivity. In 
patients requiring subsequent courses of therapy, CIPRO® should be used alternately with 
other anti-pseudomonal agents. Some strains of Pseudomonas aeruginosa may develop 
resistance during treatment. Therefore, susceptibility testing should be performed periodi­
cally during therapy to detect the emergence of bacterial resistance.
URINARY TRACT INFECTIONS:
Upper and lower urinary tract infections, such as complicated and uncomplicated cystitis, 
pyelonephritis, and pyelitis, caused by
C itrobacterd ivetm  
Citrobacter freundii 
Enterobacter cloacae 
Escherichia coli 
Klebsiella pneumoniae 
Klebsiella oxytoca 
Morganella morganii 
SKIN AND SOFT TISSUE INFECTIONS: 
caused by:
Enterobacter cloacae 
Escherichia coli 
Klebsiella pneumoniae 
Proteus vulgaris 
Proteus mirabilis 
BONE AND JOINT INFECTIONS: 
caused by:
Enterobacter cloacae 
Pseudomonas aeruginosa
INFECTIOUS DIARRHEA: (When antibacterial therapy is indicated) 
caused by:
Escherichia coli (enterotoxigenic strains) Shigella flexneri
Campylobacter jejuni Shigella sonnei
Appropriate culture and susceptibility tests should be performed prior to initiating treatment 
in order to isolate and identify organisms causing the infection and to determine their 
susceptibilities to ciprofloxacin. Therapy with CIPRO® may be initiated before results ot 
these tests are known. However, modification of this treatment may be required once results 
become available or if there is no clinical improvement. Culture and susceptibility testing 
performed periodically during therapy will provide information on the possible emergence or 
bacterial resistance.
CONTRAINDICATIONS
CIPRO" (Ciprofloxacin Hydrochloride Monohydrate) is contraindicated in patients who have 
shown hypersensitivity to ciprofloxacin or other quinolone antibacterial agents.
Proteus mirabilis 
Pseudomonas aeruginosa 
Serratia mamescens 
Staphylococcus dureus > ; 
Staphylococcus epidermidis 
Streptococcus faecalis
Pseudomonas aeruginosa 
Streptococcus pyogenes 
Staphylococcus aureus 
Staphylococcus epidermidis
Serratia marcescens 
Staphylococcus aureus
WARNINGS
Children
The safety of CIPRO® (Ciprofloxacin Hydrochloride Monohydrate) in children has not yet 
been established. Damage to juvenile weight-bearing joints and lameness were observed 
both in rat and dog studies out not in weaned piglets (see Product Monograph: TOXI­
COLOGY). Histopatnological examination of the weight-bearing jo in ts  of immature dogs 
revealed permanent lesions of the cartilage. Consequently. CIPRO" should not be used in 
prepubertal patients.
Pregnancy
The safety of CIPRO" in the treatment ot infections in pregnant women has not yet been 
established (see PRECAUTIONS).
PRECAUTIONS
General
Anaphylactic reactions including cardiovascular collapse have occurred rarely in patients 
receiving therapy with CIPRO" (Ciprofloxacin Hydrochloride Monohydrate). These reactions 
have occurred within the first 30 minutes following the first dose and may require epineph­
rine and other emergency measures.
CIPRO" may cause central nervous system (CNS) stimulation which may lead to tremor, 
restlessness, light-headedness, confusion, and very rarely to hallucinations or convulsive 
seizures. Therefore, CIPRO" should be used with caution in patients with CNS disorders, 
such as severe cerebral arteriosclerosis or epilepsy. Patients with known convulsive seizure 
disorders should only be treated with CIPRO" if anticonvulsive therapy has been initiated. 
Crystalluria related to ciprofloxacin has been reported only rarely in man because human 
urine is usually acidic. Patients receiving ciprofloxacin should be well hydrated and alkalinity 
of the urine should be avoided. The recommended daily dose should not be exceeded. 
Crystals ot ciprofloxacin have been observed rarely in the urine of human subjects but more 
frequently in the urine of laboratory animals.
Prolonged use of CIPRO" may result in the overgrowth of nonsusceptible organisms. Careful 
observation of the patient is therefore essentia), and if superinfection should occur during 
therapy, appropriate measures should be taken.
Pregnancy
The safety of CIPRO" in pregnancy has not yet been established. CIPRO® should not be used 
by pregnant women unless tne likely benefits outweigh the possible risk to the fetus. CIPRO'" 
has been shown to be non-embryotoxic and non-teratogemc in animal studies.
Nursing Mothers
It is not known whether ciprofloxacin is excreted in human milk. However, it is known that 
ciprofloxacin is excreted in the milk of lactating rats and that other drugs of this class are 
excreted in human miik. A decision should be made to discontinue nursing or to discontinue 
the administration of CIPRO® taking into account the importance of the drug to the mother 
and the possible risk to the imant.
Drug Interactions
Concurrent administration of ciprofloxacin with theophylline may lead to an elevated plasma 
concentration and prolongation of elimination half-life of theophylline. This may result in 
increased risk of theophylline-related adverse reactions. If concomitant use cannot be 
avoided, plasma concentrations of theophylline should be monitored and dosage adjust­
ments made as appropriate
Ciprofloxacin has been shown to interfere with the metabolism and pharmacokinetics of 
caffeine. Excessive caffeine intake should be avoided.
Probenecid blocks renal tubular secretion of ciprofloxacin and has been shown to produce an 
increase in the level ot ciprofloxacin in the serum.
Concomitant administration of a nonsteroidal anti-inflammatory drug with ciprofloxacin has 
been reported to increase the risk of CNS stimulation and convulsive seizures.
Antacids containing aluminum or magnesium hydroxide have been shown to reduce the 
absorption of ciprofloxacin. Concurrent administration with these agents should be avoided. 
Renal Impairment
Since ciprofloxacin is eliminated primarily by the kidney. CIPRO* should be used with 
caution and at a reduced dosage in patients with impaired renal function (see DOSAGE AND 
ADMINISTRATION).
ADVERSE REACTIONS
CIPRO ‘ (Ciprofloxacin Hydrochloride Monohydrate) is generally well tolerated. During worldwide 
clinical investigation, 8,861 courses ot ciprofloxacin treatment were evaluated tor drug 
safety. (Included in this evaluation were data from 283 patients who received ciprofloxacin 
only intravenously and 169 patients who received sequential rntravenous/oral ciprofloxacin 
therapy.)
Adverse events, whether drug-related or not, occurred in 10.2% of patients. These adverse 
events occurred in the following frequencies: Gastrointestinal System (5.0%), Central 
Nervous System (1.6%), Skin/Hypersensitivity (1.4%), and Adverse Laboratory Changes
(5.6%). ’ ", !
The most frequently reported events, drug-related or net were nausea (.}.#%> and diarrhea
Additional events that occurred in less than 1 % of ciprofloxacin courses are listed beibw:
Gastrointestinal vomiting, dyspepsia, abdominal pain, anorexia
Central Nervous System: dizziness, light-headedness, headadtfe, Cervoustless, anxiety,
agitation, restlessness, tremor, lethargy, drowsiness, somnolence
Skin/Hypersensitivity: rash, pruritus, local edema, urticaria, increased perspiration,
photosensitivity
Most of the adverse events were described as only mild or moderate in severity.
There have been 9 reports of arthropathy associated with CIPRO". Three of these reports 
involved children. Arthralgia was usually the first symptom which led to rapid assessment 
and withdrawal of the drug. No irreversible arthropathies have been observed.
Adverse Laboratory Changes
Changes in laboratory parameters listed as adverse events without regard to drug relationship (5.6%): 
Hepatic: Elevations of: SGPT (1.3%), SGOT (1.4%),
Alkaline Phosphatase (0.4%), y  glutamyl transpeptidase (0.3%),
LDH (0.3%), Serum bilirubin (9.1%)
Hematologic: Eosinophilia (0.6%), leukopenia (0.2%)
Renal: Elevations of: Serum creatinine (0.3%), BUN (0.3%)
Other changes occurring in less than 0.1% of courses were: elevated uric acid, elevated 
cholesterol, increase in blood platelets, monocytes, and leukocytes.
SYMPTOMS AND TREATMENT OF OVERDOSE
Overdose has not yet been reported with CIPRO" (Ciprofloxacin Hydrochloride Mono­
hydrate). In the event of acute overdosage, the stomach should be emptied by inducing 
vomiting or by gastric lavage. The patient should be carefully observed and given sup­
portive treatment.
DOSAGE AND ADMINISTRATION
The determination of dosage for any particular patient must take into consideration the 
severity and nature ot the infection, the susceptibility of the causative organism and the 
status ot renal function.
CIPRO® (Ciprofloxacin Hydrochloride Monohydrate) may be taken before or after meals. 
Absorption is faster on an empty stomach. Patients should be advised to drink fluids liberally 
and not take antacids containing magnesium or aluminum.
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Adult
The recommended dosages of CIPRO*' are:
Location of 
Infection Type/Severity
Unit
Dose
Fre­
quency
Daily
Dose
Urinary Tract Mild/Moderate
Severe/Complicated
250 mg 
500 mg
q 12h 
q 12h
500 mg 
1000 mg
Lower Respiratory 
Tract
Bone & Joint 
Skin 8 Soft Tissue
Mild/Moderate
Severe/Complicated*
500 mg 
750 mg
q 12h 
q 12h
1000 mg 
1500 mg
Infectious Diarrhea M i Id/Moderate/Severe 500 mg q 12h 1000 mg
*  e.g. hospital-acquired pneumonia, osteomyelitis.
Depending on the severity of the infections, as well as the clinical and bacteriological 
responses, the average treatment period should be approximately 7 to 14 days. Generally, 
treatment should last 3 days beyond the disappearance of clinical symptoms or until 
cultures are sterile. Patients with osteomyelitis may require treatment for a minimum of 6 
to 8 weeks and up to 3 months. With acute cystitis, a five-day treatment may be sufficient. 
Impaired Renal Function
Ciprofloxacin is eliminated primarily by renal excretion. However, the drug is also metabo­
lized and partially cleared through the biliary system of the liver and through the intestine 
(see Product Monograph: HUMAN PHARMACOLOGY). This alternate pathway of drug 
elimination appears to compensate for the reduced renal excretion of patients with renal 
impairment. Nonetheless, some modification of dosage is recommended, particularly for 
patients with severe renal dysfunction. The following fable provides dosage guidelines for 
use in patients with renal impairment. However, monitoring of serum drug levels provides 
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nephrostomy dislodgement (1), fail­
ure of a dilated balloon catheter to 
deflate (1), formation of a urinoma 
(1), retroperitoneal hematoma (1), 
pleural effusion (2), delayed he­
morrhage (3), splenic laceration (1), 
renal artery pseudoaneurysm (1), 
renal artery laceration (1) and septic 
shock (10).
Discussion
Since percutaneous renal access 
has become a routine urologic pro­
cedure, the incidence of related 
complications has increased. Those 
reported include bleeding requiring 
transfusion, infection, urinoma, pel­
vic laceration, ureteral avulsion, ob­
struction at the ureteropelvic junc­
tion or ureteral stricture, pneumo­
thorax or hemothorax, bowel inju­
ry, renal vein thrombosis, arteriove­
nous fistula formation, renal or pe­
rirenal abscess, and death second­
ary to myocardial infarction, sepsis
or respiratory failure.1-7 Most of 
these complications can be man­
aged conservatively1-6 as we have 
illustrated.
With improved angiographic ex­
pertise, vascular complications such 
as pseudoaneurysm, laceration of a 
branch of the renal artery and arte­
riovenous fistulas can be managed 
by techniques of vascular access 
and embolization.4-6 Case 1, in 
which Gelfoam embolization in the 
percutaneous tract was used, is a 
recent variation of previous tech­
niques.4-6
Advances in intensive care medi­
cine have permitted successful man­
agement of septic shock and hemol­
ysis-hyponatremia-renal shutdown 
syndrome, conditions that are po­
tentially fatal. Increasing expertise 
has resulted in percutaneous ne­
phrolithotomy and extracorporeal 
shock-wave lithotripsy virtually re­
placing open surgical lithotomy and 
permits nonoperative management 
of associated complications.
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Natural History of Vertical Abdominal 
Parietal Closure: Prolene Versus Dexon
R.T. Lewis, MD, FRCSC, FACS;* F.M. Wiegand, MD, FRCSCf
The long-term outcome of laparotomy incisions after mass closure (taking large 
tissue bites through all layers) with continuous polypropylene (Prolene) in 95 
patients or interrupted poly glycolic acid (Dexon) sutures in 105 patients was 
compared by randomized prospective study. Of the 200 patients, 194 incisions were 
median and 2 were paramedian (4 patients were excluded). There was one wound 
dehiscence (0.51%) due to slippage of a polypropylene knot. At 5-year follow-up,
4 hernias were found in incisions repaired with polypropylene, compared with 11 
in the polyglycolic acid group; 10 of the 11 occurred after the first year (p = 0.01). 
Wound infections were slightly more frequent in patients whose incision was closed 
with polypropylene. Only two hernias in each group occurred in patients who had 
had wound infections. Polypropylene and polyglycolic acid both allow rapid and 
secure closure of vertical laparotomy incisions, but late herniation is more common 
when polyglycolic acid sutures are used.
Dans une etude prospective et randomisee, on a compare 1’evolution a long terme 
des incisions de laparotomie, soit apres fermeture large chez 95 patients (en prenant 
de larges piqures a travers toutes les couches de tissus) a l’aide de polypropylene 
continu (Prolene), soit apres suture a points separes chez 105 patients a l’aide de fil 
d’acide polyglycolique (Dexon). Chez ces 200 patients, on a compte 194 incisions 
medianes et 2 paramedianes (4 cas ayant ete elimines). On a enregistre une seule 
desunion de suture de plaie (0.51%) due au lachage d’un noeud de polypropylene. 
Apres 5 ans de surveillance des suites therapeutiques, on a denombre 4 hernies 
d’incisions reparees avec du polypropylene, comparativement a l l  dans le groupe 
acide polyglycolique; 10 des 11 sont survenues apres la premiere annee (p = 0.01). 
Les infections de plaie ont ete legerement plus frequentes chez les patients dont 
l’incision avait ete refermee avec le polypropylene. Seulement deux hernies dans 
chaque groupe ont ete notees chez des patients qui avaient subi des infections de 
plaie. Le polypropylene et l’acide polyglycolique assurent, tous deux, une fermeture 
rapide et solide des incisions verticales de laparotomie, mais les hernies tardives 
sont plus frequentes avec les sutures d’acide polyglycolique.
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A lthough the incidence of wound dehiscence has de­
creased to nearly 1% with the use of 
mass closure (through and through, 
taking large tissue bites) and proper 
surgical technique,1'4 wound failure 
because of incisional hernia remains 
a problem.5 In addition to a 5% to 
7% incidence of herniation in the 
first year after laparotomy,1 just as 
many hernias appear again later,6'8 
and the results of repair by conven­
tional methods are still poor.910
The main causes of herniation 
are wound dehiscence1 Land postop­
erative complications, such as 
wound infection, pulmonary compli­
cations and abdominal disten­
sion.112 The role played by the type 
of suture material in causing post­
operative herniation is uncertain. 
Many studies13-17 have shown no 
difference in the incidence of her­
niation with either absorbable or 
nonabsorbable sutures, but the fol­
low-up has been short. Others1819 
have noted more hernias when ab­
sorbable sutures were used.
We conducted a prospective ran­
domized study of patients who had 
mass closure of vertical laparotomy 
wounds to identify and compare the 
outcomes of incisions closed with 
absorbable and nonabsorbable su­
tures.
Patients and Methods
Two hundred consecutive vertical 
laparotomy wounds longer than 10
1
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cm were randomized at operation 
by the last digit of the patient’s year 
of birth. Patients born in even years 
had the wound closed with inter­
rupted Smead-Jones sutures20 of 
no. 1 polyglycolic acid (Dexon; 
Davis and Geek, Markham, Ont.), 
and patients born in odd years had 
the wound closed with continuous 
simple sutures of no. 1 poly­
propylene (Prolene; Ethicon Ltd., 
Peterborough, Ont.). In each case, 
care was taken to include mus- 
culoaponeurotic tissue bites at least 
1 cm from the wound edge. Sutures 
were not pulled tight and they were 
placed 1 to 2 cm apart. The subcu­
taneous fat was approximated with 
interrupted sutures of 4-0 poly­
glycolic acid and the skin with 
simple sutures of 5-0 nylon (Ethi- 
lon; Ethicon Ltd.).
For each patient, the age, sex, 
weight and height and preoperative 
blood concentrations of hemoglo­
bin, urea nitrogen and bilirubin 
were recorded. Values of ideal body 
weight for height and body build 
were obtained from standard ta­
bles,21 and the percentage actual of 
ideal body weight was derived for 
each patient. The operative diagno­
sis, type of operation, degree of 
wound contamination,22 presence of 
a previous abdominal wound, ur­
gency of operation and periopera­
tive use of antibiotic prophylaxis 
and steroids were noted. For some 
patients, we measured the time 
taken to close the fascia and the 
length of the wound.
After operation, the patients were 
followed up daily by physiotherapy 
personnel for development of pul­
monary complications. Sputum cul­
ture and chest x-ray films were 
obtained as indicated clinically. A 
scoring system was used to evaluate 
postoperative pulmonary complica­
tions, four or more points being 
regarded as significant.23 The 
wounds were inspected by infection 
control personnel 5 days after oper­
ation and before the patient was 
discharged. A further follow-up was 
made 1 month later.
A wound infection was diagnosed 
when pus drained from the 
wound.24 A sample of the draining 
material was cultured. Wounds that 
were erythematous or tender were 
monitored until they drained pus or 
the signs subsided. The surgeon 
evaluated clinically any gross ab­
dominal distension caused by uri­
nary bladder, bowel or ascites dur­
ing the first week postoperatively.
After discharge from hospital, 
the patients were followed up by a 
single surgeon at 1, 3, 6, 12, 24 
and 60 months. The end-points for 
wound failure were wound dehis­
cence, diagnosed only when eviscer­
ation occurred, and incisional her­
nia, defined as a defect with sharp 
fascial margins and presenting as a 
bulge when the patient strained 
while standing. The outcomes with 
respect to these end-points were 
analysed by the life-table meth­
od.2526
Statistical analysis was performed
when necessary by Student’s f-test, 
Fisher’s exact test and x2 analysis 
with the Yates modification, and 
the outcomes derived from life-table 
data were compared by the log rank 
X 2 equivalent.
Results
Of the 200 patients who entered 
the study, 105 had fascial closure 
of the laparotomy wound with 
Dexon and 95 with Prolene. Two 
patients from each treatment group 
were excluded from further analy­
sis. Two died within a week of 
surgery, a third required reopera­
tion on the first postoperative day 
and in the fourth the protocol was 
violated by the use of retention 
sutures in addition to fascial clo­
sure. Thus, 196 incisions were eval­
uated; 194 were median and 2 pa­
ramedian. Fifty-two incisions were 
confined to the lower abdomen. In a 
few patients in each group, the 
incision was made through a previ­
ous laparotomy scar. Table I com­
pares the treatment groups and 
shows that they were similar in 
mean age, sex distribution and pa­
tient weight, and in the frequency 
of anemia, jaundice, uremia, malig­
nant disease and preoperative ste­
roid usage.
Wound infections were slightly 
more frequent in incisions closed 
with Prolene, which was used more 
for emergency operations, than in 
incisions closed with Dexon, but the 
difference was not significant. Pro­
phylactic use of antibiotics and 
wound class were also similar in the 
two groups (Table II). Table III 
shows the frequency of wound in­
fection and type of operation per­
formed in each treatment group.
Respiratory complications devel­
oped in 26 wounds closed with 
Prolene and in 21 closed with Dex­
on. Abdominal distension was re­
corded postoperatively in 33 pa-
Table  1. Patient Data
Dexon Prolene
(n =  103) (n =  93 )
Mean age, yr (±  SEM) 56.8 ±  17 55.8 ± 18
Sex (male/female), no. 44 /59 48/45
Weight, actual/ideal, % 111.5 ±  20 111.6 ± 24
Hemoglobin (<  100 g /L), no. 
Blood urea nitrogen
8 13
(>  10.7 m m ol/L  urea), no. 10 5
Bilirubin (>  34.2 Mmol/L), no. 6 6
Malignant disease, no. 29 21
Steroid use, no. 6 4
Primary/repeat incisions, no. 80 /23 73/20
CJS. VOL. 32. NO. 3. MAY 1989 197
LEWIS & WIEGAND
tients in the Prolene group and in 
27 in the Dexon group (not signifi­
cant). Fascial closure time was 49 
s/cm  for Dexon and 41 s/cm  for 
Prolene (p < 0.05).
The only case of wound dehis­
cence was caused by slipping of a 
Prolene knot. Incisional hernias 
were more frequent in the Dexon 
group, and the majority were seen 
after the first year of follow-up 
(Table IV). In each group, only two 
hernias developed in patients who 
had had wound infections. In Fig. 
1, the outcomes in the two treat­
ment groups are evaluated by the 
life-table method (p < 0.05).
Discussion
The ideal suture for fascial clo­
sure should not cause infection or 
irritation; it should achieve its pur­
pose in holding the wound edges 
together but disappear when its 
work is done.27 This implies that an 
absorbable suture should be ideal. 
However, studies have shown that 
when catgut, the natural absorbable 
suture, is used to close median and 
standard paramedian laparotomy 
wounds, the incidence of wound 
dehiscence is unacceptably high.3 
The reason is that catgut loses its
tensile strength after only 10 days, 
well before healing fascia has 
gained sufficient strength. This is 
not a problem when modern syn­
thetic sutures are used. Synthetic 
nonabsorbable sutures and absorb­
able sutures have markedly de­
creased the incidence of wound de­
hiscence, particularly when the 
technique of mass closure is ap­
plied.20 In addition, Jenkins2 and 
others,161728 have shown that for 
mass closure a continuous suture is 
as effective as interrupted sutures 
in preventing wound dehiscence, 
and can be placed more quickly. 
The present study, then, is an ethi­
cal and valid comparison of mass 
closure comparing polypropylene 
with polyglycolic acid sutures.
In our trial, the rate of wound 
dehiscence was 0.51%. Thus, we 
have confirmed that mass closure 
using either of these suture materi­
als effectively prevents abdominal 
wound dehiscence. In mass closure, 
large tissue bites avoid the zone of 
increased collagenase activity that 
extends up to 5 mm from the 
wound margin,29 and, compared 
with small bites, they distribute the 
tension in the suture over a large 
area, making tissue necrosis less 
likely.4'30 As in previous studies,1617 
continuous suture closure in our
trial was completed more quickly 
than closure with interrupted su­
tures.
We have also shown that Dexon 
sutures are associated with more 
late herniations through laparoto­
my incisions than Prolene. This 
preponderance of late herniation in 
the polyglycolic acid group was not 
due specifically to postoperative 
complications, for only two hernias 
in each group developed after 
wound infections; also, pulmonary 
complications and abdominal disten­
sion were less frequent in the 
Dexon group than the Prolene 
group.
It seems likely that most hernias 
were caused by failure of the poly­
glycolic acid suture material. Apo­
neurotic incisions of the abdominal 
wall are much less vascular and 
heal more slowly than skin wounds. 
They require about 120 days to 
regain strength.31 Unfortunately, 
polyglycolic acid loses 80% of its 
tensile strength within 2 weeks of 
operation,32 and more than 90% 
within 3 weeks.3334 At that time, 
aponeurotic wounds have reached 
only 20% of the preoperative 
strength of the fascia. It is assumed 
that the tensile strength of poly­
glycolic acid is sufficient to prevent 
wound dehiscence, but that the su­
ture fails during the collagen matu­
ration phase of wound healing.35 
The resulting weakness presents 
later as an incisional hernia. Play- 
forth and colleagues,36 found that 1 
month after operation radiopaque 
markers placed on the fascial mar­
gins at surgery showed a separation 
of more than 10 mm, predicting
T a b le  II. C o m p a riso n  o f F a c to rs  R e la tin g  to  W ound  S eps is
D exon P rolene
W o u n d  in fe c tio n 11 19
E m e rg e n c y /e le c tiv e  la p a ro to m y 2 1 /8 2 3 0 /6 3
P ro p h y la c tic  use o f a n tib io t ic s 67 64
W o u n d  c la s s
C lean 31 26
C le a n -c o n ta m in a te d 53 51
C o n ta m in a te d 19 16
T a b le  II I .  W o u n d  S e p s is  b y  T y p e  o f O pe ra tion
T y p e  of D exon P rolene G roup
o p e ra tio n In fec ted Uninfected Infected U ninfected S eq ue la Dexon P rolene
B ilia ry 8 40 4 31 W o u n d  in fe c tio n 11 19
U p p e r g a s tro in te s tin a l 2 21 8 30 W o u n d  deh iscence 0 1
C o lo re c ta l 1 29 5 19 In c is ion a l he rn ia 11 4
V a s c u la r 0 7 0 7 E arly 1n ?
M is c e lla n e o u s 0 6 2 6 Late i o l p _ 0.01 2
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incisional herniation that may not 
be clinically apparent until more 
than 1 year after operation.
What, then, can be done to pre­
vent postoperative incisional hernia­
tion? It remains to be seen whether 
more durable absorbable sutures 
such as polydioxanone (PDS; Ethi- 
con),37 or polyglactin 910 (Vicryl; 
Ethicon) will be more effective than 
polyglycolic acid in preventing late 
herniation. But it seems unlikely 
that they will, because Leese and 
Ellis38 found that 20% of laparoto­
my wounds closed with PDS su­
tures developed incisional hernias 
compared with 8.5% closed with 
nylon. Moreover, of seven h ial 
hernias found by Wasiljew Win­
chester39 during a mean ionth 
follow-up of 244 pat: whose
laparotomy wounds closed
with continuous m uture of 
polyglactin 910, or e followed 
a wound infectio- alternative 
course is to accept Hie thesis of 
Douglas31 that all aponeurotic 
wounds are potential sites of her­
niation. If this is so, delayed hernia­
tion can only be prevented by repair 
with nonabsorbable sutures, or by 
operating through muscle-sparing
incisions in which intact muscle 
helps to buttress the repair.4041
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BOOK REVIEWS
ABO INCOMPATIBILITY AND 
TRANSPLANTATION. Edited by 
Aaron D. Bannett, Hans Brynger, Bo 
Samuelsson, Robert F. McAlack and 
Michael Breimer. 246 pp. Illust. Grune 
& Stratton, Inc., Philadelphia; W.B. 
Saunders Company Canada Limited, 
Toronto, Ont., 1988. $81.95. ISBN 
0-8089-1951-2.
ABO-incompatible transplantation is be­
coming an important issue as the limita­
tions of our pool of donor organs are 
reached. This book is a Transplanta­
tion Proceedings reprint from December 
1987. It includes papers from the com­
bined proceedings of the First Interna­
tional Symposia on ABO Incompatibility 
and Transplantation (Philadelphia, 
March 1987 and Gothenburg, Sweden, 
June 1987).
The book is divided into three sec­
tions. The first, on the basic science of 
the ABH system, emphasizes new devel­
opments in solving its underlying com­
plexity. Papers on the current under­
standing of ABH antigen structure and 
tissue distribution are presented. In 
their paper, Socha and colleagues dis­
cuss the analogous animal blood-group 
systems and their place on the evolu­
tionary scale.
The next section is on experimental 
transplantation. Because the ABO-
incompatible transplant represents a 
model for acute humoral rejection, 
many of the papers are on xenograft- 
ing. Indeed, many of the techniques 
presented for removal of pre-formed 
natural antibodies are applicable to the 
ABO-incompatible transplant. Cerilli 
presents an interesting paper on the 
importance of vascular endothelial anti­
gen matching in kidney allografts, 
based on monocyte cross-matching. 
Paul’s review of humoral rejection 
mechanisms is excellent. In several pa­
pers, Romano and colleagues discuss 
the removal of anti blood group A 
antibodies using synthetic trisaccharide 
analogues of the A antigen. The results 
of a limited trial of intravenous adminis­
tration of these trisaccharides to human 
volunteers and their therapeutic use in 
three infants with hemolytic disease due 
to ABO incompatibility are presented.
In the last section, the clinical as­
pects of transplantation are discussed. 
It is divided into sections on the major 
transplant organs — kidney, liver, 
heart-lung and bone marrow. A clinical 
overview of ABO-incompatible trans­
plantation is provided in two separate 
papers, by Starzl and colleagues and 
Rappaport and Dausset. The majority of 
the papers include results of ABO-mis- 
matched kidney allografts, with particu­
lar emphasis on the A2 to O graft.
Different techniques for dealing with 
the anti blood group antibodies are put 
forward, including the use of im- 
munoadsorbent columns produced by 
Chembiomed in Edmonton. Finally, the 
importance of Lewis blood-group 
matching in kidney allografts is re­
viewed in two articles presenting oppo­
site viewpoints.
The section on liver transplantation 
deals primarily with survival following 
ABO-identical, ABO-compatible but 
nonidentical and ABO-incompatible 
transplants. Papers on hyperacute rejec­
tion, the importance of the Lewis blood- 
group system in liver transplantation 
and hemolysis after nonidentical trans­
plants are presented.
The section on ABO-incompatible 
heart-lung transplantation includes 
only two case reports. The first involves 
hemolysis after ABO-incompatible but 
nonidentical heart-lung transplant and 
the second, acute humoral rejection 
after an ABO-incompatible transplant.
The section on bone-marrow trans­
plantation includes papers that compare 
techniques for dealing with the prob­
lems of delayed or acute hemolysis, 
delayed hemopoiesis and graft rejection 
in ABO-incompatible bone-marrow 
transplants. Techniques discussed
continued on page 206
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Ketoconazole in the Treatment of 
Osteomyelitis Due to Candida albicans
R.M. Bannatyne, MB, ChB, Dip Bact, MRCPath, FRCPC;* H.M. Clarke, MD, PhD, FRCSCt
Osteomyelitis caused by Candida albicans is a rare condition. The authors report its 
occurrence as an infective complication in the fractured phalanx of a 3-year-old boy. 
The infection was first thought to be due to Staphylococcus aureus, but a course of 
doxacillin was unsuccessful, and when cultures of the injured finger grew C. 
albicans, a 3-month course of ketoconazole orally was begun. Ketoconazole was 
prescribed because, unlike amphotericin B, the antibiotic usually used in such cases, 
it is not nephrotoxic, it can be taken orally and it has proved successful in other 
reported cases of osteomyelitis due to C. albicans. The boy’s infection resolved and 
fracture healing was confirmed radiologically.
L’osteomyelite a Candida albicans est une affection rare. Les auteurs en decrivent un cas 
qui est survenu comme complication infectieuse de la fracture d’une phalange chez un 
garf on de 3 ans. Au debut, l’infection fut attribuee a Staphylococcus aureus, mais un 
traitement a la cloxacilline s’avera inefficace. Quand les cultures du doigt blesse mirent en 
evidence le C. albicans, une therapie de 3 mois au ketoconazole par voie orale fut mise en 
route. On a present le ketoconazole parce que, contrairement a l’amphotericine B qui est 
habituellement employee dans ces cas, cet antibiotique n’est pas nephrotoxique et il peut 
etre pris par voie orale. De plus, il s ’est deja montre efficace dans d’autres cas 
d’osteomyelite a C. albicans. L’infection du gareonnet disparut et la radiographie vint 
confirmer la guerison de la fracture.
O steomyelitis caused by Candida albicans is rare, and its optimal 
treatment is unknown. The toxicity 
of amphotericin B and the develop­
ment of resistance to 5-fluorocyto- 
sine limit the use of these custom­
ary antifungal agents. We report a 
case of osteomyelitis due to C. al­
bicans affecting the middle phalanx 
of an index finger; it was success­
fully treated with a 3-month course 
of ketoconazole taken orally.
Case Report
A 3-year-old boy sustained a cut 
to his left index finger at play. 
Within a week the digit became red 
and swollen. An x-ray film was 
made and amoxicillin was pre­
scribed. The laceration healed over 
the next 7 days but the swelling 
and redness remained. Review of 
the x-ray film revealed a transverse 
fracture of the distal shaft of the
middle phalanx of the injured fin­
ger, with a suggestion of superim­
posed infection (Fig. 1). The boy 
was admitted to hospital and started 
on an empirical 1-week course of 
doxacillin (200 m g/kg daily intra­
venously, given every 6 hours) for 
infection assumed to be caused by 
Staphyloccus aureus. There was no 
evident improvement, so explorato­
ry surgery with open debridement 
was performed. No pus was found. 
Easy mobility of the fracture indi­
cated lack of healing. A deep swab 
and two curettage specimens were 
taken from the fracture site. Cefo­
taxime (100 m g/kg  daily given 
every 6 hours) was administered 
intravenously for several days. 
When the culture results from the 
operative specimens all indicated C. 
albicans a 3-month course of keto-
FIG. 1. Infected fracture of distal shaft 
of middle phalanx of left index finger.
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conazole taken orally (50 mg/d in 
a single dose) was begun. During 
this period, progressive healing was 
observed both clinically and radio- 
logically (Fig. 2). No serious side 
effects of the drug were encoun­
tered, and the infection did not 
recur on 2-year follow-up.
Antifungal susceptibility tests 
showed that the Candida isolate 
was resistant to ketoconazole, but 
we decided to persist with the thera­
py in view of the boy’s early clinical 
improvement.
Discussion
A recent review1 uncovered only 
58 cases of osteomyelitis due to C. 
albicans in the English literature. 
Our case, which meets the diagnos­
tic criteria of Edwards and col­
leagues2 — radiologic evidence of 
osteomyelitis plus isolation of C. 
albicans from deep tissue — was 
unusual in several respects. First, 
the infection involved a digit,
FIG. 2. Healing of lesion of middle 
phalanx.
whereas C. albicans usually affects 
single long bones, contiguous verte­
bral bodies or the sternum. Second, 
the infection appeared to be prima­
ry, following trauma, rather than 
secondary to bloodstream involve­
ment or a surgical procedure. Final­
ly, we used ketoconazole in place of 
the more widely favoured am­
photericin B.
This decision was based on the 
success of ketoconazole in blasto­
mycosis,3 another yeast-like fungal 
infection in which bone involvement 
is a prominent part. The relative 
resistance of our patient’s isolate 
did not deter us from persisting 
with the drug, since previous inves­
tigators4-5 have noted a poor corre­
lation between its in-vitro activity 
and clinical performance. In addi­
tion, ketoconazole has been used as 
the primary agent in five reported 
cases of osteomyelitis due to C. 
albicans with favourable clinical re­
sponses.1 It is not associated with 
the undesirable, nephrotoxic side 
effects of intravenously adminis­
tered amphotericin B and its ease of 
administration is an attractive fea­
ture.
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BMEFOXIN®
(sterile cefoxitin sodium, MSD Std.)
ANTIBIOTIC
ACTION
In vitro studies demonstrate that the bactericidal 
action of cefoxitin, a cephamycin derived from 
cephamycinC, results from the inhibition of 
bacterial cell wall synthesis. Evidence suggests 
that the methoxy group in the 7a position is 
responsible for the resistance of cefoxitin to 
degradation by bacterial beta-lactamases.
INDICATIONS AND CLINICAL USES
TREATMENT
The treatment of the following infections when 
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo­
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and 
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and joint infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies 
should be performed to determine the suscepti- 
b ility  of the causative organism(s) to 
MEFOXIN®. Therapy may be started while 
awaiting the results ot these tests, however, 
modification of the treatment may be required 
once these results become available.
Organisms particularly appropriate for therapy 
with MEFOXIN® are:
Gram positive
Staphylococci, penicillinase producing and 
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing and 
non-producing strains)
E. coli
Klebsiella species (including K. pneumoniae) 
Proteus, indole positive and negative 
Haemophilus influenzae 
Providencia species 
Anaerobes 
Bacteroides fragilis
MEFOXIN® may also be appropriate for the 
treatment of infections involving susceptible 
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas, 
most strains of enterococci, many strains of 
Enterobacter cloacae, and methicillin-resistant 
staphylococci and Listeria monocytogenes. 
Clinical experience has demonstrated that 
MEFOXIN® can be administered to patients who 
are also receiving carbenicillin, gentamicin, 
tobramycin, or amikacin (see PRECAUTIONS 
and ADMINISTRATION).
Intravenous Administration 
The intravenous route is preferable for patients 
with bacteremia, bacterial septicemia, or other 
severe or life-threatening infections, or for 
patients who may be poor risks because of 
lowered resistance resulting from such debili­
tating conditions as malnutrition, trauma, 
surgery, diabetes, heart failure, or malignancy, 
particularly if shock is present or impending.
PROPHYLACTIC USE
MEFOXIN® may be administered periopera- 
tively (preoperatively, intraoperatively and post- 
operatively) to patients undergoing vaginal or 
abdominal hysterectomy and abdominal 
surgery when there is a significant risk of 
postoperative infection or where the occurrence 
of postoperative infection is considered to be 
especially serious.
In patients undergoing cesarean section, intra­
operative (after clamping the umbilical cord) 
and postoperative use of MEFOXIN® may 
reduce the incidence of surgery related post­
operative infections.
Effective prophylactic use depends on the time 
of administration. MEFOXIN® usually should be 
given one-half to one hour before the operation. 
Prophylactic administration should usually be 
stopped within 12 hours. It has been generally
A
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reported that continuing administration of any 
antibiotic beyond 24 hours following surgery 
increases the possibility of adverse reactions 
but, in the majority of surgical procedures, does 
not reduce the incidence of subsequent 
infection.
If signs of postsurgical infection should appear, 
specimens for culture should be obtained for 
identification of the causative organism(s) so 
that appropriate therapy may be instituted.
CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who 
have shown hypersensitivity to cefoxitin or to 
the cephalosporin group of antibiotics.
WARNINGS
Before therapy with MEFOXIN® is instituted, 
careful inquiry should be made to determine 
whether the patient has had previous hyper­
sensitivity reactions to MEFOXIN®, cephalo­
sporins, penicillins or other drugs. MEFOXIN® 
should be given with caution to penicillin- 
sensitive patients.
There is some clinical and laboratory evidence 
of pa rtia l c ro s s -a lle rg e n ic ity  between 
cephamycins and the other beta-lactam anti­
biotics, penicillins and cephalosporins. Severe 
reactions (including anaphylaxis) have been 
reported with most beta-lactam antibiotics. 
Pseudomembranous colitis has been reported 
with virtually all antibiotics. This colitis can 
range from mild to life threatening in severity. 
Antibiotics should therefore be prescribed with 
caution in individuals with a history of gastro­
intestinal disease, particularly colitis. It is 
important to consider a diagnosis of pseudo­
membranous colitis in patients who develop 
diarrhea in association with antibiotic use. While 
studies indicate that a toxin produced by 
Clostridium difficile is one primary cause of 
antibiotic-associated colitis, other causes 
should also be considered.
Any patient who has demonstrated some form of 
allergy, particularly to drugs, should receive 
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs, 
administration of the drug should be discon­
tinued. Serious hypersensitivity reactions may 
require treatment with epinephrine and other 
emergency measures.
PRECAUTIONS
The total daily dosage should be reduced when 
MEFOXIN® is administered to patients with 
transient or persistent reduction of urinary 
output due to renal insufficiency (see DOSAGE 
AND ADMINISTRATION) because high and 
prolonged serum antibiotic concentrations can 
occur from usual doses.
In patients treated with MEFOXIN® a false­
positive reaction to glucose in the urine may 
occur with Benedict's or Fehling’s solutions but 
not with the use of specific glucose oxidase 
methods.
Using the Jaffe Method, falsely high creatinine 
values in serum may occur if serum concen­
trations of cefoxitin exceed 100pg/mL. Serum 
samples from patients treated with MEFOXIN® 
should not be analyzed for creatinine if with­
drawn within two hours of drug administration, 
increased nephrotoxicity has been reported 
fo llow ing concom itant adm inistration of 
cephalosporins and aminoglycoside antibiotics. 
The safety of MEFOXIN® in the treatment of 
infections during pregnancy has not been 
established. If the administration of MEFOXIN® 
to pregnant patients is considered necessary, its 
use requires that the anticipated benefits be 
weighed against possible hazards to the fetus. 
Reproductive and teratogenic studies have been 
performed in mice and rats and have revealed no 
evidence of impaired fertility or harm to the fetus 
due to MEFOXIN®.
Cefoxitin has been observed in the milk of 
nursing mothers receiving the drug.
Prolonged use of MEFOXIN® may result in the 
overgrowth of non-susceptible organisms. 
Repeated evaluation of the patient’s condition is 
essential and if superinfection occurs during 
therapy, appropriate measures should betaken. 
Should an organism become resistant during 
antibiotic therapy, another antibiotic should be 
substituted.
In children 3 months of age or older, higher 
doses of MEFOXIN® (100mg/kg/day and
above) have been associated with an increased 
incidence of eosinophilia and elevated SGOT.
ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse 
reactions rarely required cessation of treatment 
and usually have been mild and transient.
Local Reactions
Thrombophlebitis has occurred with intra­
venous administration. Some degree of pain and 
tenderness is usually experienced after intra­
muscular injections using water. Induration has 
occasionally been reported.
Allergic
Maculopapular rash, urticaria, pruritus, eosino­
philia, fever and other allergic reactions have 
been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can 
appear during or after antibiotic treatment. 
Nausea and vomiting have been reported rarely.
Blood
Transient eosinophilia, leukopenia, neutropenia, 
hemolytic anemia, and thrombocytopenia have 
been reported. Some individuals, particularly 
those with azotemia, may develop positive direct 
Coombs tests during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum 
LDH, and serum alkaline phosphatase have 
been reported.
Kidney
Elevations in serum creatinine and/or blood 
urea nitrogen levels have been observed. As 
with the cephalosporins, acute renal failure has 
been reported rarely. The role of MEFOXIN® in 
changes in renal function tests is difficult to 
assess, since factors predisposing to prerenal 
azotemia or to impaired renal function have 
often been present.
TREATMENT OF OVERDOSE
Other than general supportive treatment, no 
specific antidote is known. MEFOXIN® can be 
eliminated by dialysis in patients with renal 
insufficiency.
DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously 
or in tram uscu larly  when required. (See 
complete monograph on ADMINISTRATION 
and RECONSTITUTION.)
TREATMENT DOSAGE 
Adults
The usual adult dosage is 1 g or 2 g of 
MEFOXIN® every 6 to 8 hours. Dosage and route 
of administration should be determined by 
severity of infection, susceptibility of the 
causative organisms, and condition of the 
patient. The usual adult dosages are shown in 
the Table below.
Usual Adult Dosage
T y p e  o f 
In fe c tio n
D a ily
D o s a g e
F re q u e n c y  
a n d  R o u te
Uncomplicated 
forms* of in­
fections such as 
pneumonia, 
urinary tract 
infection, soft 
tissue infection
3-4 g 1 g every 6-8 h 
I.V. or I.M.
Moderately 
severe or severe 
infections
6-8 g 1 g every 4 h
or
2 g every 6-8 h I.V.
Infections 
commonly 
needing anti­
biotics in higher 
dosage (e.g. gas 
gangrene)
12 9 2 g every 4 h
or
3 g every 6 h I.V.
•Including patients 
absent or unlikely
in whom bacteremia is
Therapy may be started while awaiting the 
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic 
streptococcal infections should be maintained 
for at least 10days to guard against the risk of 
rheumatic fever or glomerulonephritis. In 
staphylococcal and other infections involving a 
collection of pus, surgical drainage should be 
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients with 
reduced renal function but a reduced dosage
should be employed and it is advisable to 
monitor serum levels in patients with severe 
impairment.
In adults with renal insufficiency, an initial 
loading dose of 1 g to 2 g should be given. After 
a loading dose, the following recommendations 
for maintenance dosage may be used as a guide:
R ENAL C R E A T IN IN E
F U N C T IO N C L E A R A N C E
m L /m ln
D O S E F R E Q U E N C Y
Mild
impairment
Moderate
50-30 1-2 g every 8-12 h
impairment 29-10 1-2 g every 12-24 h
impairment
Essentially
9-5 0.5-1 g every 12-24 h
no function <5 0.5-1 g every 24-48 h
In the patient undergoing hemodialysis, the 
loading dose of 1 - 2 g should be given after each 
hemodialysis, and the maintenance dose should 
be given as indicated in the Table above. 
Neonates (Including Premature Infants), Infants 
and Children (See WARNINGS for Neonates 
under ADMINISTRATION in the complete 
monograph.)
P re m a tu re  In fa n ts  
w ith  B o d y  W e ig h ts  
A b o v e  1 5 0 0  g 20-40 mg/kg every 12 h I.V.
N e o n a te s
0- 1 week of age
1- 4 weeks of age
20-40 mg/kg every 12 h I.V. 
20-40 mg/kg every 8 h I.V.
In fa n ts
1 month to 2 years 
of age
20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
C h ild re n 20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
In severe infections, the total daily dosage in 
infants and children may be increased to 
200mg/kg, but not to exceed 12 g per day. 
MEFOXIN® is not recommended for the therapy 
of meningitis. If meningitis is suspected, an 
appropriate antibiotic should be used.
At present there is insu ffic ien t data to 
recommend a specific dosage for children with 
impaired renal function. However, if the 
administration of MEFOXIN® is deemed to be 
essential the dosage should be modified 
consistent with the recommendations for adults 
(see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of 
MEFOXIN® is recommended as follows: 
Vaginal or abdominal hysterectomy and 
abdominal surgery
2g  administered intramuscularly or intra­
venously just prior to surgery (approximately 
one-half to one hour before initial incision).
The second and third 2 g doses should be 
administered at 2-6 hour intervals after the initial 
dose.
Cesarean Section
The first dose of 2g should be administered 
intravenously as soon as the umbilical cord has 
been clamped. The second and third 2g doses 
should be given in travenously o r intra­
muscularly four hours and eight hours after the 
first dose.
AVAILABILITY
MEFOXIN® is supplied as sterile powder in 
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt 
Storage
MEFOXIN® in the dry state should be stored 
below 30° C.
PRODUCT MONOGRAPH AVAILABLE 
ON REQUEST
(425-a,6,87x)
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Studies of DNA Content in Cervical 
Intraepithelial Neoplasia by Cytologic and 
Histologic Flow Cytometry
B. Lambert, MD, FRCSC;* B. Barrette, MD;* Y. LePage, PhDt
Flow cytometry was done on 82 specimens of cervical cytologic scrapings and 
biopsies from patients with cervical intraepithelial neoplasia or condyloma. This 
study yielded significant results when compared with standard cytologic (p < 0.01) 
and histopathologic studies (p < 0.05). Histologic evaluation by flow cytometry 
required more examinations and did not give significant results. The authors 
conclude that cytologic flow cytometry, though not a replacement for standard 
cytologic examination, may be of help in establishing therapeutic strategies and 
follow-up protocols for patients with cervical precancerous conditions.
Un examen fluorocytometrique a ete pratique sur 82 prelevements cytologiques ou 
biopsies cervicales provenant de patientes porteuses de neoplasies intra-epitheliales 
cervicales ou de condylomes. Cette etude a revele des differences significatives par 
rapport aux examens cytologiques (p < 0.01) et histologiques (p < 0.05) courants. 
L’evaluation histologique par fluorocytometrie a necessity des examens plus nombreux et 
n’a pas apporte de resultats significatifs. Les auteurs conduent que meme si la 
cytofluorocytometrie ne remplace pas l’examen cytologique standard, elle peut contri- 
buer a l’etablissement des strategies therapeutiques et du suivi clinique des patientes 
souffrant de pre-cancer cervical.
A bnormal DNA content is known to influence tumour ag­
gressiveness and the malignant po­
tential of cervical intraepithelial 
neoplasia (CIN).1-2 We studied DNA 
indices by flow cytometry in rela­
tion to cytologic and histopatholog­
ic findings in patients with CIN.
We wanted to verify the clinical 
applicability of cytologic flow cy­
tometry as a screening test for 
cellular malignancy, to evaluate the 
association between DNA content
Accepted fo r publication Oct. 12, 1988
and histologic interpretation and to 
evaluate the malignant potential of 
the different degrees of CIN.
Patients and Methods
Patients with abnormal cervical 
smears were seen at colposcopy 
clinics for evaluation of CIN. Crit­
eria for eligibility were: proposed 
conservative treatment for CIN and 
a lesion with a minimum surface
area of 50 mm2. Cervical scrapings 
were taken for the Papanicolaou 
test and for cytologic flow cytome­
try.
Originally, 97 patients underwent 
two cytologic examinations for eval­
uation of cytoploidy and one stan­
dard cytologic examination.
In 82 patients, two biopsies were 
taken using Kervorkian forceps — 
one for histologic diagnosis, the 
other for histologic flow cytometry. 
Controls chosen had negative Papa­
nicolaou test results, no colposcop- 
ic aceto-white epithelium, and no 
punctate or mosaiform changes. Cy­
tologic identification of a condylo­
ma was the presence of cytoplasmic 
koilocytosis, with enlarged hyper- 
chromatic nuclei and, histologically, 
the partial replacement of the cervi­
cal epithelium with koilocytes. Cy­
tologic features of CIN were the 
presence, in variable quantities, of 
cervical cells with hyperchromatic 
nuclei and an increase in the nu­
clear-cytoplasmic ratio. The histo­
logic features of CIN corresponded 
to those of progressive replacement 
of the cervical epithelium by malig­
nant cells with an increased nu­
clear-cytoplasmic ratio varying in 
thickness from one-third of the epi­
thelium in CIN grade I to two- 
thirds in CIN grade II and at least 
seven-eighths in CIN grade III.
In the laboratory, the specimens 
were processed to obtain a unicellu­
lar suspension. The spatula of the 
cervical scraping was washed with
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fDepartment o f  Mathematics, Universite de Montreal, Montreal, PQ
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normal (0.9%) saline and fixed in 
95% ethanol. The microbiopsy spec­
imen was minced mechanically with 
a scalpel, passed through a 21 
gauge needle, washed in normal 
(0.9%) saline, then fixed. Before 
staining with fluorochrome, fixed 
cells were treated with 0.5% pepsin 
for 8 minutes and then neutralized 
with TRIS-buffer. They were 
stained with propidium iodide for 
20 minutes at 4°C. The cells were 
then passed through a 70-gauge 
nylon mesh filter and treated with 
ribonuclease. Normal human lym­
phocytes were used as normal dip­
loid standard for the DNA content. 
Statistical analysis was by the x2 
test.
Results
Cytoploidy and Cytologic Findings
Study of the association between 
cytologic and cytoploidy findings 
revealed that condyloma (HPV) and 
CIN grade III yielded the highest
percentage of abnormal DNA con­
tent (70% and 64.7% respectively) 
as opposed to CIN I and normals (< 
24%) (Table I).
Inversely, the normal content in 
condylomas and CIN III fell to 30% 
and 35.3% respectively. Despite the 
small number of patients in each 
group, comparison of CIN and con­
dylomas with controls gave a sig­
nificant result (p < 0.01). When 
CIN I and CIN II were compared 
with CIN III the difference was 
mildly significant (p < 0.06).
Cytoploidy and Histologic Findings
The same tests were applied 
when the cytoploidy findings were 
compared with the histopathologic 
findings (Table II). Condylomas and 
CIN III behaved differently (p < 
0.05) from the milder degrees of 
CIN and controls. There was a 
significant difference (p =  0.02) 
between CIN I and CIN II versus 
CIN III, although the difference 
between CIN I versus CIN II and 
CIN III was not significant.
T a b le  1. Association Between Cytoploidy and Cytologic Findings (N =  97)
C ytologic  find ing s, no. (% )
C ytoploidy C ontrols HPV CIN 1 CIN  II C IN  III
Normal
Abnormal
34 (77.3) 
10 (22.7)
3 (30) 
7 (7 0 )
10 (76.9) 
3 (23.1)
8 (61.5) 
5 (38.5)
6 (35.3) 
11 (64.7)
Totals 44 10 13 13 17
T a b le  II. Association Between Cytoploidy and Histologic Findings (N =  82)
H isto log ic  find ings, no. (% )
C ytoploidy Controls HPV CIN 1 C IN  II C IN  I I I
Normal 20 (76.9) 3 (42.8) 13 (76.5) 9 (7 5 ) 8 (40)
Abnormal 6 (23.1) 4 (57.2) 4 (23.5) 3 (2 5 ) 12 (60)
Totals 26 7 17 12 20
T a b le  III .  Association Between Histoploidy and Histologic Findings (N =  82)
H is to log ic  find ing s, no. (% )
H istoplo idy Controls HPV CIN I C IN  II C IN  III
Normal 14 (73.7) 6 (54.5) 7 (63.6) 8 (61.5) 12 (42.9)
Abnormal 5 (26.3) 5 (45.5) 4 (36.4) 5 (38.5) 16 (57.1)
Totals 19 11 11 13 28
Histoploidy and Histologic Findings
Finally, when we compared biop­
sies by fluorocytometry to histopa­
thologic findings (Table III), no sig­
nificant difference was found. Con­
tamination by normal stromal tissue 
underlying the cervical epithelium 
could be a factor in this unexpected 
finding.
Discussion
Our study showed that, com­
pared with standard cytologic and 
histologic studies, flow cytometry, 
which assesses DNA content, gave 
significant results when condylomas 
and CIN III were compared with 
control specimens.
Similarly, Jakobsen and col­
leagues3 found a majority (78%) of 
aneuploid cells in severe dysplasias 
and carcinomas in situ, in spite of 
diploidy in mild and moderate dys­
plasias. They then associated the 
aneuploidy index with both progres­
sive and regressive characteristics. 
Tsou and colleagues4 observed clus­
ter cells in early S-phase region and 
a higher DNA content in 74.5% of 
patients who had condyloma.
We also found higher aneuploidy 
in condylomatous lesions, as if the 
viral infection was severely disturb­
ing the DNA cellular content. Bar- 
res and associates5 delineated tetra- 
ploidy indices as a demarcation be­
tween CIN grade I and CIN grades 
II and III. We found discrimination 
between CIN grades I and II and 
CIN grade III, but we conclude that 
cytologic flow cytometry is not real­
ly suitable for cytologic mass 
screening because we found abnor­
mal patterns in 22% of control 
specimens but normal cells in 35% 
of CIN III specimens. It seems that 
the numerous abnormal cells in the 
latter indicate a greater malignant 
potential than in CIN I and CIN II. 
The fact that histologic flow cy-
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tometry does not give significant 
results may be explained by the 
probable contamination of stromal 
tissue in the biopsies; this will have 
to be verified by control biopsies of 
normal areas in the vicinity of CIN. 
Further research is needed to refine 
flow cytometry; this technique 
should not be considered a replace­
ment for cytology, but an aid in the 
clinical evaluation of CIN.
We thank Dr. J. Latreille for technical
help and Dr. Harry Bard for reviewing 
the manuscript.
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range from plasma exchange and im- 
munoadsorption to cryofiltration and 
in-vivo adsorption using incompatible 
red blood cell transfusions. The last 
article reports the effects of a new 
immunosuppressive agent, Spergualin, 
on the humoral immune system.
Overall, the book is an excellent 
reference manual for physicians inter­
ested in ABO-incompatible transplanta­
tion and is essential for anyone with 
research interest in xenotransplanta­
tion. It lacks the general overview and 
cohesiveness of a textbook but makes 
up for this by being up to date. The 
editors have included papers that pres­
ent opposite viewpoints so that readers 
can formulate their own opinions on the 
controversial topics that surround ABO- 
incompatible transplantation.
Francis Sutherland, MD, FRCSC
Clinical Fellow,
Transplantation,
University Hospital,
London, Ont.
APPLICATIONS OF NONINVASIVE 
VASCULAR TECHNIQUES. Amil J. 
Gerlock, Jr., Vishan L. Giyanani and 
Carol Krebs. 541 pp. Illust. W.B. 
Saunders Company, Philadelphia; 
W.B. Saunders Company Canada Lim­
ited, Toronto, Ont., 1988. $93.60. 
ISBN 0-7216-2335-2.
This text provides an enormous amount
of anatomic and physiologic data and 
describes in detail numerous noninva- 
sive vascular techniques. There is excel­
lent anatomic, angiographic and patho­
logic correlation. The role of duplex 
ultrasonography in extracranial carotid 
artery disease is adequately discussed, 
but its role in evaluating peripheral 
arterial and venous disease is understat­
ed. Other obvious omissions include 
colour-encoded Doppler and abdominal, 
pelvic and obstetric applications of no- 
ninvasive vascular techniques. The text 
is verbose and somewhat repetitive, par­
ticularly in the discussion of plethys­
mography evaluating cutaneous and 
digital perfusion. In many chapters, the 
number of figures and examples is 
excessive.
The description of instrumentation 
and Doppler principles is simple but too 
concise, and the use of nonstandardized 
terminology causes some confusion. 
The concept of aliasing is not explained 
or discussed and no references have 
been included at the end of this section.
The section on extracranial carotid 
arteries is organized, comprehensive 
and well referenced. High-quality, real­
time ultrasound images and various 
spectral analysis patterns are included. 
The text refers to “frequency shift” 
based on a kilohertz scale, but the 
spectral images depict a velocity format, 
which is more meaningful clinically and 
should have been used throughout the 
text. Plaque morphology is well de­
scribed and illustrated, but the limita­
tion of duplex ultrasonography in the 
presence of heavily calcified plaque is 
not emphasized. Correlative duplex ul­
trasonography and angiography are 
nicely illustrated. The authors describe 
five categories of internal carotid artery 
stenosis but do not elaborate on how 
the grading system was derived. Exter­
nal carotid, common carotid and perior­
bital flow patterns are clearly explained.
The section on peripheral venous 
anatomy, flow hemodynamics, deep-vein 
thrombosis and venous insufficiency is 
well organized and beautifully illustrat­
ed. Nonimaging modalities, particularly 
photoplethysmography and strain- 
gauge plethysmography are empha­
sized.
An extensive, well-organized section 
describes systolic pressure measure­
ments and indices and peripheral arteri­
al waveforms as they pertain to aor- 
toiliac and lower-extremity arterial dis­
ease. Again, nonimaging noninvasive 
techniques are emphasized but duplex 
ultrasonography is only mentioned 
briefly.
The section on upper-extremity anat­
omy and pathology is excellent. In this 
section the chapter on duplex ul­
trasonography of superficial masses, 
however, seems rushed and incomplete, 
and greater emphasis should be placed 
on its role in the assessment of patients 
after reconstructive vascular surgery.
This text is comprehensive, accurate,
continued on page 209
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Prophylaxis of Deep-Vein Thrombosis in 
Total Hip Surgery
Richard Hu, MD
Thromboembolism is a common and serious complication of total hip replacement. 
Methods of prophylaxis include combinations of physical compression of the legs 
and anticoagulation. Results of treatment are difficult to document and quantitate. 
The authors reviewed 122 patients who underwent hip arthroplasty with 
intermittent pneumatic calf compression, intravenous administration of dextran and 
platelet inhibitors. In 20% of them, clinically suspected pulmonary embolism was 
confirmed by ventilation perfusion lung scanning. The true incidence of pulmonary 
embolism is probably greater than this and it appears that the prophylactic regimen 
used in this study does not confer any benefit.
La thromboembolie est une complication frequente et grave de l’arthroplastie totale 
de la hanche. Les moyens prophylactiques comprennent diverses associations de 
compression physique de la jambe et d’anticoagulation. Les resultats de ces 
traitements sont difficiles a verifier et a quantifier. Les auteurs ont etudie 122 
patients qui ont subi une arthroplastie de la hanche avec compression pneumatique 
intermittente du mollet, administration intraveineuse de dextran et d’inhibiteurs de 
l’agregation plaquettaire. Dans 20% des cas, une embolie pulmonaire diniquement 
soupconnee fut confirmee par scintigraphie pulmonaire de perfusion. L’incidence 
reelle des embolies pulmonaires est probablement superieure a cela et il semble que 
le traitement prophylactique utilise dans cette etude n’ait eu aucun effet favorable.
Deep-vein thrombosis and pul­monary embolism are major 
complications of total hip replace­
ment. It is estimated that 40% to 
60% of patients who do not receive 
prophylaxis will suffer deep-vein 
thrombosis.1 Pulmonary embolism 
occurs in 10% to 15% of patients 
after hip replacement, and 1% to 2% 
of all those who undergo elective 
hip replacement will die if no pro­
phylactic measure is used.2
Accepted for publication Aug. 30, 1988
The magnitude of thromboembol­
ic disease has spurred clinicians to 
attempt to lower its incidence. Dex­
tran has been used by many34 and 
in combination with intermittent 
pneumatic compression of the legs 
has proven useful in preventing 
deep-vein thrombosis and, by infer­
ence, pulmonary embolism.
At one institution in Edmonton, 
dextran combined with intermittent 
calf compression was begun on an
empirical basis for all patients ad­
mitted for total hip surgery. It is 
the aim of this paper to review the 
results of this regimen in terms of 
its effect upon the occurrence of 
pulmonary embolism.
Patients and Methods
A retrospective survey was done 
of all 122 patients admitted for 
total hip replacement surgery be­
tween January 1984 and December 
1987. Charts were reviewed for 
pertinent aspects of patient history, 
physical examination, laboratory in­
vestigations, preoperative, intraop­
erative and postoperative care as 
well as diagnosis of thromboembol­
ic disease and other complications.
All patients met the following 
criteria: they were operated on by 
one group of surgeons; they had 
pre- and postoperative prophylaxis 
for deep-vein thrombosis; the in­
traoperative management and surgi­
cal technique were similar; a ce­
mented Charnley total hip replace­
ment prosthesis was used.
The end-point of the study was 
clinically detectable pulmonary em­
bolism proven by lung scanning.
Differences were analysed by Stu­
dent’s f-test.
Prophylactic Regimen
All patients were admitted to hos­
pital at least 2 days before the 
operation and started on Persantine
From the Division o f Orthopedic Surgery, Department o f Surgery, University o f Alberta, 
Edmonton, Alta.
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(Boehringer Ingelheim [Canada] 
Ltd., Burlington, Ont.) 50 mg three 
times daily. They were instructed 
on the postoperative use of the 
circoelectric bed and the intermit­
tent pneumatic compression (IPC) 
boots.
The IPC apparatus (ALP 501; 
Twee Corp., Lake Oswego, Ore.) 
with a sterile boot was placed on 
the operative leg and a non-sterile 
boot on the opposite leg at the time 
of operation. Immediately postoper- 
atively, 500 ml of dextran 70 solu­
tion was given intravenously. Over 
the next 3 days the patient was 
given a total of 1 litre of low 
molecular weight dextran (dextran 
40).
Patients continued to have IPC of 
the calf for 1 week postoperatively. 
Weight bearing and active assisted 
physiotherapy were begun on post­
operative day 2 or 3.
Results
Of the 122 patients, 60 met the 
inclusion criteria for further analy­
sis. The remainder were excluded 
for various reasons (Table I).
Age, weight, sex, operating time, 
blood loss and volume of blood 
replacement were analysed (Table 
II). There was an equal distribution 
of male and female patients. Associ­
ated major medical problems oc­
curred in 50% of patients.
In these 60 patients, 12 had 
clinically detected pulmonary embo­
li proven by lung scanning. There 
did not appear to be any statistically 
significant difference in these pa­
T a b le  1. R easons fo r  E xc lu s io n o f P a tie n ts
R easo n No.
H e m ia r th ro p la s ty 18
H y b rid  p ro ce d u re 12
R e v is io n 8
N o n ce m e n te d  p ro s th e s is 16
In s u ff ic ie n t data 8
T o ta l 62
tients in any of the factors analysed 
compared with the nonembolism 
group.
Complications included three 
wound hematomas and three hip 
dislocations, two in the group of 
patients who had pulmonary embo­
lism. There were no episodes of 
congestive heart failure and no al­
lergic reactions to dextran. There 
were no postoperative deaths.
Discussion
Many methods of prophylaxis 
have been used in an attempt to 
manipulate Virchow’s triad of vas­
cular stasis, blood hypercoagulabili­
ty and vessel wall damage. Dextran 
is thought to alter blood coagulabil­
ity through a number of mecha­
nisms. Lowering of blood viscosity 
is important as is a slight heparin­
like effect. Intermittent compres­
sion of the leg makes intuitive 
sense in that it directly affects the 
vascular stasis limb of the triad.
In our patients, those treated 
with dextran and IPC of the calf 
had a frequency of pulmonary em­
bolism equal to that in previous 
reports of those who did not receive 
prophylactic measures.2 The rea­
sons for this high rate of pulmo­
nary embolism can only be speculat­
ed upon. However, some factors in 
our patient population were of 
prime importance in thrombus pro­
duction.
Surgical approach may have a 
bearing on the occurrence of embo­
lism. The anterolateral approach 
with trochanteric osteotomy has 
been shown to produce more deep- 
vein thrombosis than the posterior 
approach.1 This is possibly a result 
of the more extensive soft-tissue 
dissection required to reach the hip 
joint.
Type of prosthesis inserted may 
have a bearing upon thrombus pro­
duction. Francis and associates5 
have reported a far higher incidence 
of deep-vein thrombosis in patients 
with cemented total hip prostheses 
than with noncemented ones. They 
believe that the type of prosthesis 
inserted may have more impact on 
thromboembolism than the prophy­
lactic regimen.
Intermittent compression of the 
calf alone has little effect on those 
thrombi that originate in the thigh 
(approximately 20%). Full length 
compression of the limb is effective 
on its own and is a useful adjunct 
to thromboembolism prophylaxis.24
Conclusions
Intermittent pneumatic compres­
sion of the calf in association with 
dextran confers no benefit in pa­
tients who undergo cemented total 
hip replacement.
The empiric use of a therapeutic 
regimen should be monitored regu­
larly to ensure that it is efficacious.
T a b le  II. F a c to rs  A na lysed  in P a tie n ts  W ith  and W ith o u t P u lm on a ry  E m b o lism
P ulm onary  em bo lism
W ithout W ith
(n  =  48 ) (n =  12)
A ge, y r 6 0 .5 6 2 .5
W e ig h t, kg 77 72
O pe ra ting  tim e , m in 85 84
B lo o d  loss , m l 5 4 0 5 1 8
D ro p  in h e m o g lo b in , g /L 32 28
B lo o d  re p la ce m e n t, u n its 2 .4 2 .5
N o. w ith  a ss oc ia ted  m ed ica l p ro b le m s 23 6
C o m p lic a tio n s
H e m a tom a 2 1
D is lo ca tio n 1 2
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I thank Drs. Joseph and Paul Moreau 
and Dr. Paul Leung for allowing me to 
review their patients.
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practical and easy to read. Although it 
has a few limitations, it is an appropri­
ate reference for anyone interested in 
learning noninvasive vascular tech­
niques.
Anne R. Buckley, MB, FRCR, FRCPC
Section o f  Ultrasound,
Department o f Radiology,
Vancouver General Hospital,
University o f British Columbia,
Vancouver, BC 
V5Z 1H9
THE BASIC SCIENCE OF VASCU­
LAR SURGERY. Edited by Joseph M. 
Giordano, Hugh H. Trout, III and 
Ralph G. DePalma. 773 pp. Illust. 
Futura Publishing Co., Inc., Mount 
Kisco, New York, 1988. $89.00 (US). 
ISBN 0-87993-321-6.
Despite the recent publication of a 
number of textbooks of vascular sur­
gery, this book fulfils a vital need 
because it presents under one cover 
information that has been spread 
through a number of publications, 
many of which are not readily available 
to the vascular surgeon. The editors are 
three senior vascular surgeons from the 
George Washington University Medical 
Center. Each of the 22 chapters is 
written by an expert in the field, includ­
ing vascular surgeons, internists and 
anesthetists. The textbook covers the 
basic science and related clinical fea­
tures of vascular embryology, the lym­
phatic system, endothelial cells, cere­
brovascular disease and arteriovenous
fistulas; the physiologic and biochemi­
cal events associated with mesenteric 
vascular insufficiency and infarction; 
the anatomy and physiology of male 
sexual function; the role of the carotid 
sinus and other baroreceptors; and ar­
terial and vascular graft infections. Of 
value is the presentation, in an objective 
and mature fashion, of the controversial 
aspects of each topic, reflecting the 
authors’ wide experience and knowl­
edge of the subject.
In their introduction the editors state 
“Within three decades vascular surgery 
evolved into a unique specialty dedicat­
ed to treatment of patients with vascu­
lar diseases. Vigorous local and national 
certification in vascular surgery all at­
test to the maturation of a distinct 
discipline.” Professor John Bergan 
summarizes the need for this book in 
his preface: “This volume identifies the 
components of basic sciences peculiar 
to vascular surgery, clarifies each and 
relates them to practice. Thus, vascular 
surgery which once was just technique 
and mechanics has become an intellec­
tual endeavor as well.”
Despite the number of authors, this 
book reads well. It should be in the 
library of all practising vascular sur­
geons and candidates for certification in 
vascular surgery, since it covers the 
basic science portion of this specialty, 
filling in the gaps in standard text­
books.
T. Keith Scobie, MD, MSc, FRCS,
FACS
120 Clearview Ave.,
Ottawa, Ont.
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ESSENTIAL SURGICAL PRACTICE. 
2nd edition. Edited by A. Cuschieri, 
G.R. Giles and A.R. Moosa. 1438 pp. 
Illust. Butterworth International Edi­
tion, Stoneham, Mass., 1988. $125.00 
(US). ISBN 0-7236-1127-0.
This textbook has been extensively 
modified and revised, and a new section 
on trauma has been added since its first 
edition.
The first section is devoted to gener­
al aspects of surgical disease and covers 
common surgical problems. I particular­
ly liked the chapters on surgical infec­
tion, in which bacterial, viral, fungal 
and parasitic infections are discussed, 
the one on oncology, which covers 
chemotherapy and radiation and that on 
cutaneous disorders and malignancy, 
which will be of use to general sur­
geons who have to deal with these 
problems without the help of a derma­
tologist.
The eight chapters on the various 
aspects of trauma were written by 
North American authors, because it is 
acknowledged that this area of surgery 
is more fully developed on this conti­
nent. This section is particularly appro­
priate in light of the current interest in 
trauma training for surgical residents. 
The nine chapters on head and neck 
surgery provide a wider scope than 
most general textbooks on this subject 
and include chapters on nose and para­
nasal sinuses, the ear and ocular trau­
ma. The general surgeon will find the 
chapters on intracranial emergencies, 
spinal injury and the surgery of pain of 
interest.
continued on page 217
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sterile ceftizoxime sodium
THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of ceftizoxime results from in­
hibition of cell-wall synthesis in aerobic and anaerobic gram-positive and gram­
negative organisms. In vitro, ceftizoxime shows a strong affinity for penicillin­
binding proteins la, lbs and 3 of E. coli.
INDICATIONS AND CLINICAL USES
CefizoxTM (sterile ceftizoxime sodium) may be indicated in the treatment of the 
infections listed below when caused by susceptible strains of the designated 
microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus sp. (includ­
ing S. pneumoniae but excluding enterococci); Klebsiella sp.; Proteus mirabilis; 
Escherichia coli; Haemophilus influenzae (including ampicillin-resistant strains); 
Staphylococcus aureus (including penicillinase-producing but excluding 
methicillin-resistant strains); Serratia sp.; and Enterobacter sp.
URINARY TRACT INFECTIONS caused by Escherichia coli; Staphylococcus epider- 
midis; Pseudomonas aeruginosa; Proteus mirabilis; Klebsiella sp.; Serratia 
marcescens; and Enterobacter sp.
Due to the nature of the underlying conditions which usually predispose patients to 
Pseudomonas infections of the urinary tract, a good clinical response accompanied 
by bacterial eradication may not be achieved despite evidence of in vitro sensitivity.
INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus 
epidermidis; Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides 
sp. (including B. fragilis); Peptococcus sp.; and Peptostreptococcus sp.
SEPTICEMIA caused by Streptococcus sp. (excluding enterococci but including S. 
pneumoniae); Staphylococcus aureus (excluding methicillin-resistant strains); 
Escherichia coli; Bacteroides sp. (including B. fragilis); Klebsiella sp.; and Serratia 
marcescens.
SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding 
methicillin-resistant strains); Staphylococcus epidermidis; Escherichia coli; 
Klebsiella sp., (including K. pneumoniae); Streptococcus sp. (excluding enterococci 
but including Group A B-hemolytic Streptococcus pyogenes); Proteus mirabilis; 
Serratia sp.; Enterobacter sp.; Bacteroides sp. (including B. fragilis); Peptococcus 
sp., and Peptostreptococcus sp.
BONE AND JOINT INFECTIONS caused by Staphylococcus aureus (excluding 
methicillin-resistant strains); Proteus mirabilis; Peptococcus sp.; and Pepto­
streptococcus sp.
Specimens for bacteriologic culture should be obtained prior to therapy in order to 
identify the causative organisms and to determine their susceptibilities to cefti­
zoxime. Therapy with CefizoxTM may be initiated before results of the susceptibility 
studies are known. However, modification of the treatment may be required once 
these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have 
shown hypersensitivity to ceftizoxime or other members of the cephalosporin group 
of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful 
inquiry should be made to determine whether the patient has had previous hyper­
sensitivity reactions to cephalosporins, penicillins, or other drugs. CefizoxTM 
should be given cautiously to penicillin-sensitive patients. Antibiotics, including 
CefizoxTM, should be administered with caution to any patient who has demon­
strated some form of allergy, particularly to drugs. If an allergic reaction to Cefi­
zoxTM occurs, its administration should be discontinued. Serious acute hyper­
sensitivity reactions may require epinephrine and other emergency measures. 
Pseudomembranous colitis has been reported with the use of CefizoxTM (and other 
antibiotics). Therefore, it is important to consider this diagnosis in patients adminis­
tered CefizoxTM who develop diarrhea.
Treatment with broad-spectrum antibiotics alters normal flora of the colon and may 
permit overgrowth of Clostridia. Studies indicate a toxin produced by Clostridium 
difficile  is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe 
cases should be managed with fluid, electrolyte and protein supplementation as 
indicated. When the colitis is not relieved by drug discontinuance or when it is 
severe, consideration may be given to the administration of oral vancomycin or 
other suitable therapy. Other possible causes of colitis should also be considered.
PRECAUTIONS
General: Transient elevations of BUN and serum creatinine have been observed in 
clinical studies. However, there is no other evidence that CefizoxTM (sterile cefti­
zoxime sodium) has produced alterations in renal function. Renal status should be 
periodically evaluated, especially in seriously ill patients.
Prolonged use of CefizoxTM may result in the overgrowth of nonsusceptible 
organisms including species originally sensitive to the drug. Careful observation of 
the patient is essential. If superinfection occurs during therapy, appropriate 
measures should be taken.
CefizoxTM should be administered with caution to individuals with a history of 
gastrointestinal disease, particularly colitis.
Impaired Renal Function: Since ceftizoxime is excreted primarily in the urine, 
patients with impaired renal function (i.e., creatinine clearance <1.32 mUs or 
^7 9  mL/min) should be placed on a special dosage schedule recommended under 
DOSAGE AND ADMINISTRATION. Normal dosages in these individuals are likely to 
produce excessive serum concentrations of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and 
aminoglycosides has caused nephrotoxicity. The effect of administering CefizoxTM 
concomitantly with aminoglycosides is not known.
Pregnancy: The safety of CefizoxTM jn pregnancy has not been established. The 
use of CefizoxTM jn pregnant women requires that the likely benefit from the drug 
be weighed against the possible risk to the mother and fetus. The pharmacokinetics 
of CefizoxTM jn pregnant patients has not been investigated. Reproduction studies 
performed in rats and rabbits have revealed no evidence of impaired fertility or harm 
to the fetus caused by ceftizoxime. Animal reproduction studies, however, are not 
always predictive of human response.
Labour and Delivery: The safety and efficacy of CefizoxTM use during labour and 
delivery has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations 
(less than 4% of serum concentrations at 1 hour after dosing). The clinical signifi­
cance of this is unknown; therefore caution should be exercised if CefizoxTM jS to 
be administered to a nursing woman.
Infants and Children: The safety of CefizoxTM jn infants less than 6 months of age 
has not been established. In children six months of age and older, treatment with 
CefizoxTM has been associated with transient elevated levels of eosinophils, 
SGOT, SGPT and CPK (creatine phosphokinase). The CPK elevation may be related 
to intramuscular administration.
Elderly Patients: The elimination of ceftizoxime may be reduced due to an age- 
dependent reduction in renal function.
ADVERSE REACTIONS
CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated.
Adverse
Reaction
Incidence
< 1 %
Incidence 
>1% but <5%
Hypersensitivity: Rash
Pruritus
Fever
Liver: Transient elevation of SGOT, 
SGPT and alkaline phosphatase
Blood: Neutropenia
Leukopenia
Thrombocytopenia
Transient eosinophilia
Thrombocytosis
Positive direct Coombs’ test
Renal: Transient elevation 
of BUN and creatinine
Local: Injection site: burning, cellulitis, 
phlebitis (with IV administration), 
pain, induration, tenderness, 
parasthesia
Genitourinary: Vaginitis
Gastro­
intestinal:
Diarrhea, Nausea, Vomiting, Pseudomembranous colitis
No disulfiram-like reactions have been reported with CefizoxTM
TREATMENT OF OVERDOSAGE
No case of acute overdosage has been reported to date; consequently there is no 
specific information available on symptoms or treatment. In cases of suspected 
overdosage, supportive therapy should be instituted according to symptoms. Serum 
ceftizoxime levels can be reduced by hemodialysis.
DOSAGE AND ADMINISTRATION
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly 
or intravenously after reconstitution.
Dosage and route of administration should be determined by the condition of the 
patient, severity of the infection and susceptibility of the causative organism(s). The 
intravenous route may be preferable for patients with bacterial septicemia, or other 
severe or life threatening infections.
The usual course of treatment should be 7-14 days, and should normally continue at 
least 48 hours after evidence of bacterial eradication has been obtained. For 
B-hemolytic streptococcal infections, a minimum of 10 days of treatment is 
recommended.
DOSAGE
Adults: The recommended daily dosage of CefizoxTM js 1 to 12 grams admin­
istered in equally divided doses every 8 or 12 hours (see Table 1 below).
TABLE 1
Type of Infection Daily Dose 
(Grams)
Frequency and Route
Uncomplicated 
Urinary Tract
1 500mgq12h, IVorIM
Other Sites 2-3 1 g q8h orq12h, IV or IM
Severe or 
Refractory
3-6 1 g q8h, IV or IM, to 
2g q8horq12h, IVorIM*
Life-Threatening 9-12 3 or 4 gq8hIV
*When administering 2 g intramuscularly, the dose should be divided and injected 
into different large muscle masses.
Because of the serious nature of urinary tract infections due to Pseudomonas 
aeruginosa and because many strains are only moderately susceptible to CefizoxTM, 
higher dosage may be appropriate when urinary tract infections are caused by 
these organisms. Other therapy should be instituted if the response is not prompt.
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Adults with Impaired Renal Function: In patients in whom the creatinine clearance 
is 1.32 mL/s (79 mL/min) or less, the dosage of CefizoxTM must be reduced. Follow­
ing an initial loading dose of 500 mg to 1.0 g IM or IV, the maintenance dosing 
schedule presented in Table 2 should be followed in patients with reduced renal 
function.
TABLE2
Renal
Function
Creatinine 
Clearance 
m U s mL/min
Less Severe 
Infections
Life-Threatening
Infections
Mild
Impairment
0.83-1.32 50-79 500 mg 
q8h
750 mg to 1.5 g 
q8h
Moderate to 
severe impairment
0.08-0.82 5-49 250 or 500 mg 
q12h
500 mg to 1.0 g 
q12h
Hemodialysis
patients*
0-0.07 0-4 500 mg q48h or 
250 mg q24h
500 mg to 1.0g 
q48h or 500 mg 
q24h
*ln patients undergoing hem odia lysis no additional supplemental dosing is 
required. DOSING, HOW EVER, SH OU LD  BE SCHEDULED  SO THAT THE PATIENT 
RECEIVES THE DOSE AT THE END O F  THE DIALYSIS. When started 24 hours after 
administration of 1 g of CefizoxTM, hem odialysis has been shown to reduce serum 
levels by 50%.
When only the serum creatinine level is available, creatinine clearance may be 
calculated from the following formulae (for patients 18 years and over only). The 
serum creatinine level should represent renal function at the steady state.
Males:
Creatinine Clearance Weight (kg) x (140-age)
(mL/min) 72 x serum creatinine (mg/100 mL)
Creatinine Clearance 
(mL/s)
Weight (kg) x 140-age)
49 x serum creatinine ( /zmol/L)
Females: 0.85 of the above values
Infants and Children: The following dosage schedule is recommended:
TABLE 3
Age Group Unit Dosage Frequency and Route
Infants (6 mo-2 yrs.), 
and 50 mg/kg IVorIM q6horq8h, IVorIM
Children (2-12 yrs.)
The pediatric dosage should not exceed the maximum adult dosage for serious 
infections.
ADMINISTRATION
Intramuscular. The reconstituted solution of CefizoxTM should be injected well 
within the body of a relatively large muscle, such as the gluteus. When adm inister­
ing 2 g IM doses, the dose should be divided equally and then injected into different 
large muscle masses.
Intravenous: Injection (bolus): The reconstituted solution of CefizoxTM should be 
injected slow ly over 3 to 5 minutes, d irectly or through the tubing system by which 
the patient is receiving another com patib le intravenous solution. During adm inistra­
tion of the so lution containing CefizoxTM, it is desirable to temporarily discontinue 
administration of the other solution.
Intermittent or continuous infusion: The further diluted reconstituted solution of 
CefizoxTM should be administered over a 20 to 30 minute period.
NOTE: CefizoxTM so lutions should not be physically mixed with any other drug. 
There is a known incompatib ility with am inoglycoside antib iotics. Therefore, they 
should not be physically mixed with CefizoxTM so lutions nor administered at the 
same site.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFIZOXTM 
Proper Name: Ceftizoxime Sodium
Chemical Name: Sodium (eR-JS0*, 7B (Z)]]-7-[[(2 ,3 -d ihydro-2-im ino-4-th iazo ly l) 
(m ethoxyim ino)acetyl]am ino]-8-oxo-5-th ia-1-azabilcyclo[4.2.0] o c t-2 -e n e -2 -  
carboxylate
Structural Formula:
COON,
J X H ,  O 
N 
II
HN-------r - C —CONH-
Molecular Formula: C 13H 12 N 5 0 s S 2 Na 
Molecular Weight: 405.38
Description: Ceftizoxime Sodium  is a white to pale yellow crysta lline powder.
Composition: CefizoxTM via ls contain ceftizoxime sodium (expressed in terms 
of free acid). The sodium content of each gram of CefizoxTM js approximately 
60
mg (2.6 mEq sodium ion).
Solutions of CefizoxTM range from colourless to pale yellow, depending upon the 
diluent and volume used. The solution should be discarded if it becomes cloudy. 
The pH of freshly reconstituted so lutions usually ranges from 6.0 to 8.0.
A solution of 1 g CefizoxTM in 13 mL Sterile Water for Injection is isotonic.
RECONSTITUTION
STANDARD V IALS (1 GRAM  and 2 GRAMS)
For Intramuscular Injection: Reconstitute with Sterile Water for Injection or Bac­
teriostatic Water for Injection.
Reconstitution Table for Standard Vials -  I.M. Injection
Approximate Approximate
Vial Diluent to be Available Average
Size Added to Vial Volume Concentration
i g 3.0 mL 3.7 mL 270 mg/mL
2g 6.0 mL 7.4 mL 270mg/mL
Shake well until dissolved.
For Intravenous Injection: Reconstitute only with Sterile W ater for Injection.
Reconstitution Table for Standard Vials - I.V. Injection
Approximate Approximate
Vial Diluent to be Available Average
Size Added to V ia l Volume Concentration
ig 10 mL 10.7 mL 95 mg/mL
29 20 mL 21.4 mL 95 mg/mL
Shake well until dissolved.
For Intravenous Infusion: Reconstitute as for intravenous injection. Further 
dilute the reconstituted solution to 50 to 100 mL with one o f the “ So lu tions for 
Intravenous Infusion" (see below).
TABLE 4: Solutions for Intravenous Infusion
Sodium Chloride Injection 
5% or 10% Dextrose Injection
5% Dextrose and 0.9%, 0.45% or 0.2% Sodium Chloride Injection
Ringer’s Injection
Lactated R inger’s Injection
10% Invert Sugar in Sterile Water for Injection
5% Sodium Bicarbonate in Sterile Water for Injection
5% Dextrose in Lactated R inger’s Injection O N LY  when reconstituted with 
4% Sodium Bicarbonate Injection.
STABILITY OF SOLUTIONS
Storage: A ll reconstituted so lu tions and those further diluted should be used 
w ithin 24 hours if stored at room temperature or w ith in 48 hours if refrigerated. 
These storage lim its are from the time of the initial reconstitution.
Incompatibility: CefizoxTM should not be added to blood products, protein 
hydrolysates or amino acids. CefizoxTM should not be m ixed together with an 
am inoglycoside.
DOSAGE FORMS
Availability: CefizoxTM js availab le as a sterile powder in Standard V ia ls  of 
1 gram or 2 grams, contain ing ceftizoxim e as sodium  salt.
Storage: CefizoxTM powder for injection should be stored at room temperature 
(15°-30°C).
FOOTNOTES
'As indicated in the manufacturer's product monograph Cefizox, Sm ith Kline &  French Canada Ltd . 1988 
2As indicated in the manufacturer's product monograph cefoxitin, Merck Sharp & Dohme Canada, 1985 
3Lou M.A. et al.: 14th International Congr. Chemother.. Kyoto, Japan, June 1985, pp 2378-2379.
4Neu H.C.. Chin N X :  The activity and beta-lactamase stability of cefotetan compared to other beta-lactam antibiotics 
Chemioterapia 1985;4:271-277
5Fu K.P., Neu H C : Antibacterial activity of ceftizoxime, a B-lactamase-stable cephalosporin Antimicrob. Agents 
Chemother. 1980;12:583-590
6Thornsberry C : Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics 
against clin ically important bacteria Am. J. Med 1985;79 (Suppl. 2A): 15-20.
7Drulak M .W ., Chow A W : Comparitive in vitro activity of ceftizoxime cefoperazone and cefoxitin against anaerobic 
bacteria. Antimicrob. Agents Chemother. 1981;20:683-685.
*Aldridge K.E et a l.: Comparision of the activities of penicillin G and new B-lactam antibiotics against clin ical isolates of 
Bacteroides species Antimicrob Agents Chemother 1984:26(3) 410-413.
9Adapted from Parker D .D : Abstr. Annu Meet Am . Soc. Microbiol. .Atlanta, GA. March 1987, Abstract no. A-107, p. 18. 
' “Kitzmann R. Cost analysis of the ecom om ic effect of replacement of cefoxitin with ceftizoxime. Presented at the 45th 
Annual Meeting, American Society of Hospital Pharmacists. San Francisco, California.
"Guastell C. Cost savings realized from interchanging ceftizoxime for cefoxitin. Am  J  Hosp Pharm 1988 
Nov;45:2376-2377.
,2Wikler M .A  et al : Efficacy of ceftizoxime administered twice daily for the treatment of serious infections in hospitalized 
patients Infect Med 1986;(Suppl ):9-12.
,3Data on file. Sm ith Kline & French Canada Ltd
,4Sanford J  P : Guide to Antimicrobial Therapy. West Bethesda. MD:Antim icrobial Therapy Inc., 1988:50.
,5R ichardsDM  Heel RC Ceftizoxime: A  review of its antibacterial activity, pharmacokinetic properties and therapeutic 
use Drugs 1985:29:281-329.
,6DiPiro J  May JR  Use of cephalosporins with enhanced antianaerobic activity for treatment and prevention of 
anaerobic and mixed infections Clin Pharm 1988 Apr:7:285-302
,7Bellomo S. Antimicrobial activity of cefizoxime sodium: Com parision with cefoxitin. Hosp Formul 1988:23 
(Suppl. D): 18-27
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Spontaneous Rupture of the Diaphragm 
in Labour: a Case Report
D.B. Ross, MD; G.E. Stiles, MD, FRCSC, FACS
Spontaneous rupture of the diaphragm during normal labour is extremely rare. It 
requires emergency surgical correction. The authors report what they believe is 
only the second reported case. Eleven hours after delivery of a male infant, a 
27-year-old woman experienced severe epigastric pain, vomiting and dyspnea, 
followed by cardiopulmonary arrest. Although the ruptured diaphragm was 
diagnosed and repaired, she suffered severe anoxic encephalopathy and died 3 weeks 
after operation without regaining consciousness. Clinicians must be aware of the 
existence of this rare condition because failure to diagnose and treat the ruptured 
diaphragm will almost certainly lead to the patient’s death.
La rupture spontanee du diaphragme durant le travail est extremement rare. Elle 
exige une correction chirurgicale immediate. Les auteurs decrivent ce qu’ils croient 
etre le deuxieme cas rapporte seulement. Onze heures apres la naissance d’un 
garcon, la mere de 27 ans souffrit de douleurs epigastriques intenses, de 
vomissements et de dyspnee, suivis d’un arret cardiorespiratoire. Malgre le 
diagnostic de rupture du diaphragme et sa reparation, la femme souffrit d’encephalo- 
pathie anoxique grave et elle mourut 3 semaines apres l’operation, sans avoir repris 
conscience. Les medecins doivent etre sensibilises a l’existence de cette affection 
rare car, faute d’avoir diagnostique et traite une rupture du diaphragme, le deces 
suivra presque invariablement.
S pontaneous rupture of the dia­phragm during labour is ex­
tremely rare. To our knowledge 
only one such case has been report­
ed.1 We describe another case.
Case Report
A 27-year-old primigravid woman 
was delivered of a healthy 3640-g 
infant boy after a 20-hour labour at 
another hospital. The second stage 
was prolonged at 3 hours and vacu­
um extraction was necessary. Elev­
en hours after delivery, the woman
Accepted fo r publication Aug. 15, 1988
complained of severe epigastric pain 
radiating to her left shoulder, asso­
ciated with vomiting and shortness 
of breath. Thirty-two hours after 
delivery she had a full cardiopulmo­
nary arrest on her way to the 
radiology department for a chest 
x-ray. She was successfully resusci­
tated, but it was approximately 1 
hour before her blood pressure was 
restored. A chest x-ray film showed 
an air-fluid level in the chest on the 
left side. A tube thoracostomy was 
performed and gastric contents 
were drained. The patient was then 
transferred to our hospital.
On arrival, she was intubated, 
unresponsive and the pupils were in 
the mid-position. Blood pressure 
was 70/50 mm Hg, heart rate 95 
beats/min and she was markedly 
cyanosed. Breath sounds were de­
creased on the left side. The initial 
arterial blood gas values demon­
strated a metabolic acidosis with 
the pH 7.22, Po2 77 mm Hg, PC02 
22 mm Hg, HC03 10 mmol/L 
on F,o2 1.0. The chest x-ray film 
showed loops of bowel and stomach 
in the left hemithorax with devia­
tion of the mediastinum to the right 
(Fig. 1).
The diagnosis of rupture of the 
left hemidiaphragm with herniation 
of abdominal contents was made 
and the patient was taken immedi­
ately to the operating room. At 
laparotomy the transverse colon, 
stomach and spleen were found in
FIG. 1. Portable chest x-ray film dem­
onstrating mediastinal shift to right, 
nasogastric tube in left chest and loop 
of bowel in left hemithorax.
From the Department o f  Surgery, Daihousie University, Halifax, NS
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the left side of the chest. These 
were easily reduced and the small 
hole in the stomach caused by the 
chest tube was oversewn. There 
was a large fresh tear in the left 
hemidiaphragm extending from the 
hiatus to the posterolateral chest 
wall. This was closed with inter­
rupted 0  Ethibond (Ethicon Ltd., 
Peterborough, Ont.) sutures.
Postoperatively, she showed 
signs of severe anoxic encephalopa­
thy and did not regain conscious­
ness. She died 3 weeks after admis­
sion from anoxic brain damage sec­
ondary to the initial cardiopulmo­
nary arrest.
Discussion
Spontaneous rupture of the dia­
phragm during labour is extremely 
rare, only one other case having 
been reported in the literature.1 
Strangulation of abdominal viscera 
in a pre-existing congenital or trau­
matic diaphragmatic defect is more 
common, 21 such cases having 
been reported during pregnancy (16 
congenital, 4 acquired, 1 spon­
taneous).13
Our patient’s presentation was 
similar to the other reported case, 
that is, chest pain radiating to the 
left shoulder and progressive dys­
pnea. Unfortunately, the correct di­
agnosis was not entertained until 
the patient had sustained irrevers­
ible brain damage secondary to car­
diopulmonary arrest, probably 
caused by the mediastinal compres­
sion.
The site of the rupture of the 
diaphragm in this case was the left 
posterolateral region which is the 
most common site for a ruptured 
diaphragm in blunt abdominal trau­
ma, and is probably due to a con­
genital weakness in the area.4 The 
fact that a fresh tear was present in 
the diaphragm with no apparent 
congenital defect suggests that the
rupture was precipitated by the dif­
ficult labour and not by strangula­
tion of viscera in a congenital de­
fect. Both conditions are lethal if 
untreated.
Once suspected, the diagnosis is 
easily confirmed by chest x-ray. 
Pleural aspiration or decompression 
is unnecessary and dangerous. Salo­
mon and associates4 reported an 
iatrogenic injury to the spleen 
caused by this maneuver and our 
patient sustained a perforation of 
the stomach. Treatment consists of 
reduction of the herniated contents 
and suturing of the diaphragmatic 
edges through either a laparotomy 
or thoracotomy. In our opinion, 
laparotomy is the procedure of 
choice because it facilitates resec­
tion of any nonviable abdominal 
tissue.
Although uncommon, spontane­
ous rupture of the diaphragm or
strangulation of abdominal viscera 
in a pre-existing diaphragmatic her­
nia during pregnancy are potential­
ly lethal conditions and should be 
suspected in any pregnant or post­
partum woman with chest pain and 
dyspnea.
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Undiversion in Patients With 
Meningomyelocele
David Stewart, MD, FRCSC;* Hjalmar W. Johnson, MD, FRCSC;* Patrick J. Moloney, MD, FRCSC;* 
William J.D. Arnold, MD, FRCPC;f Bonita J. Sawatzky, BPE*
Since 1981, 12 patients with neurogenic bladder due to meningomyelocele who had 
had previous ileal conduit urinary diversions underwent assessment for undiversion. 
Two important criteria for undiversion were motivation and a reconstructable 
bladder. Four patients either did not fulfil these criteria or refused surgery. Eight 
patients (six females and two males) underwent undiversions. Uretero- 
ureteral anastomosis was achieved in 13 ureters and ureteroneocystostomy in 2; 
transureteroureterostomy was necessary in 1 ureter. Augmentation cystoplasty and 
vesicourethropexy were important in establishing continence postoperatively; these 
procedures were not performed in two patients whose undiversion failed early in the 
series. The evolution of an investigation protocol, surgical technique and final 
approach to this complex problem are discussed.
possible candidates for an undiver­
sion. Four were deemed unsuitable 
because of low intelligence or un­
willingness to undergo the proce­
dure. The evolution of investiga­
tions considered necessary in prepa­
ration for undiversion and the sur­
gical techniques employed have 
been an instructive process for us 
and are described.
Depuis 1981,12 patients souffrant de vessie neurogene due a un meningomyelocele 
et qui avaient subi une derivation ileale du conduit urinaire ont ete reevalues en vue 
de retablir la continuite des voies urinaires. Deux criteres importants etaient retenus 
pour justifier l’operation, soit la motivation du patient et la possibility de 
reconstruire la vessie. Quatre patients n’ont pu rencontrer ces criteres ou ont refuse 
la chirurgie. Huit patients (six filles et deux garfons) ont ete operes. Une 
anastomose uretero-ureterale a pu etre pratiquee sur 13 ureteres et une uretero-cys- 
toneostomie sur 2; une transuretero-ureterostomie fut necessaire pour 1 uretere. En 
vue d’obtenir la continence, il etait important de pratiquer, en postoperatoire, une 
cystoplastie de dilatation et une vesico-uretropexie; ces interventions n’ont pas ete 
effectuees chez deux patients pour qui l’operation s’etait soldee par un echec, tot au 
debut de la serie. On commente revolution du protocole experimental, de la 
technique chirurgicale et de l’approche finalement retenue pour corriger ce 
probleme complexe.
The goals of urinary undiversion are to preserve renal function, 
to establish good bladder capacity 
and to preserve or establish conti­
nence.1 With these goals in mind, in 
1981 we embarked on a program to 
select patients with m enin­
gomyelocele for undiversion. At the
British Columbia Children’s Hospi­
tal, a multidisciplinary team of urol­
ogists, neurosurgeons, orthope­
dists, pediatricians, nurses, thera­
pists and social workers have con­
tributed to the assessment of pa­
tients with meningomyelocele. 
Twelve patients were selected as
From the *Department o f  Surgery (Urology) and fDepartment o f Pediatrics, University o f British 
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Patients and Methods
Undiversion was performed on 
six females and two males. All me­
ningomyeloceles were lumbosacral 
or sacral. All patients were ambula­
tory, well-motivated and of normal 
intelligence, and all had undergone 
ileal conduit diversion in the late 
1960s or early 1970s at ages rang­
ing from 13 months to 6 years. A 
review of the indications for the 
initial diversion included frequent 
lower and upper urinary tract infec­
tions, progressive hydronephrosis 
or unmanageable incontinence (in 
older children). The long-term com­
plications of ileal conduits are well 
known.2 3 Four of our eight patients 
required stomal revision for steno­
sis, three had partial ureteroileal 
anastomotic obstruction (Fig. 1) 
and five suffered from recurrent 
pyelonephritis. One teenager found 
her ileal conduit with external appli­
ance socially unacceptable.
Urologic evaluation included as­
sessment of upper tracts, bladder 
and bladder outlet. Intravenous uro­
grams and loopograms (retrograde
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filling of ileal segment and ureters 
with Hypaque) were used to assess 
renal function and identify the 
length of the proximal ureter. Renal 
function was grossly normal (serum 
creatinine less than 100 jumol/L) in 
all patients; isotope renography was 
not routinely performed. Ureteral 
dilatation ranging from mild to se­
vere was noted in 7 of 16 ureters.
All patients underwent cystos­
copy and retrograde ureterography 
to identify the distal ureteral stump 
for measurement (Fig. 2). Ureteral 
stumps varied in length from 2 to 9 
cm, with 13 having stump lengths 
of 4 to 6 cm. Cystoscopy revealed
FIG. 1. Preoperative ureteroileal anas­
tomotic obstruction with left-sided hy­
dronephrosis.
FIG. 2. Preoperative retrograde cysto- 
gram showing ureteral stump lengths 
of approximately 3 cm and 5 cm.
an incompetent bladder neck in all 
female patients. Voiding cys- 
toureterography was performed if 
reflux was known to be a problem 
prior to diversion, although reflux 
in an undiverted bladder may not be 
important.4
Urodynamic tests were performed 
on all patients, with virtually all 
showing a poorly compliant bladder 
with a low urethral pressure profile. 
All had perineal electromyographic 
activity. Bladder cycling was initial­
ly attempted with a suprapubic cys- 
tocath and later in conjunction with 
the teaching of clean intermittent 
catheterization. Continent cycled 
volumes were less than 150 mi in 
four patients, 150 to 200 ml in two 
and 250 ml in two patients. Initial­
ly, we used these data to estimate 
which patients would need augmen­
tation cystoplasty, but this ap­
proach failed and we now routinely 
perform this procedure.
Surgical Procedures
Undiversion involves re-establish­
ing continuity of upper and lower 
urinary tracts, with or without aug­
mentation cystoplasty or proce­
dures to prevent incontinence. The 
initial procedure consisted of a 
ureteroureterostomy in 13 of the 16 
renal units. Intraoperative place­
ment of a ureteral stent to identify 
the stump greatly facilitated this, 
since the proximal end of the distal 
stump was otherwise difficult to 
identify because of the dense scar 
tissue. Transureteroureterostomy
was performed in one case because 
of a short (2 cm) distal stump and 
because the proximal ureter was 
not long enough to be reimplanted 
into the bladder. In another patient, 
two grossly dilated ureters second­
ary to ureteroileal anastomotic ob­
struction required trimming and 
reimplantation into an augmented 
bladder.
Neither of the two male patients 
underwent a procedure to prevent 
incontinence. Both were undiverted 
after puberty (at 17 and 21 years) in 
the anticipation that normal bladder 
neck growth would aid in conti­
nence. A standard Burch vesicoure- 
thropexy was performed on four of 
the six female patients to prevent 
incontinence. The first two females, 
who did not undergo a vesicoure- 
thropexy, were both incontinent 
postoperatively. We now perform 
Burch repairs on all females.
Our initial surgical approach with 
augmentation cystoplasty is sum­
marized in Table I. Bladders were 
augmented with the ileal conduit, in 
most cases as a cupped patch 
opened on the antimesenteric bor­
der and sutured to the superior 
surface of the open bladder. These 
patients were selected for augmen­
tation because of a small capacity 
bladder on cycling.
Results
Early complications of undiver­
sion were minimal. They included 
one wound infection, two persistent
Table I. Cycled Bladder Capacities
Patient
no. Sex
Augmentation
cystoplasty
Cycled 
capacity, ml
1 F Yes, own loop 100
2 M Yes, ileum 1 0 0 -1 5 0
3 F Yes, own loop 1 0 0 -1 5 0
4 F Yes, own loop 150 -  200
5 F No 200 -  250
6 F No 200 -  250
7 M No 150 -  200
8 F No 1 0 0 -1 5 0
►
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leaks (one ureteral, one ileal cysto- 
plasty) managed by conservative 
means and one urinary tract infec­
tion due to Pseudomonas sp that 
was difficult to eradicate because of 
multiple antibiotic resistance. There 
were two early failures (patients 6 
and 8, Table II). Both were inconti­
nent and had vesicoureteral reflux. 
Neither had undergone augmenta­
tion cystoplasty or vesicoure- 
thropexy. Initially, patient 5 did 
well, but increasing incontinence 
developed associated with uterine 
prolapse. Cycled bladder capacities 
in patients 5 and 6 were good 
before undiversion and they were 
selected to forgo augmentation cys­
toplasty (Table I). All three of these 
patients were managed early in our 
series and none underwent anti­
incontinence or augmentation pro­
cedures. Patients 5 and 6 had aug­
mentation ileocystoplasties and 
Burch vesicourethropexies, which 
in the case of patient 5 was a repeat 
procedure with bladder neck recon­
struction.
Our final results are listed in 
Table II. Both male patients were 
continent using anticholinergic 
drugs. Four of the six females were 
continent (three without anti­
cholinergics). Two patients contin­
ued to have problems: patient 8 had 
to catheterize herself every 2 hours 
to avoid incontinence and patient 4 
had stress incontinence, not consid­
ered serious enough to warrant fur­
ther surgery.
Follow-up ranged from 48 to 72 
months. Follow-up intravenous pye­
lography or ultrasonography 
showed improvement or resolution 
of hydronephrosis in all the ureters 
that were markedly dilated preoper- 
atively (Fig. 3).
All patients were taking low-dose 
antibiotics prophylactically. One pa­
tient had two episodes of cystitis, 
but there was no episode of pyelo­
nephritis and no deterioration in 
renal function. Two patients suf­
fered mucus retention necessitating 
an emergency room visit early after 
hospital discharge. Both were cath- 
eterized and more than 700 ml of 
urine drained, indicating the suc­
cess of augmentation cystoplasty.
Discussion
Undiversion has clearly emerged 
as a viable option for patients with 
meningomyelocele who have previ­
ously undergone supravesical diver­
sion, provided they are carefully 
selected. The extent of our assess­
ment of these patients has been 
modified by our management expe­
rience.
Bladder cycling was initially per­
formed by way of a suprapubic 
cystocatheter, but it became evident 
that this could be more readily 
accomplished in conjunction with 
the teaching of clean intermittent 
catheterization. Moreover, the cy­
cled capacity eventually reached
was not predictive of good operative 
results in terms of continence. We 
now augment all bladders in this 
type of patient regardless of cycled 
capacity. Perlmutter5 rejected pa­
tients for undiversion who had se­
vere incontinence and small bladder 
capacity after cycling, apparently 
because of the complexity of aug­
mentation cystoplasty and ure- 
throvesical suspension. However, 
we found that the ileal conduit can 
usually be readily mobilized into the 
pelvis and used to augment the 
bladder.6’7 Similarly, a simple Burch 
vesicourethropexy does not add 
complexity or time to the operation 
and has been successful in our 
hands. We also prefer to perform 
this suspension on all our patients 
at the time of original undiversion. 
Our patients are prepared to main­
tain clean intermittent catheteriza­
tion for life as a consequence of 
their original affliction and so blad­
der emptying problems are not a 
concern.8
In summary, our clinical experi­
ence has modified our approach to 
undiversion in patients with menin-
FIG. 3. Postoperative ureteroureteros­
tomy and resolution of left-sided hy­
dronephrosis approximately 6 months 
after undiversion.
T a b le  II. R e su lts  o f  P o s to p e ra tiv e  U n d ive rs io n
P a tie n t C lean  in term itten t M ean A nticholinergic
no. c a th e te riza tio n , h vo lum e, m i* C ontinence agent
1 3 300 Y es No
2 4 2 5 0 Y es Yes, D itropan
3 3 3 5 0 Y es Y es, T o fra n il
4 3 2 5 0 S tre s s Y es, T o fra n il
in c o n tin e n c e
5 4 2 5 0 Y es No
6 3 2 5 0 Y es No
7 3 2 5 0 Y es Y es, D itropan
8 2 150 No Yes, D itropan
'C o n t in e n t  v o lu m e s  n o t m a x im u m  vo lu m e s .
i
4
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gomyelocele. We prefer to augment 
all bladders and perform a Burch 
vesicourethropexy on all our female 
patients. Ipsilateral ureteroureteros­
tomy is almost always possible; one 
available intraoperative option in­
cludes transureteroureterostomy. 
Although this is primarily a cosmet­
ic operation resulting in improved 
quality of life and a better body 
image, the resolution of hy- 
droureteronephrosis and absence of 
upper tract infections in our pa­
tients suggest that it provides some 
protection from future deterioration 
in renal function.
BOOK REVIEWS
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We thank Drs. G. Coleman and J. 
Masterson for allowing us to include 
their patients in this study.
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aware of changes in style between au­
thors. Photographs and x-rays clearly 
illustrate the points made, and the 
many line diagrams are of excellent 
quality. Of interest is that many chap­
ters end with a prediction as to the 
direction in which the field is heading. 
The bibliography is adequate and pre­
dominantly from the 1980s.
The authors state that their intention 
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covering the core material for those 
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Transplantation is a surgical specialty 
in continuous evolution as principles 
are modified by new concepts, better 
understanding and research. This book, 
written by 57 contributors who are well 
known in their fields, reflects the opin­
ions and experience of many transplan­
tation centres in the United States and 
France.
The first section of the book is a 
review of basic science aspects of im­
munology. The authors describe the 
immune system in its two parts, the 
cellular and the humoral. They cover
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new concepts of cellular interaction 
with antigen, immunoglobulin structure 
and lymphokine function. The major 
histocompatibility complex is well de­
scribed with its class I and II antigens. 
Two other chapters are dedicated to 
immunobiology — one on im- 
munohematology, the second on effects 
of blood transfusion in transplantation. 
These are excellent reviews of the im­
portance of blood-group antigens in 
transplantation. The immunologic as­
pect of blood transfusion and its clinical 
application in renal allografts is also 
mentioned.
The second section describes the 
basic principles of transplantation, in­
cluding immunogenetics, immune regu­
lation and methods of histocompatibility 
testing. The author mentions all possi­
ble immunologic tests identifying the 
most important and applicable in clini­
cal use. Pre- and post-transplant sero­
logic tests to improve recipient selection 
and predict graft survival are also de­
scribed. The rejection phenomenon, its 
immunobiologic features, mechanism 
and specific pathologic characteristics 
regarding the kidney, liver, heart and 
lungs, is also explained in this section. 
Finally, the main author presents a 
good review of immunosuppressive 
therapy, the drugs and methods used in
continued on page 223
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(imipenem and cilastatin sodium 
for injection)
Antibiotic
CNS adverse experiences such as myoclonic 
activity, confusional states, or seizures have 
been reported with PRIMAXIN® especially when 
recommended dosages based on renal function 
and body weight were exceeded. These expe­
riences have occurred most commonly in patients 
with CNS disorders (e.g., brain lesions or 
history of seizures) and/or who have compro­
mised renal function. However, there were rare 
reports in which there was no recognized or 
documented underlying CNS disorder. Close 
adherence to recommended dosage schedules 
is urged, especially in patients with known 
factors that predispose to seizures.
ACTION
Imipenem exerts a bactericidal action by inhibiting 
cell wall synthesis in aerobic and anaerobic gram­
positive and gram-negative bacteria.
PRIMAXIN® consists of tw o com ponents: 
(1) im ipenem, a derivative of thienamycin, a 
carbapenem antibiotic; and (2) cilastatin sodium, a 
specific inhibitor of dehydropeptidase-l a renal 
enzyme w hich metabolizes and inactivates 
imipenem. Cilastatin blocks the metabolism of 
imipenem in the kidney, so that concomitant 
administration of imipenem and cilastatin allows 
antibacterial levels of imipenem to be attained in the 
urine.
Inhibition of cell-wall synthesis is achieved in gram­
negative bacteria by the binding of imipenem to 
penicillin binding proteins (PBPs). In the case of 
E s c h e r ic h ia  c o li and se le c te d  s tra in s  of 
Pseudomonas aeruginosa, imipenem has been 
shown to have highest affinity for PBP-2, PBP-1a 
and PBP-1 b, with lower activity against PBP-3. The 
preferential binding of imipenem on PBP-2 and 
PBP-1 b leads to direct conversion of the individual 
cell to a spheroplast resulting in rapid lysis and cell 
death without filament formation. When imipenem 
is removed prior to complete k illing of gram­
negative species, the remaining viable cells show a 
measurable lag, termed a "post-antibiotic effect" 
(PAE), prior to resumption of new growth.
INDICATIONS AND CLINICAL USE
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) may be indicated in the treatment of 
serious infections when caused by sensitive strains 
of bacteria Where considered necessary, therapy 
may be initiated on the basis of clinical judgment 
before results of sensitivity testings are available. 
Continuation of therapy should be reevaluated on 
the basis of bacteriological findings and of the 
patient's clinical condition.
Imipenem is active in vitro against a wide range of 
gram-positive and gram-negative aerobic and 
anaerobic bacteria, including most strains which 
are beta-lactamase producing. Patients have 
responded while under treatment with PRIMAXIN® 
for single or mixed infections of the following body 
systems, when they were associated with a number 
of pathogenic species and strains of the genera 
listed:
1. Lower Respiratory Tract Infections
2. Urinary Tract Infections
3. Intra-Abdominal Infections
4. Gynecological Infections
5. Septicemia
6. Endocarditis caused by Staphylococcus 
aureus
7. Bone and Joint Infections
8. Skin Structure Infections
Gram-positive Aerobes
•  Listeria monocytogenes
•  Nocardia asteroides
• Staphylococcus (excluding many strains 
which are methicillin resistant)
•  Streptococcus (excluding S. laecium)
Gram-negative Aerobes
•  Acinetobacter
•  Citrobacter
•  Enterobacter
•  Escherichia coli
•  Haemophilus influenzae
•  Haemophilus parainfluenzae
•  Klebsiella
•  Morganella morganii
•  Neisseria
•  Proteus (indole positive and indole negative 
strains)
•  Providencia
•  Pseudomonas aeruginosa
•  Serratia marcescens
Gram-positive Anaerobes
•  Clostridium (excluding C. difficile)
•  Peptococcus
•  Peptostreptoccus
Gram-negative Anaerobes
•  Bacteroides fragilis
•  Bacteroides (non-fragilis)
CONTRAINDICATIONS
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is contraindicated in patients who have 
shown hypersensitivity to either component of this 
product.
WARNINGS
PRIMAXIN® (imipenem and cilastatin sodium for 
in jection) SHOULD BE ADMINISTERED WITH 
CAUTION TO ANY PATIENT WHO HAS DEMONS­
TRATED SOME FORM OF ALLERGY, PARTICULARLY 
TO STRUCTURALLY-RELATED DRUGS. IF AN 
ALLERGIC REACTION TO PRIMAXIN® OCCURS, 
DISCONTINUE THE DRUG. SERIOUS HYPER­
SENSITIVITY REACTIONS MAY REQUIRE 
EPINEPHRINE AND OTHER EMERGENCY 
MEASURES.
Pseudomembranous colitis
Pseudomembranous colitis has been reported with 
the use of PRIMAXIN®. Therefore it is important to 
consider this diagnosis in patients who develop 
diarrhea during or after therapy. This colitis may 
range from mild to life threatening in severity.
Mild cases of pseudomembranous colitis may 
respond to drug discontinuance alone. In more 
severe cases, m anagem ent may in c lu d e  
sigm oidoscopy, appropria te  bacte rio log ica l 
studies, fluid, electrolyte and protein supple­
mentation, and the use of a drug such as oral 
vancomycin, as indicated. Other causes of colitis 
should also be considered.
PRECAUTIONS
General
Prolonged use of PRIMAXIN® (imipenem and 
cilastatin sodium for in jection) may result in 
overgrowth of resistant organisms. Repeated 
evaluation of the patient's condition is essential. If 
superinfection occurs during therapy, appropriate 
measures should be taken.
CNS adverse experiences such as myoclonic 
activity, confusional states, or seizures have been 
reported with PRIMAXIN® especially when recom­
mended dosages based on renal function and body 
weight were exceeded. These experiences have 
occurred most commonly in patients with CNS 
disorders (e.g., brain lesions or history of seizures) 
and/or who have compromised renal function. 
However, there were rare reports in which there was 
no recognized or documented underlying CNS 
disorder. Close adherence to recommended dosage 
schedules is urged especially in patients with 
known factors that predispose to seizures (see 
DOSAGE AND A D M IN IS T R A T IO N ). A n t i­
convulsant therapy should be continued in patients 
with a known seizure disorder. If focal tremors, 
myoclonus, or seizures occur, patients should be 
evaluated neurologically and placed on anti­
convulsant therapy if not already instituted. If CNS 
symptoms continue, the dosage of PRIMAXIN® 
should be decreased or discontinued.
Use in Patients with Impaired Renal Function
Dosage in patients with impaired renal function is 
based on the severity of infection but the maximum 
daily dose varies with the degree of renal functional 
im pa irm ent (see DOSAGE AND A D M IN IS­
TRATION - Dosage in Patients w ith  Renal 
Insufficiency).
Use In Pregnancy
The use of PRIMAXIN® in pregnant women has not 
been studied, therefore, PRIMAXIN® should be 
used during pregnancy only if clearly needed. Use 
of this drug in women of childbearing potential 
requires that the anticipated benefits be weighed 
against possible hazards.
Reproduction studies with bolus I. V. doses suggest 
an apparent intolerance to PRIMAXIN® (including
emesis, inappetence, body weight loss, diarrhea 
and death) at doses equivalent to the average 
human dose in pregnant rabbits and cynomolgus 
monkeys that is not seen in non-pregnant animals in 
these or other species. In other studies, PRIMAXIN® 
was well tolerated in equivalent or higher doses (up 
to 11 times the average human dose) in pregnant 
rats and mice (see REPRODUCTION STUDIES 
under TOXICOLOGY in the complete monograph).
Nursing Mothers
It is not known whether PRIMAXIN® is excreted in 
milk. If the use of PRIMAXIN® is deemed essential, 
the patient should stop nursing.
Pediatric Use
Efficacy and tolerability in infants under the age of 
3 months have not yet been established; therefore, 
PRIMAXIN® is not recommended in the pediatric 
age group below the age of 3 months.
Drug Interactions
Concomitant administration of PRIMAXIN® and 
probenecid results in only minimal increases in 
plasma levels of imipenem and plasma half-life. It is 
not recommended that probenecid be given with 
PRIMAXIN®.
PRIMAXIN® should not be mixed with or physically 
added to other antibiotics. PRIMAXIN® has been 
administered concomitantly with some antibiotics, 
such as aminoglycosides.
There is no evidence to suggest that association of 
PRIMAXIN® with any other beta-lactam antibiotics 
has any therapeutic advantage.
ADVERSE REACTIONS
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is generally well tolerated. The following 
adverse reactions were reported on 1,723 patients 
treated in clinical trials. Many of these patients were 
severely ill and had multiple background diseases 
and physiological impairments, making it difficult to 
determine causal relationship of adverse ex­
periences to therapy with PRIMAXIN®.
Local Adverse Reactions
Adverse local clinical reactions that were reported 
as possibly, probably or definitely related to therapy 
with PRIMAXIN® were:
Incidence (%)
Phlebitis/thrombophlebitis 1.7
Infused vein pain 0.6
Vein induration 0.2
Infused vein infection 0.1
Systemic Adverse Reactions
Adverse clinical reactions that were reported as 
possibly, probably, or d e fin ite ly  related to 
PRIMAXIN® were:
Gastrointestinal
Incidence (%)
nausea 2.0
diarrhea 1.7
vomiting 1.6
tongue papillar hypertrophy 
pseudomembranous colitis
0.2
(see WARNINGS) 0.1
hemorrhagic colitis <0.1
gastroenteritis <0.1
abdominal pain <0.1
glossitis <0.1
heartburn <0.1
pharyngeal pain <0.1
increased salivation <0.1
CNS
fever 0.4
dizziness 0.3
seizures
(see PRECAUTIONS)
0.2
somnolence 0.2
confusion 0.2
myoclonus 0.1
vertigo 0.1
headache 0.1
encephalopathy <0.1
paresthesia 
Special Senses
transient hearing loss in
<0.1
patients with impaired hearing <0.1
tinnitus <0.1
Respiratory
dyspnea 0.1
hyperventilation <0.1
thoracic spine pain <0.1
Cardiovascular
hypotension 0.4
palpitations 0.1
tachycardia <0.1
Renal
oliguria/anuria <0.1
polyuria <0.1
Skin
rash 0.9
pruritus 0.3
urticaria 0.2
skin texture changes 0.1
candidiasis 0.1
erythema multiforme <0.1
facial edema <0.1
flushing <0.1
cyanosis <0.1
hyperhidrosis <0.1
pruritus vulvae <0.1
Body as a whole
polyarthralgia <0.1
asthenia/weakness <0.1
Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug 
relationship, that were reported during clinical trials 
were:
Hepatic: Increased SGPT, SGOT, alkaline phospha­
tase, bilirubin and LDH.
Hemic: Increased eosinophils, positive Coombs 
test, decreased WBC and neutrophils, increased 
WBC, increased platelets, decreased platelets, 
decreased hemoglobin and hematocrit, increased 
monocytes, abnormal prothrombin time, increased 
lymphocytes, increased basophils.
Electrolytes: Decreased serum sodium, indreased 
potassium, increased chloride.
Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red 
blood cells, urine white blood cells, urine casts, 
urine bilirubin, and urine urobilinogen.
TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is cleared by hemodialysis.
DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN® 
(imipenem and cilastatin sodium for injection) 
represent the quantity of imipenem to be ad­
ministered by I V. infusion only. An equivalent 
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN® should be determined 
by the severity of the infection, renal function, body 
weight, the antibiotic susceptibility of the causative 
organism(s) and the condition of the patient. Doses 
cited are based on body weight of 70 kilos.
The median duration of treatment with PRIMAXIN® 
in clinical trials for infections of the various body 
systems ranged from 6 to 10 days except for 
endocarditis and bone and joint infections for which 
the median duration of treatment was 4 weeks.
Dosage in Adults
The recommended daily dose is 1 to 2 g adminis­
tered in equally divided doses every 6 to 8 hours 
(see Table 1).
TABLE 1
ADULT DOSAGE OF PRIMAXIN®
I.V. Adm inistration
Severity  
of Infection
Dose
(m g of im ipenem )
Dosage
Interval
Daily
Dose
Mild 250 mg 6 h 1.0 g
Moderate 500 mg 8 h 1.5 g
Severe (fu lly 
susceptible)
500 mg 6 h 2.0 g
Severe* infections
due to less
susceptible
organisms
or life threatening
conditions
1000 mg 
1000 mg
8 h 
6 h
3.0 g
4.0 g
x P rim a rily  som e  s tra in s  o f Ps. aeruginosa.
The maximum daily dose should not exceed 4 g or 
50 mg/kg, which ever is less.
Dosage in Elderly Patients
The recommended dosage of PRIMAXIN® in elderly 
patients with normal renal function is the same as 
given for adults above. Renal status of elderly 
patients may not be accurately portrayed by 
measurement of BUN or creatinine alone. Deter­
mination of creatinine clearance is suggested to 
provide guidance for dosing in such patients.
Dosage in Patients with Renal Insufficiency
P a tie n ts  w ith  c re a t in in e  c le a ra n c e s  o f 
<5 mL/min/1.73m2 (<0.08 mL/s/1.73m2) should 
not receive PRIMAXIN® unless hemodialysis is 
instituted within 48 hours. Both imipenem and 
cilastatin are cleared from the circulation during 
hem odia lys is . The p a tie n t should rece ive  
PRIMAXIN® after hemodialysis and at 12 hour 
intervals timed from the end of that hemodialysis 
session. Dialysis patients, especially those with 
background CNS disease, should be carefu lly 
m o n ito re d ; fo r pa tien ts  on h e m o d ia lys is , 
PRIMAXIN® is recommended only when the benefit 
outweighs the potential risk of seizures (see 
PRECAUTIONS). Currently, there are inadequate 
data to recommend the use of PRIMAXIN® in 
patients undergoing peritoneal dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN®
IN RELATION TO RENAL FUNCTION
RENAL
FUNCTIO N
CREATININE
CLEARANCE
mL/mln/1.73 mJ 
(mL/s/1.73 m*)
DOSE
(9)
DOSAGE
INTERVAL
(h)
M AXIM UM
TO TA L
DAILY
DOSAGE
(9)
M ild
im pairm ent 3 1 -7 0
(0.52-1.17 )
0.5 6 - 8 1 .5 - 2
M oderate
im pairm ent 2 1 -3 0  
(0.35 - 0.50)
0.5 8 -1 2 1 - 1 .5
Severe*
im pairm ent 0 - 2 0  
(0 -  0.33)
0.25 - 0.5 12 0 .5 - 1 .0 * *
P a t ie n ts  w ith  c r e a t in in e  c le a ra n c e  o f  6  to  
20  m L /m in /1 .7 3  m 2 (0.1 -  0.3 m L /s/1 .73  m 2) s h o u ld  
be tre a te d  w ith  250 m g (o r 3.5 m g /kg  w h ic h e v e r is 
lo w e r) every 12 h o u rs  fo r  m o s t pathogens. W h e n  
th e  5d0 m g dose  is used in the se  patients, th e re  m a y  
be an increased  risk  o f se izures.
x x  T h e  h ig h e s t  d o s e  is  o n ly  re c o m m e n d e d  f o r  
in fe c t io n s  d u e  to  le ss  s u s c e p t ib le  o rg a n is m s  
p r im a rily  som e s tra ins  o f Ps. aeruginosa.
When only the serum creatinine level is available, 
the following formula (based on sex, weight, and 
age of the patient) may be used to convert this value 
into creatinine clearance (mL/min). The serum 
creatinine should represent a steady state of renal 
function.
Males: Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL) 
Females: 0.85 x above value.
When using the International System of units (SI), 
the estimated creatinine clearance (mL/s) in males 
can be calculated as follows:
(lean body weight, kg) x (140 - age, years) x 1.4736 
(72) x (serum creatinine concentration, pmol/L)
and in females the estimated creatinine clearance 
(mL/s) is:
(lean body weight, kg) x (140 - age, years) x 1.2526 
(72) x (serum creatinine concentration, pmol/L)
PRIMAXIN® is cleared by hemodialysis. After each 
dialysis session the dosage schedule should be 
restarted.
Each reconstituted 250 mg or 500 mg dose should 
be given by intravenous infusion over twenty to 
th irty  minutes. Each 1000 mg dose should be 
infused over 40 to 60 minutes. In patients who 
develop nausea during the infusion, the rate of 
infusion may be slowed.
RECONSTITUTION
Contents of the vials must be suspended and 
transferred to 100 mL of an appropriate infusion 
solution.
A suggested procedure is to transfer approximately 
10 mL from the 100 mL of the appropriate infusion 
solution to the vial (see list of diluents under 
COMPATIBILITY AND STABILITY). Shake well. 
Return the resulting 10 mL of suspension to the 
remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to 
ensure complete transfer of the contents of the vial 
to the infusion solution.
CAUTION: CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection 
5% or 10% Dextrose Injection 
5% Dextrose Injection with 0.02% sodium 
bicarbonate solution
5% Dextrose and 0.9% Sodium  Chloride 
Injection
5% Dextrose Injection with 0.225% or 0.45% 
saline solution 
NORMOSOL-M in D5-W 
5% Dextrose Injection with 0.15% potassium 
chloride solution 
Mannitol 2.5%, 5% and 10%
Reconstituted solutions
Solutions of PRIMAXIN® range from colourless to 
yellow. Variations of colour within this range do not 
affect the potency of the product.
PRIMAXIN®, as supplied in vials and reconstituted 
as above maintains satisfactory potency for four 
hours at room temperature and for 24 hours under 
refrigeration (4°C). PRIMAXIN® has been found to 
be stable in 0.9% Sodium Chloride Injection for 
10 hours at room temperature and 48 hours under 
refrigeration.
DOSAGE FORMS 
AVAILABILITY
PRIMAXIN® is supplied as a sterile powder mixture 
in vials conta in ing imipenem anhydrous and 
cilastatin sodium as follows:
3514 Ca - 250 mg imipenem equivalent and 250 mg 
cilastatin equivalent in vials.
3516 Ca - 500 mg imipenem equivalent and 500 mg 
cilastatin equivalent in vials.
STORAGE
The dry powder should be stored at a temperature 
below 30° C.
FULL PRODUCT MONOGRAPH 
AVAILABLE ON REQUEST
(318-b,1,89)
®Trademark Merck S Co., Inc./ 
Merck Frosst Canada Inc., R.U.
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Dosage in Infants and Children
The recom m ended to ta l d a ily  dosage of 
PRIMAXIN® in children and infants 3 months of age 
and older is 60 to 100 mg/kg of body weight divided 
into 4 equal doses given at six hour intervals. The 
higher dosages should be used for infants and 
young children. The total daily dosage should not 
exceed 2 grams. Clinical data are insufficient to 
recommend an optimum dose for infants and 
children with impaired renal function.
Administration
CAUTION: CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
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Difficult Implant Retrieval: a Case Report
Hugh U. Cameron, MB, ChB, FRCSC
Artificial joint prostheses can be expected to fail eventually. The author describes 
the case of a woman whose cemented knee-joint hinge prosthesis failed and required 
revision. This prosthesis was designed so that the stem became thinner as it 
approached the bearing surfaces. As a result the implant could not be removed from 
the cement and the cement could not be removed without severe destruction of 
surrounding bone. Although this prosthesis is no longer being used, there may be 
patients having this implant who will require revision in the future. This paper 
warns surgeons that its removal will be extremely difficult and appropriate plans 
should be made preoperatively. The author concludes that no stemmed implant 
should be cemented in place if it cannot readily be removed from the cement.
On peut toujours s’attendre a la defaillance eventuelle des protheses d’arthroplastie. 
L’auteur decrit le cas d’une femme dont la prothese a charniere du genou, cimentee 
a 1’os, fit defaut et necessita une revision. Cette prothese etait con$ue de fa?on a ce 
que la tige soit plus mince a proximite des surfaces d’appui. II en suivit que 
l’implant ne pouvait etre degage du ciment et que le ciment ne pouvait etre enleve 
sans causer une importante destruction de l’os adjacent. Bien que cette prothese ne 
soit plus en utilisation, certains patients peuvent encore en etre porteurs et devoir 
faire Tobjet d’une revision future. Cet article vise a informer les chirurgiens que 
l’enlevement de ces protheses se revelera extremement difficile et qu’une bonne 
planification preoperatoire s’impose. L’auteur conclut qu’un implant a tige ne 
devrait jamais etre cimente en place s’il ne peut etre degage du ciment.
A lthough the short-term success rate of artificial joint replace­
ment is high, the predictions from 
Sweden1 suggest that all joints will 
eventually fail. Revision, therefore, 
should be anticipated and implants 
designed to allow a quick, simple, 
change of prosthesis because soft- 
tissue scarring and loss of bone 
stock will make the surgery difficult 
enough.
I recently encountered a case in 
which the implant violated these 
precepts; revision was extremely
difficult and a multistage revision 
was required.
Case Report
A 65-year-old woman had injured 
her knee in 1937. She had under­
gone a number of subsequent oper­
ations and at one of these a hinge 
prosthesis had been inserted and a 
patellectomy performed. The tibial 
stem on the hinge prosthesis frac­
tured. This was revised to an un-
From the Department o f Surgery, The Orthopaedic and Arthritic Hospital, University o f 
Toronto, Toronto, Ont.
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FIG. 1. Broken stem of original hinge 
prosthesis can clearly be seen. Some 
radiolucency surrounds tibial compo­
nent which was relatively loose. There 
is no femoral radiolucency and femoral 
component was firmly fixed to bone.
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FIG. 2. What was not realized before removal of prosthesis was that femoral 
component was thicker proximally than distally, thus making extraction by 
longitudinal driving impossible. Distal femur was severely damaged in extraction of 
stem.
FIG. 3. After two sessions of allograft­
ing, length was restored. Guepar long 
stem was cemented in place. It was 
necessary to cement these stems in 
order to gain stability to allow healing 
of grafts.
linked type of hinge prosthesis (Fig.
1 ) .
When seen, she had severe patel­
lar tendon symptoms probably be­
cause the implant had no anterior 
femoral condylar bearing flange. 
She also had tibial pain from mild 
loosening of the tibial stem.
During revision surgery, the tibi­
al component and broken tibial 
stem and cement were fairly easy to 
remove, but the femoral side simply 
could not be extracted by conven­
tional methods. The cement was 
broken up as far as possible with 
curved osteotomes, but the bone, 
which was thin and osteoporotic, 
began to disintegrate long before 
the stem tip was reached. When the 
femoral stem was eventually ex­
tracted it was found to be widened 
proximally in both planes (Fig. 2) 
(i.e., it was wedge shaped in the
wrong direction). Attempts to re­
move the implant simply tightened 
it in place.
A long-stem Guepar II hinge was 
inserted to act as an internal splint 
and the patient was placed in trac­
tion. Four weeks later, extensive 
allografting was carried out around 
the Guepar II stems. The allografts 
were allowed to heal for 9 months 
then the knee was again opened. 
Much of the allograft had united, 
but further extensive grafting was 
needed to restore length; the Gue­
par II stems were then cemented in 
place (Fig. 3).
Comment
This case illustrates one of the 
truths of orthopedic surgery; if a 
prosthesis cannot be extracted from
cement, the cement cannot be re­
moved without splitting the bone. 
Had the reverse wedge nature of 
the prosthesis in this patient been 
recognized before surgery, a formal 
split of the femur should have been 
performed removing a huge window 
for later replacement.
This prosthesis is obsolete. How­
ever, there may still be patients who 
have this implant and will need 
revision surgery in the future. The 
moral of this case report is quite 
clear: a prosthesis should never 
be inserted if it cannot easily be re­
moved.
Reference
1. Ryd L: Micromotion in knee arthroplasty. 
A roentgen stereophotogrammetric analy­
sis of tibial component fixation. Acta 
Orthop Scand Suppl 1986; 220: 1-80
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clinical practice and their indications, 
mode of action and side-effects.
The third section is on the major 
organs transplanted in clinical practice. 
The largest part, on renal transplanta­
tion, covers the causes of chronic renal 
failure and methods of dialysis and 
describes the technique and indications 
for creating an arteriovenous fistula. 
The authors then describe the mode of 
assessment of donors and recipients in 
renal transplantation. Immunosuppres­
sive therapy, mainly with cyclosporine, 
corticosteroids and anti-lymphocyte 
globulin, and their side-effects, is dis­
cussed. Infectious complications in 
renal transplant patients are well de­
scribed in one chapter that covers 
cause, diagnosis and treatment. Finally, 
the follow-up of patients is studied and 
an overview provided of the differential 
diagnosis in the rejecting kidney allo­
graft.
Transplantation of other organs is 
also described by different authors, well 
known in their fields. Each author 
presents a historical review, followed by 
clinical and research information and 
own experience. Chapters on liver, pan­
creas, bone marrow, heart and lungs 
are interesting because they offer the 
reader general concepts in an under­
standable manner. However, each is 
based solely on the techniques and 
practice of the author’s centre.
In the final section, information on 
the criteria of brain death, selection of 
donors, organ preservation and anesthe­
siology are discussed. The risk of malig­
nant disease in the transplant patient is 
also covered.
Overall, the book is a good reference 
for physicians and fellows interested in 
organ transplantation.
Maroun Abou-Jaoude, MD
Clinical Fellow,
Transplantation,
University Hospital,
PO Box 5339, Station A,
London. Ont.
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Decision Making in Surgery of the 
Chest. Edited by Laurens R. Pickard. 
168 pp. Illust. W.B. Saunders Company 
Canada Limited, Toronto, 1989. 
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Disorders of the Spleen. Pathophysi­
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Pochedly, Richard H. Sills and Allen D. 
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stated. ISBN 0-471-91956-X.
Second Opinion. What’s Wrong With 
Canada’s Health-Care System and How 
to Fix It. Michael Rachlis and Carol 
Kushner. 371 pp. Collins Publishers, 
Toronto, 1989. $26.95. ISBN
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0-387-17116-9.
Textbook of Microsurgery. Edited by 
G. Brunelli. 1038 pp. Illust. Masson, 
Milano, 1988. Price not stated.
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Dalacin® C  Phosphate steme solution
(clindamycin phosphate)
Antibiotic
Recommended Applications
Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and 
also by causing a reduction in the rate of synthesis of nucleic acids.
Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infec­
tions where the oral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections due to sensitive anaerobic 
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci, Clostridium 
species and micro-aerophilic streptococci.
Dalacin C Phosphate is also indicated in serious infections due to sensitive Gram-positive organisms 
(staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci) 
when the patient is intolerant of, or the organism resistant to other appropriate antibiotics. 
Warnings: Some cases of severe and persistent diarrhea have been reported during or after 
therapy with Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally 
associated with blood and mucus in the stools and has at times resulted in acute colitis. When 
endoscopy has been performed, some of these cases have shown pseudomembrane formation.
If significant diarrhea occurs during therapy, this drug should be discontinued or, if necessary, 
continued only with close observation. Significant diarrhea occuring up to several weeks post­
therapy should be managed as if antibiotic-associated.
If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes 
may respond to simple drug discontinuance. Moderate to severe cases, including those showing 
ulceration or pseudomembrane formation, should be managed with fluid, electrolyte, and protein 
supplementation as indicated. Corticoid retention enemas and systemic corticoids may be of help 
in persistent cases. Anticholinergics and antiperistaltic agents may worsen the condition. Other 
causes of colitis should be considered.
Contraindications: The use of Dalacin C Phosphate (clindamycin phosphate) is contraindicated in 
patients previously found to be hypersensitive to this compound, the parent compound, clinda­
mycin, or clindamycin palmitate. Although cross-sensitization with Lincocin® (lincomycin hydro­
chloride) has not been demonstrated, it is recommended that Dalacin C Phosphate not be used in 
patients who have demonstrated lincomycin sensitivity.
Until further clinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn 
(infants below 30 days of age), or in pregnant women. Studies indicate a toxin(s) produced by 
Clostridia (especially Clostridium difficile) may be a principal cause of clindamycin and other 
antibiotic-associated colitis. These studies also indicate that this toxigenic Clostridium is usually 
sensitive in-vitro to vancomycin. When 125 mg to 500 mg of vancomycin were administered orally 
four times a day for 5 -1 0  or more days, there was a rapid observed disappearance of the toxin 
from faecal samples and a coincidental recovery from the diarrhea.
It should be noted that serious relapses have occurred up to one month after apparently successful 
treatment. A relatively prolonged period of continuing observation is therefore recommended. 
Precautions: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed 
with caution in atopic individuals. Dalacin C Phosphate must be diluted for intravenous admin­
istration. (See Dosage and Administration) The use of antibiotics occasionally results in overgrowth 
of nonsusceptible organisms - particularly yeasts. Should superinfections occur, appropriate 
measures should be taken as dictated by the clinical situation.
As with all antibiotics, culture and sensitivity studies in conjunction with drug therapy should 
be performed.
Since abnormalities of liver function tests have been noted occasionally in animals and man, 
periodic liver function tests should be performed during prolonged therapy. Blood counts should 
also be monitored, during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in 
patients with impaired hepatic function is greater than that found in normal patients, the dose of 
Dalacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are 
not effective means of removing the compound from the blood. Periodic serum levels should be 
determined in patients with severe hepatic and renal insufficiency.
Adverse Reactions: Local
(a) Intramuscular Injections: Of 404 patients treated with Dalacin C Phosphate (clindamycin 
phosphate) intramuscularly (with a solution containing 150 mg/mL), six (1.5%) demonstrated 
local reactions as follows: Two complained of pain at the injection site, two demonstrated indura­
tion at the injection site and two developed sterile absesses.
(b) Intravenous Infusions: Of 192 patients with Dalacin C Phosphate by intravenous infusion, 
14 (7.3%) demonstrated local reactions. Eleven patients developed superficial thrombophlebitis 
and one patient developed both superficial and deep thrombophlebitis. The majority of these 
cases developed in conjuction with the use of indwelling I V. catheters and it is difficult to know 
how much the drug contributed to the irritation. Two patients developed localized erythema, 
swelling and pain at the site of the infusion.
Systemic Side Effects: Twenty-eight patients of 596 treated with Dalacin C Phosphate (clinda­
mycin phosphate) by either the intramuscular or intravenous routes developed systemic side 
effects as follows:
Number o f Patients
Rash........................................................................................................................................................ 7
Urticaria.................................................................................................................................................. 1
P ru ritu s .................................................................................................................................................. 1
Fever, Leucocytosis ..............................................................................................................................  1
Nausea, with or without vomiting ........................................................................................................ 1
Diarrhea (See also under "Warnings").................................................................................................  4
Hypotension...........................................................................................................................................  1
Hypertension......................................................................................................................................... 1
Shortness of Breath..............................................................................................................................  1
Superinfection* .............................................................................................................................................. 4
Cardiac a r re s t" ..................................................................................................................................... 1
Bad or bitter taste in m outh.................................................................................................................. 5
* Superinfection is a complication of antibiotic therapy in general and is not necessarily a true 
side effect of clindamycin phosphate.
** Due to underlying myocarditis in this patient.
Clinical and Laboratory Findings: Patients treated during clinical trials of Dalacin C Phosphate 
(clindamycin phosphate) were followed with clinical laboratory tests, including complete hema­
tology, urinalysis and liver and kidney function tests. Some of these tests were abnormal initially 
and returned to normal during therapy with Dalacin C Phosphate, while others were normal initially 
and became abnormal during therapy. Overall evaluation of clinical laboratory values in these 
patients does not indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, 
hepatic or renal systems. Transient elevations of serum transaminases have occured in some 
patients, but other liver function tests (alkaline phosphatase, serum bilirubin) have not shown any 
tendency to increase and there have not been clinical signs of drug-induced hepatic toxicity. 
Symptoms and Treatment of Overdosage: No cases of overdosage have been reported. No 
specific antidote is known. Doses as high as 1200 mg every six hours (4800 mg/day) by infusion 
for five days have been given without adverse effects.
DOSAGE AND ADMINISTRATION 
Adults:
Intramuscular Injection: 600 mg/day in 2 equal doses.
Moderately severe infections: 600 to 1200 mg/day in 2 or 3 equal doses.
Severe infections: 1200 to 2400 mg/day in 2 ,3  or 4 equal doses. Intramuscular injections of more 
than 600 mg into a single site are not recommended.
Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior 
to  I.V. administration to a concentration of 600 mg in 50 mL of diluent (12 m g/m L or less) and 
infused in not less than 10 minutes. Administration of more than 1200 mg in a single 1 hour 
infusion is not recommended. Dalacin C Phosphate should not be injected intravenously undiluted 
as a bolus.
Moderately severe infections: 900 to 1800 mg/day by continuous drip or in 2 or 3 equal doses, 
each infused over 20 minutes or longer.
Severe infections: 1800 to 2700 mg/day by continuous drip or in 3 or 4 equal doses, each infused 
over 20 minutes or longer. In life-threatening infections, doses of 2700 to 4800 mg/day by con­
tinuous drip or in 3 or 4 equal doses each infused over 20 minutes or longer may be given.
Dilution and infusion rates:
Dose Diluent Time
300 mg 50 mL 10 min.
600 mg 50 mL 20 min.
900 mg 100 mL 30 min.
1200 mg 100 mL 45 min.
Alternatively, the drug may be administered in the form of a single rapid infusion of the 
followed by continuous I.V. infusion as follows:
To maintain serum Rapid Maintenance
clindamycin levels infusion rate infusion rate
Above 4 mcg/mL 10 mg/min. for 30 min. 0.75 mg/min.
Above 5 mcg/mL 15 mg/min. for 30 min. 1.00 mg/min.
Above 6 mcg/mL 20 mg/min. for 30 min. 1.25 mg/min.
Children (Over one month of age):
Intramuscular injection: 10 to 15 mg/kg/day in 2, 3 or 4 equal doses.
Moderately severe infections: 15 to 20 mg/kg/day in 3 or 4 equal doses.
Severe infections: 20 to 30 mg/kg/day in 3 or 4 equal doses.
Intravenous Administration: Moderately severe infections: 15 to 25 mg/kg/day by continuous 
drip or in 3 or 4 equal doses, each infused over 20 minutes or longer.
Severe infections: It is recommended that children be given no less than 300 mg/day regardless 
of body weight.
Preparation for Intravenous use: 4 mL (600 mg) Dalacin C Phosphate when diluted with 1000 mL 
of the following commonly used infusion solutions was found to be physically compatible and 
demonstrated no significant change in pH or antimicrobial potency over a period of 24 hours: 
Sodium chloride injection 
Dextrose 5% in water 
Dextrose 5% in saline 
Dextrose 5% in Ringer's Solution
Dextrose 5% in half-strength saline plus 40 mEq potassium chloride 
Dextrose 21/2% in Lactated Ringer's Solution (Hartman’s Solution)
Compatibility with other products: Dalacin C Phosphate was not stable when added to Dextrose 
5% in water plus vitamins. Therefore it is not recommended that Dalacin C Phosphate be mixed 
with any infusion solution containing B vitamins. Dalacin C Phosphate has been shown to be 
compatible with Gentamicin sulfate, Tobramycin sulfate and Amikacin sulfate.
Composition: Each mL of Dalacin C Phosphate Sterile Solution contains Clindamycin phosphate 
equivalent to clindamycin base 150 mg, Benzyl alcohol 5 mg, Disodium edetate 0.5 mg, Water for 
injection q.s. When necessary the pH is adjusted with sodium hydroxide and/or hydrochloric acid 
to maintain a pH range of 5.5 to 7.0.
Dosage forms:
Availability: Dalacin C Phosphate Sterile Solution is available in 2 mL and 4 mL ampoules as well 
as a 6 mL vial.
Pharmacy Bulk Vial: Dalacin C Phosphate Sterile Solution is also available in a 60 mL Pharmacy 
Bulk Vial. The availability of the Pharmacy Bulk Vial is limited to hospitals with a pharmacy 
based IV admixture program. The Pharmacy Bulk Vial is intended for single puncture, multiple 
dispensing for intravenous use only.
NOTE: Do not store below 15°C.
Product Monograph available upon request. CE 1377.D
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CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The deadline is 1 
month before issue date. Regular classified rates (for each insertion): $45.00 for the first 40 words or less, additional words 604 each (additional 
$17.00 for frame). Special Display under 100 words, 2'A  in. X 2 in., $110.00. $6.00 charge (first insertion only) for CJS box numbers. Display 
rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
GENERAL SURGEON: BC -  Well-estab­
lished general surgical practice for sale in 
choice lower mainland location. Canadian fel­
lowship required. Reply in confidence with 
curriculum vitae to: Box 800, Canadian 
Journal of Surgery, PO Box 8650, Ottawa. 
ONK1GOG8. -S89-13
GENERAL SURGEON AND ORTHOPEDIC 
SURGEON: BC -  For thriving BC sunshine 
coast community of 20 000 on the doorstep 
o f Desolation Sound. Fully accredited 
140-bed hospital under construction. Medical 
staff includes 17 GPs, 4 GP anesthetists, 
internist, pediatrician and 2 surgeons. Excel­
lent year round recreation and cultural attrac­
tions include boating, fishing, golfing, modern 
indoor recreation theatre complex and com­
munity college. Frequent daily air and ferry 
connections to Vancouver. Contact: Dr. B.K. 
Cutler, Department of Surgery, Powell 
River General Hospital, 5871 Arbutus 
Ave., Powell River, BC V8A 4S3. Tel: 
(604)483-3211. -S89-10
GENERAL SURGEON: MB -  Required to 
join a progressive group of twelve general 
practitioners, one obstetrician/gynecologist, 
and one orthopedic and plastic surgeon. 
Guaranteed income provided for first 12 
months, and thereafter, if mutually agreeable, 
partnership would be offered. Early partner­
ship by agreement is available. The clinic 
occupies three floors of a modern, downtown 
medical facility in a university city of 40 000, 
and services a large trading area. A 220-bed 
hospital with a 12-bed, intensive care unit, a 
201-bed geriatric and rehabilitation hospital, a 
large regional laboratory, and an ultrasound 
department, is located in the city. Interested 
persons are asked to contact: Mrs. D.J. 
Mistal, Western Medical Clinic. 144 6th 
St., Brandon, MB, R7A 3N2, Tel: (204) 
727-6451. -S89-14
SPINAL SURGERY FELLOWSHIP: ON -
Available July 1, 1989 and July 1, 1990, 
Department of Surgery, Division Orthopedic 
Surgery, University of Western Ontario, Lon-
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don. For information contact: Stewart I. Bai­
ley, MD, FRCSC, 345 Westminster Ave., 
London, ON N6C 4V3. Tel: (519)
439-0701. -S89-11
CHIEF, DEPARTMENT OF SURGERY:
ON -  The Ottawa Civic Hospital, a 
922-bed tertiary care, teaching and re­
search institution, closely associated with 
the University of Ottawa, invites applica­
tions for the position of Chief of the 
Department of Surgery. The Department 
and its appointments are closely linked to 
the University of Ottawa Department of 
Surgery. Applicants must have a Royal 
College of Physicians and Surgeons Fel­
lowship in a surgical subspecialty and 
have achieved, or be a candidate for, 
appointment at the associate or full pro­
fessor level at the University of Ottawa. 
Previous administration and clinical or 
basic research experience is essential. 
The hospital is rapidly expanding its re­
search efforts in two campus research 
institutes. The recruitment of new clinician 
scientists in hospital division is a priority 
and University, Hospital and Department 
of Research resources are dedicated to 
this. Several division head positions are 
now open and the new Chief is to be 
involved in recruitment. In accordance 
with Canadian immigration policies, initial 
preference for this position will be given 
to Canadian citizens and permanent resi­
dents of Canada. Please reply with curric­
ulum vitae, and names of three referees, 
to: Dr. J.D. Grimes, senior vice presi­
dent, Research and Clinical Adminis­
tration, Ottawa Civic Hospital. 1053 
Carling Ave., Ottawa, ON Canada K1Y 
4E9. Tel: (613) 761-4614. -S89-15
CHAIR OF UROLOGY: ON -  Applications 
are invited for the position of Chairman of the 
University Division of Urology, University of 
Ottawa, School of Medicine. The Children's 
Hospital of Eastern Ontario, the Ottawa Civic 
Hospital and the Ottawa General Hospital are 
participating institutions which offer excellent 
resources to a Urology Training Program 
which is fully approved by the Royal College 
of Physicians and Surgeons of Canada. There 
is a complement of 14 urologists with univer­
sity appointments, of which 6 are GFTs; 
currently the Division of Urology has an estab­
lishment of 9 residents in training. The suc­
cessful candidate shall be a certified specialist 
of the Royal College of Physicians and Sur­
geons of Canada and be eligible for licensure 
by the College of Physicians and Surgeons of 
Ontario. Candidates will have a proven record 
in clinical and academic urology. While the 
position requires a major leadership role in the 
university/hospital/community settings, pref­
erence will be given to a qualified individual 
devoted to the pursuit of academic excellence 
in teaching and research. Part of the mandate 
will focus on the development of research in 
urology and continuing quality teaching pro­
grams at both the undergraduate and post­
graduate levels. The successful candidate will 
hold a joint appointment as Chairman of the 
University Division of Urology and Head of
Urology at one of the teaching hospitals. 
Salary and fringe benefits are commensurate 
with qualifications and experience and are in 
accordance with existing academic scales at 
the University of Ottawa. In accordance with 
Canadian immigration requirements, priority 
will be given to Canadian citizens and perma­
nent residents of Canada. Employment equity 
is University policy. Applicants are requested 
to forward their curriculum vitae and the 
names of three referees, prior to June 1, 
1989, to: Gilles D. Hurteau, MD, dean - 
School of Medicine. University of Ottawa, 
451 Smyth Rd., Ottawa, ON K1H 8M5.
CHAIRE D'UROLOGIE: ON -  L'Universite 
d'Ottawa ouvre un concours pour le poste de 
directeur de la division d ’urologie, Universite 
d'Ottawa, Ecole de Medecine. Les candi­
d a tes  qua lifie rs  devront avoir un certificat 
du College royal des medecins et chirurgiens 
du Canada et §tre 6legibles au permis d'exerc- 
er du College des medecins et chirurgiens de 
I'Ontario. Le(la) candidat(e) choisi(e) sera le(la) 
responsable de la coordination des pro­
grammes d’enseignement integres dans les 
hopitaux affilies, soit I'Hopital General d'Ot­
tawa, I'Hopital Civic d'Ottawa, et I'Hopital 
pour enfants de I'est de I'Ontario. Le(la) candi­
date) choisi(e) aura aussi la responsabilite des 
programmes de formation au nivea pr4di- 
plome et postdoctoral et du developpement 
des programmes de recherche. Le(la) candi­
date) choisi(e) agira conjointement comme 
directeur(trice) de la division d'urologie dans 
I'un des hopitaux affilies. L'Universite et les 
hopitaux affilie offrent d'excellentes resources 
qui assurent une medecine de qualite et des 
programmes de formation bien structures. 
L'Universite d'Ottawa offre un salaire de base 
concurrentiel, ainsi que des conditions de 
travail et des avantages sociaux allechants. 
L'Universite a une politique d'egalite en ma- 
tiere d'emploi. Selons les exigences d'lmmi- 
gration Canada, cette annonce s'adresse d'- 
abord aux citoyens canadiens et aux residents 
permanents du Canada. Priere de faire par- 
venir votre curriculum vitae et la liste des 
references avant le 1 juin 1989 a I'attention 
de: Gilles D. Hurteau, MD, Doyen, Ecole de 
medecine, Universite d'Ottawa, 451, che- 
min Smyth, Ottawa, ON K1 H 8M5.
-S89-16
VASCULAR SURGEON: ON -  Applications 
are invited for a clinical position at the Ottawa 
Civic Hospital. Candidates must hold a certifi­
cate of special competence in vascular sur­
gery (or equivalent) and have added qualifica­
tions in epidemiology/public health. Training 
in critical care is an asset. The closing date for 
applications is 30 days after publication of 
this advertisement. Applications, including 
curriculum vitae and names of three referees, 
should be submitted to: C. Wm. Cole, MD, 
Division of Vascular Surgery, Ottawa Civic 
Hospital, 1053 Carling Ave., Ottawa, ON 
K1Y4E9. -S89-17
GENERAL SURGEON: SK — An opportunity 
exists for a general surgeon to join in busy 
practice of general surgery, university centre, 
western Canada. Please send CV to: Box 
726, Canadian Journal of Surgery, PO Box 
8650, Ottawa. ON K1G 0G8. -S89-01
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Whose side is your favourite
M nding  an effective treatment for intra- 
abdom inal infections has becom e much 
easier since the advent of cephalosporins. 
Their broad spectrum of activity has greatly 
improved the prognosis for many patients 
with serious infections.
The trouble is, the cost o f cephalosporins has 
been making many hospital pharmacists 
(and cost control staff) see red. It is also now 
increasingly more difficult for many hospital 
formulary committees to be able to strike an 
agreeable balance between effectiveness 
and cost control.
New Cefizox™ m ay be the  answer everyone's 
been looking for. Not only does it give m uch 
wider pa thogen coverage* (including B. 
fragilis) than  cefoxitin,1,2 bu t its superior 
dosage schedule (example: q!2h vs q6h) 
m ay make Cefizox™ m uch less expensive?'4 
It even has packaging designed for easy 
identification.
So if the cost o f e ffective cephalosporin 
therapy is just too  much for your hospital to 
handle, consider new Cefizox™ Its 
com bination o f e fficacy and low cost m ay 
just be w ha t everybody ordered.
PAAB
CCPP
Cefizox*
ceFtizoxime sodium
A cephalosporin that plays favourites with everybody.
SKGrF SMITH KLINE SfRENCH CANADA LTD. 1989 Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan
CX:M:189CA
‘ Refers to in vitro coverage; does not necessarily imply clinical coverage,
1y
CARDIOVASCULAR SUTURES
Improved Cardiovascular Needles
• Special highly adherent silicone 
lubricant further reduces 
resistance...first pass, last pass
• Securely attached to the suture
Needles Resist Bending t
<• New, stronger needle configuration
• Superior sharpness >
• Lower penetration force reduces 
strain on needle -  minimizes 
bending and breaking
